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TP53 tumor protein 53 (alias: p53) 
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Abstract 
 
The function of CKS2 proteins is not clarified, but they are assumed to play a direct 
role in cell regulation because of interactions with CDKs. The aim of this project was 
to establish the Y2H method for assessing the CKS2 interactions with CDK1 and 
CDK2. In order to simulate the dephosphorylated state of CDK in vivo, CDK1AF and 
CDK2AF sequences containing T14A and Y15F mutations, were used as templates 
for the CDKs. CDK2F, a template with only a single mutation (Y15F) was also tested. 
For CKS2, normal cDNA was used as template. Primers were designed and used in 
PCR to amplify cDNA of CKS2, CDK1AF, CDK2AF and CDK2F. Fusion plasmids 
were constructed by ligating each gene sequence into both yeast expression vectors 
pGBKT7 and pGADT7. The plasmid constructs were transformed into XL 10-Gold 
Ultracompetent E. coli cells to produce many replicates of the plasmids. For CKS2 
and CDK1AF, direct cloning into pGBKT7 and pGADT7 was not successful, and 
subcloning into pGEM-T Easy vectors was performed. Plasmid constructs were 
verified by sequencing, and different combinations of plasmids were transformed into 
AH109 S. cerevisiae cells. CKS2 interactions with CDK1AF, CDK2AF and CDK2F 
were measured by growth in S. cerevisiae two-hybrid analyses. For each PPI, two 
parallels were tested both when CKS2 was used as bait (cloned in pGBKT7) and prey 
(cloned in pGADT7). The results showed that CKS2 was interacting with CDK1AF, 
CDK2AF and CDK2F in the Y2H system, regardless of whether CKS2 or the CDK 
was cloned as the bait protein. We therefore conclude that the Y2H system can be 
used to assess CKS2 interactions with CDKs. This is the first step towards 
establishment of Y2H screens for CKS2. Such screens can either contain a cDNA 
library to identify other CKS2 interacting proteins, or a library of small molecule 
compounds to find inhibitors of the CKS2 interactions. 
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Introduction 
Protein-protein interactions (PPIs) are essential in all cellular processes, for example 
cell signalling and regulation [1, 2]. Mapping of interaction networks can predict the 
functional relationship between the interacting proteins, and be of importance for 
understanding the cellular proteome. Knowledge about PPIs will also have major 
implications in the understanding of diseases and for drug discovery. The yeast two-
hybrid (Y2H) system is the most widely used methodology to identify PPIs. The 
technique is rapid, efficient and convenient, and detects in vivo interactions [1-4].  
 
Proliferating cells go through a defined sequence of molecular processes known as the 
cell cycle. Throughout the cell cycle, different proteins contribute with regulation of 
the different events, for example entry into S or M phase. Key regulatory proteins are 
the cyclin-dependent kinases (CDKs) [5, 6]. The CDKs are activated by cyclins which 
bind to the catalytic subunit of CDKs [7]. Mutations in genes important for cell cycle 
regulation can result in uncontrolled proliferation, which is associated with cancer [6].    
 
Overexpression of CDC28 protein kinase regulatory subunit 2 (CKS2), a protein 
assumed to play a direct role in cell regulation because of its interaction with CDKs 
[8], is associated with aggressive tumors and poor survival in many malignancies 
including prostate, gastric, hepatocellular, breast and cervical carcinomas [9-13]. The 
function of CKS2 has not been fully clarified, but the protein is known to interact with 
both CDK1 and CDK2 [8, 14-18]. The information of CKS2 overexpression in many 
malignancies, and acquired knowledge about its interacting partners can be used in 
development of new drugs. Therapeutic strategies based on CDK inhibition have been 
proposed. However, current CDK inhibitors like Flavopiridol and CY-202 have 
shown limited success in clinical trials [19]. Design of small molecules that inhibit 
PPIs have emerged as new potential options for targeted cancer therapy [20, 21]. A 
totally new approach for inhibiting cell proliferation in cancers would be to target the 
interaction between CKS2 and CDKs. It is therefore of interest to develop a Y2H 
screen with a library of small molecular compounds. Such a Y2H screen with 
CKS2/CDKs interactions has not been presented before. This project is a step towards 
the development of a Y2H screen by establishing the Y2H method for assessing the 
interaction between CKS2 and CDKs.  
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The purpose of the experiments carried out, was to investigate whether the Y2H 
system could be used to show CKS2 interaction with CDK1 and CDK2. 
Phosphorylations on threonine 14 (T14) and tyrosine 15 (Y15) inactivates the CDKs, 
and these sites must be dephosphorylated in order for the CDKs to be active [22, 23]. 
To simulate in vivo conditions of dephosphorylated sites, CDKs based on T14 and 
Y15 mutated cDNA sequences were used; i.e., CDK1AF, CDK2AF, and CDK2F. 
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1 Biological Background 
 
1.1 The Cell Cycle 
When cells proliferate, they go through a defined sequence of molecular processes 
[24]. This essential mechanism by which all living things reproduce is known as the 
cell cycle. The cell cycle is traditionally divided into four phases known as, G1 (gap 
1), S (synthesis), G2 (gap 2), and M (mitosis) (figure 1.1). The S phase is the interval 
where DNA replication (duplication) occurs, and mitosis is the process where the 
entire duplicated DNA is segregated accurately into two genetically identical daughter 
cells. A cell needs approximately 24 hours to complete the cell cycle, of which S 
takes 10-12 hours and M only requires about one hour. The rest of the time, the cells 
need to grow and increase their mass of proteins and organelles [25, 26].   
 
 
 
Figure 1.1: The phases of the cell cycle [25]. The cell cycle is traditionally divided into the 
four phases G1 (gap 1), S (synthesis), G2 (gap 2), and M (mitosis). Interphase is the process 
between two M phases, and consists of G1, S and G2. M is further divided into mitosis 
(division of the nucleus) and cytokinesis (division of the cytoplasm). 
 
 
G1 and G2 will also ensure that external and internal conditions are suitable for the 
cell cycle to proceed, and the time of these gap-phases will vary in time according to 
how favourable external conditions and extracellular signals from other cells are. 
When the cell first has passed through the restriction point (R) in G1, it has committed 
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to DNA replication and will continue even if the outer cell growth stimulation is taken 
away [25]. 
 
Chromosomes are structures composed of DNA, carrying the genetic information of 
an organism. After replication, the chromosomes of the cell will condensate, and this 
is a visible sign that the cell is ready to enter M. In a light microscope, the 
chromosomes can first be seen as long threads, and as they condensate, become 
thicker and shorter. The condensation progress makes the chromosomes easier to 
segregate later in mitosis [26]. 
 
The process between two M phases is called interphase (consisting of G1, S and G2). 
More detailed, M is divided into mitosis (nuclear division) and cytokinesis 
(cytoplasmic division). Mitosis is again divided into five stages; prophase, 
prometaphase, metaphase, anaphase and telophase. Figure 1.2 shows the different 
phases of mitosis [25]. 
 
 
Figure 1.2: The course of mitosis in a typical animal cell [25]. Mitosis is further divided 
into five stages; prophase, prometaphase, metaphase, anaphase and telophase. DNA is colored 
with blue and the microtubules are colored with green.  
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In prophase the replicated chromosomes, now consisting of two sister chromatids, 
start to condense. Outside the nucleus, the centrosomes have started to move apart 
forming the mitotic spindle. The mitotic spindle is composed of microtubules, and 
performs the separation of the chromosomes. At prometaphase, the nuclear envelope 
breaks down and the chromosomes attach to the mitotic spindle. The chromosomes 
then align in a plane, midway between the spindle poles in metaphase, and are 
separated in anaphase, forming two sets of daughter chromosomes. During telophase, 
a new nuclear envelope reassembles around each set. Formation of two nuclei is 
completed, and this marks the end of mitosis. In the final stage of M, the cytokinesis, 
the cytoplasm is divided in two, creating two daughter cells each with one nucleus 
[25]. 
 
 
1.2 Regulation of the cell cycle 
Throughout the process of the cell cycle, different proteins contribute to the regulation 
of the different events, for example entry into S or M. This is to ensure that the cell 
does not enter the next stage unless it is prepared, and then triggers the next stage 
when the cell is ready. Two important checkpoints occur in G1 and G2. The G1 
checkpoint ensures that environmental conditions are favourable for cell proliferation 
and that the cell’s DNA is intact before committing to S. If these conditions are not in 
order, the cell will delay progress through G1, and may even enter a resting state 
known as G0 [26]. In G0, the cells no longer proliferate [6].The G2 checkpoint ensures 
that the cell does not enter mitosis if replication is not complete. Entry into M will 
also be stopped if the cell has DNA damage. When DNA is repaired and replication is 
complete, the cell is allowed to enter M [26].  
 
1.2.1 Key proteins involved in regulation 
Key regulatory proteins are the cyclin-dependent kinases (CDKs), a family of 
serine/threonine protein kinases [5, 6]. They are present in cells throughout the cell 
cycle, but are only activated and deactivated at appropriate times. Cyclins, a set of 
proteins also important in the cell cycle control system, are partly responsible for 
switching the CDKs on and off [26]. They do so by binding to the catalytic subunit of 
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CDKs, and thereby activating them [7]. The cyclins, in contrast to the CDKs, are 
synthesized during progression through the cell cycle, and are quickly proteolysed 
after ubiquitination, and replaced by other cyclins. In this way, they periodically 
activate CDKs [24, 27]. When a CDK is activated, it induces downstream processes 
by phosphorylating certain proteins [6]. In this context, CDK1 and CDK2 will be the 
main focus (figure 1.3). 
 
1.2.2 Inhibition of CDKs 
CDK inhibitors (CKI) can counteract CDK activity by binding to CDKs alone and 
prevent association with cyclins, or directly to the CDK-cyclin complex [6]. One type 
of CKI is cyclin-dependent kinase inhibitor 1A (CDKN1A), an enzyme which inhibits 
CDK by binding to CDK-cyclin complexes, thereby preventing CDK-cyclin 
complexes from phosphorylating their target substrates. CDKN1A also inhibits DNA 
synthesis by binding to and inhibiting the proliferating cell nuclear antigen (PCNA). 
CDKN1A is activated by tumor protein 53 (TP53), a tumor suppressor gene. At the 
G1-checkpoint, cell cycle arrest induced by DNA damage is TP53-dependent. The 
cellular level of TP53 is usually low, but can have rapidly induced activity if DNA 
damage occurs. This will lead to an induction of CDKN1A followed by G1-arrest, 
thereby preventing replication of damaged DNA. If the cells are severely damaged, 
TP53 activates genes leading to apoptosis (cell death) [6]. When DNA damage occurs 
in G2, the kinase ataxia telangiectasia mutated (ATM) is activated. ATM can induce 
G2-arrest by two signal paths. ATM can stimulate the kinase CHEK2 which directly 
inhibits the phosphatase cell division cycle 25 (CDC25). Alternatively; ATM will 
stimulate the tumor suppressor gene BRCA1 which will then activate the kinase 
CHEK1. CHEK1 will directly inhibit CDC25, leading to G2 arrest [24].    
 
1.2.3 Deregulation of the cell cycle and cancer 
Mutation of genes important for the regulation of cell cycle can lead to uncontrolled 
proliferation, and is associated with cancer. Uncontrolled cell division results in 
unrestrained cell proliferation. Mutations mainly occur in two classes of genes: proto-
oncogenes and tumour suppressor genes. In normal cells, proto-oncogenes contribute 
to stimulation of cell proliferation. When mutations occur, proto-oncogenes or 
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oncogenes can promote tumour growth. Mutations in tumour suppressor genes like 
TP53, results in dysfunction of proteins that normally inhibit cell cycle progression, 
and proliferation can continue in damaged cells. The TP53 gene is the most frequently 
mutated gene in human cancer. Inactivated TP53 results in loss of regulation of 
CDKN1A, in response to DNA damage. Mutations of checkpoint proteins are 
frequent in all types of cancers [6].  
 
 
1.3 Regulation of CDKs 
CDK activity is not only regulated by cyclins, but also by phosphorylation on 
conserved threonine and tyrosine residues. Amino acid sequences of human CDK1 
and CDK2 are 65 % identical, and major phosphorylation sites are equally conserved 
for both [23]. In order for CDK1 and CDK2 to be fully activated, phosphorylations of 
T161 and T160, respectively, are required [6, 22, 23]. The conserved region in 
cyclins, important for binding to CDKs, contains 5 α-helices often referred to as a 
cyclin box [28]. The equally conserved region for CDKs is often termed the PSTAIR 
helix and contains this single-letter amino acid code, or variants of it. The PSTAIR 
helix is adjacent to the catalytic loop [27]. The catalytic loop (also termed T-loop) 
blocks the substrate binding site, and side chains in the ATP-binding site block 
phosphotransfer [7]. Binding of cyclins to a CDK results in a conformational change 
which aligns the PSTAIR helix and T-loop [29]. The crystal structure of 
CDK2/CCNA, reveals that the three-dimensional structure of the T-loop is changed 
from “closed” to “open”, thereby exposing T160 of CDK2 [30]. T160 can now be 
phosphorylated, which is carried out by the CDK-activating kinase (CAK) [31]. 
Because of structural identity among CDKs, it is predicted that conformational 
changes for CDK2/CCNA will be maintained in CDK1/CCNB. This is also supported 
by the structure of CDK2/CCNE [28]. McGrath et al. [32] refined a homology model 
of CDK1/CCNB that supports similar findings reported for CDK2/CCNA, such as 
conformational change in CDK1 induced by CCNB binding. Several studies have 
explored the binding of CCNB to CDK1 and found that the complex could form in the 
absence of phosphorylation, indicating that CAK phosphorylation of T161 occurs 
after cyclin binding [22, 31].  
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Figure 1.3: Cell cycle regulation. CDK1 and CDK2 form complexes with CCNE in G1, with 
CCNA in S, and with CCNB in G2. The active phosphorylation on T161 and T160 for CDK1 
and CDK2 respectively, is indicated by the yellow symbol P. Details on activating 
phosphorylation by CAK, deactivating phosphorylation by WEE1 and PKMYT1, and 
activating dephosphorylation by CDC25 is shown for CDK1/CCNB. This complex form the 
mitosis promoting factor (MPF) in M, and the complex in inactivated by the anaphase 
promoting complex (APC) which leads to exit from mitosis. APC mediates ubiquitination of 
CCNB which is then proteolysed.  
 
 
Inactivating phosphorylation of CDK1 is carried out by the kinases WEE1 and protein 
kinase membrane associated tyrosine/threonine 1 (PKMYT1) at tyrosine 15 (Y15) 
[33, 34]. An additional phosphorylation by PKMYT1, when Y15 is also 
phosphorylated, occurs on threonine 14 (T14) [23, 34]. CDK2 is also phosphorylated 
on T14 and Y15, and these sites need to be dephosphorylated in order for CDK1 and 
CDK2 to be active and further progress through the cell cycle. Dephosphorylation is 
carried out by the phosphatase CDC25 [23, 35].  
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1.3.1 CDKs and their cyclin-binding partners 
CDK1 and CDK2 can both bind to CCNA, CCNE and CCNB [36, 37]. In early G1, 
CDK4/6 in complex with CCND (cyclin D) will increase phosphorylation of 
retinoblastoma protein (PRB1). CDK2/CCNE completes phosphorylation of PRB1 
which releases the transcription factor E2F. E2F then controls the expression of 
different genes necessary for the progression through S [24, 37, 38]. G1/S transition 
also involves CDK1/CCNE and CDK2/CCNE. Kaldis et al. [37] demonstrated that 
CDK1 can substitute for CDK2 in this transition. It has been shown that CDK2-/- mice 
were viable, but both male and female were sterile due to meiotic defects [36, 37, 39]. 
DNA replication is controlled by the CDK2/CCNA and CDK1/CCNA, which also 
allow the cells to proceed to G2 [24, 37]. Levels of CCNB accumulate in the 
cytoplasm during S and G2, and are in complex with CDK1 and CDK2 in G2, but 
CDK1/CCNB activity is still low [23, 37]. At the onset of mitosis, CDC25 activity 
increases, thereby increasing dephosphorylation of T14/Y15 for both CDK1 and 
CDK2. At the same time, CCNB levels rise and T161 phosphorylatio increases, 
leading to an upsurge and peak in CDK1 activity at M [23]. The CDK1/CCNB 
complex is required for the G2/M transition [15], and the complex enters the nucleus 
at the beginning of mitosis [40, 41]. During mitosis, CDK1/CCNB forms the active 
mitosis promoting factor (MPF) [22]. Inactivation of CDK1 and exit from mitosis 
require the ubiquitin-dependent proteolysis of CCNB. Ubiquitination of CCNB is 
mediated by the anaphase-promoting complex (APC) [15, 42, 43]. Although CDK2 
also binds to CCNB, the functional significance of the complex is unclear, and CDK2 
cannot compensate for the loss of CDK1 [36, 37]. CDK2 activity peaks in G1/S, and 
although CDK1 activity is much lower here than in G2/M, it seems possible that 
CDK1 activity in this transition approximately equals maximum CDK2 activity [36].  
 
1.3.2 CDKs as targets in cancer therapy 
Deregulation of CDKs mediates cell cycle defects such as unscheduled proliferation, 
genomic instability and chromosomal instability. These cell cycle defects contribute 
to tumor progression and acquisition of more aggressive phenotypes. Because of the 
CDKs essential role in driving the cell cycle progression, selective CDK inhibition 
has been proposed as a therapeutic strategy [44]. A search for CDK inhibitors in the 
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registry of clinical trials conducted in the Unites States and around the world, yields 
28 matches, of which 21 trials are active (may be recruiting volunteers or not), five 
trials were completed and two trials were terminated [45]. Although the first-
generation CDK inhibitors only showed modest activity in the clinic, several second-
generation CDK inhibitors are now in clinical trials. However, the effect of such 
inhibitors are still uncertain, and therefore, development of new targets are needed.  
 
 
1.4 The role of CKS2 
The CKS proteins are essential components of the mitotic CDKs, but their precise 
function has remained unclear. Martinsson-Ahlzén et al. [8] showed in a study that 
deleting both the CKS1 and CKS2 genes in mice, leads to embryonic lethality. It has 
also been reported that CKS2 is essential for the first metaphase/anaphase transition 
of mammalian meiosis. CKS2-/- animals were viable but sterile, due to an arrest of the 
germ cells at metaphase I of meiosis [46]. Although not essential for viability, it has 
been shown that CKS proteins are required for optimal preanaphase ubiquitylation 
and degradation of cyclin A in mammalian cells [47]. Another possibility is that 
CKS2 targets CDK/cyclin complexes to phosphoproteins [48]. A targeting function 
has also been proposed in other studies, and that CKS proteins govern the interactions 
of CDK1/CCNB with both positive and negative regulators [15, 49, 50]. Targets 
proposed by Pines [17] are CDC25 in G2, and the proteolysis machinery in mitosis 
which inactivates CDK1/CCNB. After determining the atomic structure of CKS2, 
Parge et al. [51] proposed that the role of hexameric CKS2 was to serve as a hub for 
assembling kinase molecules. John et al. [27] reported that CKS proteins binds to 
CDC25 just prior to mitosis, and participates in a positive feedback loop in which 
CDC25 activates CDK1 as described previously. Activated CDK1 then activates 
CDC25 by multiple phosphorylations. 
 
1.4.1 CKS2 and interactions with CDKs 
CKS proteins are assumed to play a direct role in cell regulation because of 
association with CDKs [8]. In humans there are two homologues, CKS1 and CKS2 
[52], and their sequences are 81 % identical [53]. The CKS proteins consist of a four-
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stranded β-sheet capped at one end by two α-helices. Crystal structure of CKS2 
suggests monomer, dimer and hexamer forms for the proteins. The hexamer is formed 
by three interlocked dimers [18, 51, 53]. A β-hinge in CKS, containing the residues 
histidine-any-proline-glutamic acid-proline-histidine, can fold back on itself forming 
a monomer. When the β-hinge is extended, the proteins form a dimer. Molecular 
modelling predicts that dimerized CKS proteins would not be able to bind to CDKs 
because residues important for binding would not be able to contact the CDK. A 
possibility is thus that there is equilibrium in the cell between monomer and dimer 
forms, where only monomers can bind to CDKs [17]. Watson et al. [18] investigated 
a mutated CKS2, with replacement of glutamine 63 for glutamate (E63Q). The 
binding to CDKs was drastically impared for mutated CKS2, suggesting that 
glutamine 63 in CKS2 might be directly involved in interaction with CDKs [18]. 
Crystal structure of the CDK2/CKS1 complex revealed that CKS1 interaction with 
CDK2 involved binding of all four β-strands to the C-terminal lobe of CDK2. This 
binding site is far from the N-terminal lobe, cyclin, and regulatory phosphorylations 
sites of CDK2 [49].  
 
Studies have shown that CKS2 interacts with the CDK1/CCNB complex [8, 14, 15, 
17]. Egan and Solomon [15] demonstrated that CKS2 exhibited cyclin-stimulated 
binding to CDK1. The study indicated that the presence of cyclins increased CKS 
binding to CDK1, but it did not exclude a weak interaction of CKS proteins to 
monomeric CDKs. Also, they showed that phosphorylation of T161 stimulated 
binding of CKS2 to CDK1. The phosphorylated, cyclin-bound CDK complex is 
preferentially associated with CKS proteins [15]. The CDK1/CCNB/CKS2 complex is 
shown in figure 1.4. Interactions of CKS2 to CDK2 have also been shown in several 
studies [15, 16, 18].  
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Figure 1.4: Binding of CKS2 to CDK1/CCNB. CKS2 is interacting with the 
phosphorylated, CCNB-bound CDK1 complex.   
 
1.4.2 CKS2 and cancer 
Although the functions of CKS proteins have remained elusive, tumor profiling has 
revealed that both CKS proteins are frequently overexpressed in a variety of human 
malignancies. One study identified gene expressions associated with metastatic 
phenotypes of locally advanced cervical carcinomas. CKS2 was identified as one of 
the genes, and was upregulated in node positive compared to node negative tumors. 
High expression of CKS2 was associated with poor survival [11]. Van’t Veer and co-
workers [13] used gene expression profiling to predict clinical outcome of breast 
cancer, and CKS2 was identified as one of the genes significantly upregulated in the 
poor prognosis signature. Overexpression of CKS2 has also been reported to be 
associated with high aggressiveness and a poor prognosis in various other 
malignancies, including prostate, gastric and hepatocellular carcinomas [9, 10, 12]. 
Based on this knowledge, it would be of interest to investigate CKS2 activity. By 
targeting interactions of CKS2 with CDKs, a new concept for inhibiting cell 
proliferation is proposed. This project assesses the interaction between CKS2 and 
CDKs by establishing the use of Y2H, and is a step towards the development of 
targeted therapeutics.   
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2 Methodical background  
2.1 Yeast two-hybrid (Y2H) 
In 1989, Ok-kyo Song and Stanley Fields created the Y2H system, which is a simple 
robust assay for monitoring protein-protein interactions (PPIs). Before the Y2H 
method, mammalian PPIs were generally studied by using techniques such as 
crosslinking, co-immunoprecipitation, and co-fractionation by chromatography [54, 
55]. Today, Y2H is widely used to determine PPIs [2], and Xenarios et al. [56] reports 
that the majority of interactions in the Database of Interacting Proteins (DIP) have 
been detected by the Y2H method. They also hypothesize that many PPIs are first 
observed in Y2H, and then later confirmed by other methods like co-
immunoprecipitation.  
 
The Y2H system takes advantage of the galactose-gene activating transcription factor 
(GAL4) of the yeast Saccharomyces cerevisiae. GAL4 is required for the expression 
of genes encoding enzymes of galactose utilization. The protein consists of two 
separable domains; an N-terminal domain (amino acids 1-147), and a C-terminal 
domain (amino acids 768-881) [54]. The N-terminal domain binds to upstream 
activating sequences (UAS) that are specific DNA sequences, thereby termed DNA-
binding domain (BD or DBD). The C-terminal domain is necessary for activation of 
transcription, and is termed activating domain (AD).  Fields and Song [54] generated 
a system of two hybrid proteins containing parts of the GAL4 protein. The GAL4 BD 
was fused to a protein ‘X’, and the AD of GAL4 was fused to a protein ‘Y’. The X 
and Y proteins are also termed ‘bait’ and ‘prey’ respectively (figure 2.1 A and B) [2]. 
If X and Y interact, the GAL4 domain gets reconstituted resulting in activation of a 
reporter gene (figure 2.1 C) [3, 54]. The output of the reporter gene can be measured, 
for example as growth of yeast clones on selective medium or by a color signal [2, 3].  
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Figure 2.1: The principle of Y2H [3]. A: A protein to be investigated (bait) is fused to the 
DNA-binding domain (DBD) of GAL4. B: the other protein to be investigated (prey) is fused 
to the activating domain (AD) of GAL4. When expressed in isolation, neither the bait nor the 
prey is able to activate the reporter gene since each fusion protein lacks a domain that is 
necessary for proper transcriptional activation. C: GAL4 is reconstituted because of 
interacting proteins, and the reporter gene is activated. Output of the reporter gene is used to 
detect the PPI. Common ways of measuring output is by growth or a color marker. 
 
 
The Y2H technique involves construction of the fusion plasmids and use of different 
molecular biological methods. In constructing the fusion plasmids, the proteins of 
interest must be cloned into yeast expression vectors. Firstly, templates and primers 
for polymerase chain reaction (PCR) are prepared. PCR is performed to amplify the 
cDNAs of the fragments to be investigated. Appropriate plasmid constructs are 
transformed into bacteria in order to produce many replicates of the plasmids. 
Verified plasmid constructs are co-transformed into a yeast strain. Finally, a two-
hybrid analysis is set up to score for PPIs. The different methods will be described 
below, and an overview is given in figure 2.2.  
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Figure 2.2: An overview of the biological methods included in the Y2H technique. 
Templates are constructed and primers are designed in order to amplify the cDNA 
(fragments) of the proteins of interest by PCR. Plasmids and fragments are prepared and 
ligated together. These constructs are transformed in bacteria cells in order to get high copy 
replications of the plasmid constructs. The plasmids are screened for inserts and sequenced in 
order to verify the constructs. Different combinations of constructs are transformed in yeast 
cells, and the assay for scoring PPI is performed.  
 
2.1.1 Applications of Y2H system in drug discovery and development 
In recent years, the Y2H technique has seen extensive modifications. The system was 
originally invented to identify interactions between two defined proteins, but has been 
adjusted and can now be used for screening. By replacing the prey protein with cDNA 
or genomic libraries, interactions can be screened against the libraries and yield a set 
of proteins interacting with the bait protein. This technique can be used to discover 
novel interacting proteins, and structures that bind the bait with high affinity may 
represent important clinical targets [3]. 
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One adaptation, ‘reverse’ Y2H (rY2H), uses a Y2H setup to screen for small 
molecule-protein interaction instead of PPIs. Targets can be detected from such a 
screen with the clinical purpose of blocking PPIs by using small molecules [3]. This 
system is designed so that the interaction of two proteins activates a reporter gene 
whose product is toxic to growing cells. By screening for small molecules that block 
the PPI, activation of the toxic gene is prevented and the output is measured by 
growth. One version of this screen is to incorporate the URA3 gene in the yeast 
genome which encodes the enzyme orotidine-5-phosphate decarboxylase. This 
enzyme is involved in uracil biosynthesis, and catalyzes the transformation of pro-
toxin 5-fluoroorotic acid (5-FOA) into a toxic compound causing cell death. Yeast 
cells will not grow on medium containing 5-FOA if PPI occur, since the enzyme 
encoded by URA3 then will be transcribed. On the other hand, if a test compound is 
able to block PPI, GAL4 will not be reconstituted, allowing growth of yeast cells on 
medium containing 5-FOA [3, 4].  
 
2.1.2. Limitations of the Y2H system 
Frequent occurrence of false positives and false negatives can be a serious challenge, 
especially to large-scale Y2H [2, 3]. False positives are spurious interactions (no 
biological significance) detected in the screening in yeast which are not reproducible 
in another assay [1, 3]. In order to increase the stringency, more than one reporter 
gene can be used in parallel. This requires a more solid transcriptional activation and 
can therefore at the same time penalize detections of weak interactions. Major sources 
for false positives are non-relevant PPIs forced by the overexpression of heterologous 
proteins and self-activation of the reporter gene by the bait protein [2, 3]. Auto 
activation can be avoided by partially inhibiting the enzymatic activity encoded by the 
reporter gene. For example, imidazole glycerol phosphate dehydrase (the product of 
HIS3 reporter), is competitively inhibited by increasing concentrations of 3-
aminotriazole (3-AT) [1].  
 
False negatives are occurring PPIs that are undetectable in the Y2H system. 
Membrane proteins are mostly undetectable, so in working with such proteins, 
variants of the classical Y2H should be used. Bait or prey protein can sterically hinder 
the interaction, thereby producing false negatives. Other sources are proteins 
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depending on post-translational modifications. The modifying enzyme can be 
different or lacking in yeast when analyzing PPIs of higher eukaryotes. Coexpression 
of the modifying enzyme in yeast together with bait and prey can solve this. Improper 
folding of the fusion proteins, and very transient PPIs, may escape detection, and are 
also sources of false negatives [2, 3].  
 
Another limitation of the Y2H system is the requirement that the bait and prey must 
be able to enter the nucleus of the yeast cell to activate transcription. Also, the system 
is not suited for analysis of interaction with bait proteins that are potent activators 
themselves. Such transactive proteins would trigger transcription in absence of any 
interaction with a prey [1, 54]. 
 
 
2.2 Cloning 
Cloning refers to the process of making many identical copies of a DNA molecule. 
Cloning also describes the process of isolating a DNA fragment from the rest of the 
cell’s DNA because the process involves making many identical copies of the 
fragment of interest [26]. Further process involves making recombinant DNA by 
using plasmid DNA, restriction enzymes, ligation mixture and transformation into an 
appropriate bacterial strain, usually an Escherichia coli strain. Recombinant DNA is 
produced when two or more DNA fragments from different sources are joined 
together [25]. The transformants are screened to identify those that carry the desired 
fragment. Different screens can be used, for example hybridization, PCR or digestion 
with restriction enzymes [57].  
 
2.2.1 Polymerase chain reaction (PCR) 
PCR was invented in the 1980’s, and can be carried out entirely in vitro without using 
cells. The technique is rapid and effective in producing large amounts of the gene of 
interest. PCR is extremely sensitive, and the process is able to detect a single copy of 
a DNA sequence in a sample. The sequence is then amplified so many times that it 
can be detected by for example staining after separation by gel electrophoresis. Input 
template for PCR can be DNA or RNA, so PCR can be used to obtain either a full 
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genomic copy or a cDNA copy of the gene. There are several useful applications of 
PCR, for example for cloning short DNA fragments (below 10 000 nucleotide pairs) 
from a cell. [26].  
 
PCR is performed in a thermal cycler, and the process consists of three steps. The first 
step is denaturation, where heat is added in order to separate the strands of double-
stranded DNA. Typical temperature is about 93-95 °C. The process is followed by 
cooling where a forward and reverse primer is hybridized to complimentary 
sequences in each of the two strands. This is the second step, and is termed annealing. 
The temperature is often about 5 °C below the calculated Tm (melting temperature of 
the primer). In the third step, the polymerase starts synthesizing DNA by adding 
deoxyribonucleotide triphosphates (dNTPs). A standard mixture of dNTPs contains 
equimolar amounts of deoxyriboadenosine triphosphate (dATP), deoxyribocytidine 
triphosphate (dCTP), deoxyriboguanosine triphosphate (dGTP), and 
deoxyribothymidine triphosphate (dTTP) [58]. DNA synthesis is typically carried out 
at 70-75 °C. In the first cycle of the PCR process, two double-stranded DNA 
molecules are produced. The second cycle then starts with heat treatment, repeating 
the three steps from the first cycle, now producing four double-stranded DNA 
molecules. The third cycle produces eight double-stranded DNA molecules and so 
doubles the amount of DNA from each previous cycle. Usually, 20-30 cycles are 
required for useful DNA amplification. The newly synthesized strands serve as 
templates for the next cycle [26, 59]. DNA polymerases for PCR in current use have 
been isolated from thermophilic bacteria, and will therefore not denature at high 
temperatures. The polymerase can therefore be used again in all cycles. Many 
different polymerases are commercially available, and for routine PCR, the Taq 
polymerase is often used. Several of these polymerases will add a single, unpaired 
nucleotide at the 3’ ends of the amplified DNA fragments, thereby creating a cohesive 
end [58]. A cohesive end can leave the 5’ end and/or 3’ end with short single-stranded 
tails [25]. 
 
Preparing PCR-template by synthesizing cDNA from RNA. cDNA differs from DNA 
in that sense that is does not contain genomic DNA (chromosomal DNA), but instead 
the DNA is copied from the mRNA present in that cell culture sample. The enzyme, 
reverse transcriptase, makes DNA copies of the mRNA molecules. A very important 
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advantage of cDNA clones is that they contain the uninterrupted coding sequence of 
the gene of interest, which is crucial when the aim is to express the cloned gene in 
bacterial or yeast cells. Neither bacteria nor yeast cells are able to remove introns 
from mammalian RNA transcripts. The first step is hybridization of a short 
oligonucleotide complementary to the poly-A tail of the 3’ end of the mRNA. This 
functions as a primer for the reverse transcriptase, which in the second step makes 
DNA copies complementary to the RNA. The helix is now made up of one DNA 
strand and one RNA strand. In the final step, the enzyme RNase H will then degrade 
the RNA strand, and so the single stranded cDNA can be copied into double stranded 
cDNA by DNA polymerase [26].  
 
Primers and primerdesign. A primer is a short oligonucleotide, which base-pairs 
specifically to a target sequence to allow a polymerase to initiate synthesis of a 
complimentary strand [59]. When designing primers, several aspects must be taken 
into consideration. For optimal effect, the GC-content should be between 40 % and 60 
%, the primer length 20-30 nucleotides long, and the 3’ end should be a G or a C. [58, 
60]. Also, the calculated Tm should not differ between the forward and reverse primers 
by more than 5 °C. Primer dimers can form if the 3’ terminal sequence of one primer 
can bind to any site on the other primer, and will compete for DNA polymerase, 
primers, and nucleotides. This will greatly affect the amplification yield, and should 
therefore be avoided.  
 
2.2.2 Plasmids  
Plasmids are extrachromosomal elements of DNA, mostly double stranded, circular 
molecules that can be isolated from bacterial cells in their natural, supercoiled form. 
They contain a replication origo and can therefore replicate independently of their 
host’s chromosome [26]. Plasmids often contain genes that are advantageous to the 
host, for example genes encoding production of enterotoxins and antibiotics resistance 
(for resistance to example kanamycins, ampicillin, and tetracyclins). The genes that 
provide resistance to antibiotics can also be used as selective markers. DNA 
introduced to bacteria is often incorporated into the bacterial genome, and this can 
happen naturally by the bacteria taking up DNA molecules from its surroundings. It is 
usually though, easier to manipulate, copy and purify the recombinant DNA when it is 
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maintained in a vector, separate from the bacterial chromosome [26, 57]. A plasmid 
vector is therefore used to carry a fragment of DNA and then transformed into a 
recipient cell for the purpose of gene cloning. The development of plasmids from the 
early 1970’s to present has been through many different phases. Plasmid vectors in 
current use are small, they replicate fast, and contain one or more selective markers 
and a multiple cloning site (MCS). The MCS consists of a bank of sequences 
recognized by restriction enzymes (described below) [57].  
 
Yeast expression vectors. pGBKT7 BD and pGADT7 AD (figure 2.3, A and B 
respectively) are yeast expression vectors from Clontech. The vectors are designed to 
express a protein of interest fused to the GAL4 binding domain and activating domain 
respectively. The constitutive promoter ADH1 drives the expression of the fusion 
proteins [61, 62]. Both vectors replicates autonomously in E. coli from the pUC ori, 
and in S. cerevisiae from the 2 µ ori.  
 
 
A B
 
Figure 2.3: The yeast expression vectors pGBKT7 (A) and pGADT7 (B) [61, 62]. 
pGBKT7 can express a fragment of interest fused to amino acids 1-147 of the GAL4 binding 
domain (GAL4 DNA-BD). pGADT7 can express a fragment of interest fused to amino acids 
768-881 of the GAL4 activating domain (GAL4 AD). 
 
pGBKT7 contains a kanamycin resistance gene which enables selection in E. coli, and 
a TRP1 nutritional marker for selection in yeast. pGADT7 contains an ampicillin 
resistance gene enabling selection in E .coli, and a LEU2 nutritional marker for 
selection in yeast. Both vectors are equipped with a MCS containing several unique 
cutting sites for different restriction enzymes [61, 62].  
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Restriction endonucleases. Restriction endonucleases are enzymes that have been 
purified from many different bacteria species, and they cleave double stranded DNA 
at specific nucleotide sequences. An enzyme will always cut a given DNA molecule 
at the same site, and for the most, different enzymes each have their unique cutting 
site [26]. A few nucleotides, not complementary to the target DNA should be added to 
the 5’ end of the primers, to improve the efficiency of cleavage of restriction enzymes 
[58]. Bacteria use their restriction endonucleases as protection from viral and other 
foreign DNA, but are themselves protected by methylation in the genome at an A or a 
C residue. DNA fragments with cohesive ends are the easiest to clone. These 
protruding ends can very easily be created by digesting both vector and fragment with 
a restriction enzyme that cut asymmetrically within the recognition site. By using two 
restriction enzymes with different recognition sites, the recombinant yield will 
increase and this is known as forced ligation or directional cloning [25, 57]. When 
selecting which restriction enzymes to use, possible enzymes are checked for whether 
they cleave within the sequence of the fragments of interest or not. This can be carried 
out by the use of different programs available on the internet. When protruding ends 
are complimentary, the fragment is easily ligated with the plasmid.  
 
Under non-standard conditions, some enzymes can alter specificity and cleave 
sequences that are similar but not identical to their defined cutting site, and this is 
known as star activity. Some examples of non-standard conditions are too high 
glycerol concentration (> 5 % v/v) or use of non-optimal buffer. High fidelity (HF) 
enzymes bind tighter to the DNA. Sodium dodecyl sulfate (SDS) must therefore be 
added to disrupt binding before gel electrophoresis is conducted [63]. Digested 
fragments and vectors must be purified either by gel electrophoresis, or by the use of 
commercial kits [64]. Both purifying methods were used in this project.  
 
Gel electrophoresis. The purpose of gel electrophoresis is to separate, identify and 
purify DNA fragments of different lengths. The gel, a matrix usually made from 
agarose or polyacrylamide, contains a microscopic network of pores. Polyacrylamide 
gels are more effective for separating small fragments of DNA, and the resolving 
power is very high. Agarose is a linear polymer composed of alternating residues of 
D- and L-galactose. In chains, they form helical fibers that aggregate into supercoiled 
structures. Agarose gels have a lower resolving power, but greater range of 
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separation. The gel is placed in a buffer-filled tank. Different buffers are available, for 
example Tris-acetate and EDTA (ethylenediaminetetraacetic acid) (TAE), and Tris-
borate and EDTA (TBE). Both works well but with slightly different characteristics, 
and the choice of buffer is largely a matter of personal preference [57].  
 
Before samples are loaded in the wells, they are mixed with gel-loading buffers. 
These buffers increase the density of the sample so the DNA sinks evenly into the 
well, they color the sample so they can easily be loaded and will migrate with the 
sample through the gel. The samples are then loaded in wells on the negatively 
charged end, and voltage is applied producing an electric field. DNA is negatively 
charged and will migrate towards the positively charged end of the gel. A size 
standard (ladders of different sizes are commercially available) is also loaded to easily 
identify the fragment of interest. Larger fragments move at slower speed than smaller 
fragments, because they are more impeded by the matrix. Other factors will also 
determine the rate of migration, for example the concentration of agarose, the 
conformation of the DNA, and the applied voltage. After some time, the fragments are 
spread out across the gel forming a ladder, where each band contains DNA of equal 
length. The bands are invisible, so the gel is stained, for example with dye that 
fluoresces when exposed to ultraviolet light [26, 57].  
 
2.2.3 Transformation 
Eukaryotes and prokaryotes pass on genes to the next generation by vertical gene 
transfer. Many prokaryotes can also acquire genes from other microbes – horizontal 
gene transfer [65]. Transformation is one type of horizontal transfer, and is a process 
where cells take up DNA molecules from the surroundings and express the genes on 
that DNA. These cells are said to be competent, which means there has been an 
alteration in the cell wall and cytoplasmic membrane that allow DNA to enter the cell. 
Bacteria can also be made competent artificially, and this was the first method 
developed for transferring genetic elements. It has become an important tool in 
recombinant DNA technology, since competent cells take up DNA from any donor 
genome. Other methods of horizontal gene transfer are conjugation (DNA is 
transferred from one cell to another via cell-cell contact) and transduction (transfer of 
DNA by viral infection) [65, 66].  
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Subcloning. PCR products of the fragments of interest may not be directly cloned into 
the appropriate vector. The pGEM®-T Easy Vector System (Promega), is a system 
that makes the cloning of PCR products more convenient. The vector is cut with the 
restriction enzyme EcoRV, which adds single 3’-terminal thymidine (T) overhangs at 
both ends of the insertion site. By A-tailing the blunt-ended fragments to be inserted, 
the efficiency of ligation will greatly improve [67]. The MCS of pGEM-T Easy lies 
within the coding region of β-galactosidase (lacZ). Expression of lacZ is induced by 
the synthetic compound isopropyl- β-D-galactosidase (IPTG). 5-bromo-4-chloro-3-
indolyl-β-D-galactoside (Xgal) is a histochemical indicator. It is cleaved by β-
galactosidase to yield the deep blue dye 5-bromo-4-chloro-indigo, and this can be 
used for identification by color screening on indicator plates. When an insert is cloned 
into the vector, the coding sequence of β-galactosidase is interrupted. This will, in 
most cases, produce white colonies. If the vector is without insert, β-galactosidase 
will be expressed, Xgal will be cleaved, and blue colonies are formed [66].  
 
The vector also contains an ampicillin resistance gene, and multiple restriction sites 
within the MCS. To release the insert from the vector, double digestion can be used or 
single digestion with EcoRI, BstZI or NotI. The MCS is flanked by these three 
recognition sites, and also by the RNA polymerases T7 and SP6. Inserts can be 
sequenced using the SP6 and T7 Promoter Primers (both Promega) (described in 
appendix 14) [67]. pGEM®-T Easy Vector map is shown in appendix 1.   
 
 
2.3 Detection of PPI 
2.3.1 Transformation in S. cerevisiae AH 109 cells 
The S. cerevisiae strain AH109 (Clontech) is designed for detecting protein 
interactions during a two-hybrid screen. Strain AH109 carries mutations in four 
genes, and is not able to synthesize adenine (ade), histidine (his), leucine (leu), and 
tryptophan (trp). AH109 must therefore be grown on medium containing these 
auxotrophic markers. The strain is gal4-, and contains the four distinct reporter 
constructs ADE2, HIS3, lacZ, and MEL1, that are only expressed if PPI occur in the 
GAL4-based hybrid system. ADE2 encodes an enzyme in the biosynthesis of adenine, 
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and expression of the gene will give growth on medium lacking adenine. HIS3 
encodes an enzyme in the biosynthesis of histidine, and expression of the gene will 
give growth on medium lacking histidine. LacZ and MEL1 encodes β-galactosidase 
and α- galactosidase respectively, and expression of the genes can both be monitored 
with a color screen [64].  
 
2.3.2 The S. cerevisiae two-hybrid test 
The S. cerevisiae two-hybrid test is an assay that can be used to score PPIs. The test is 
carried out by transforming AH109 cells with the plasmid constructs of interest. 
Aliquots of the cells containing the plasmid constructs to be investigated, are spread 
onto selective plates, and then incubated at appropriate conditions. PPI is monitored 
by growth when media lacking adenine or media lacking histidine is used.   
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3 Methods 
3.1 Amplification of fragments by PCR 
PCR was used to amplify cDNA of CKS2, CDK1 and CDK2. Before PCR could be 
carried out input templates had to be constructed, and primers had to be designed and 
ordered.  
 
3.1.1 Preparation of templates 
In order to have the correct template for CKS2, cDNA was synthesized from RNA by 
using the Illumina® TotalPrep RNA Amplification Kit (Ambion). The control RNA, 
consisting of 1 mg/ml HeLa cell total RNA, from the kit was used as input. All 
procedures were carried out according to the producer’s protocol (appendix 2).  
 
For CDK1 and CDK2, the gene sequences were already present in vectors and these 
plasmids could be used directly as templates. CDK1 was fused in the vector pCMV-
HA, a gift from R. Syljuåsen (Department of Radiation Biology, the Norwegian 
Radium Hospital), and CDK2 was present in the vector pSM, a gift from Professor D. 
Morgan (Department of Physiology, University of California, San Francisco, USA). 
The templates used for CDK1 and CDK2 contained two substitutions: amino acid 14 
was changed from threonine to alanine, and amino acid 15 was changed from tyrosine 
to phenylalanine. The templates will from now on be referred to as CDK1AF and 
CDK2AF. For CDK2, a templat containing mutation in the gene sequence only in 
amino acid 15 (changing tyrosine to phenylalanine) was also tested (gift from R. 
Syljuåsen). This template, also fused in a pCMV-HA vector, will from now on be 
referred to as CDK2F. The vectors are described in appendix 14.  
 
3.1.2 Primer and layout for PCR 
Six primers were designed; one forward (F) and one reverse (Rev) for each of CKS2, 
CDK1 and CDK2. Primers were purchased from Eurogentec S.A. (Belgium). Forward 
and reverse primers contain an NdeI (upstream) and BamHI (downstream) restriction 
digestion site respectively, to facilitate their subsequent cloning into pGBKT7 and 
pGADT7. The primers that were designed are listed in table 3.1. The length of the 
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primers does not go beyond the mutations in the gene-sequences, so the same primers 
were used for both CDK2AF and CDK2F.  
 
Table 3.1: Primers designed for use in PCR amplification of cDNA for CKS2, CDK1AF, 
CDK2AF and CDK2F. 
Gene Primer sequence 
CKS2 F 
 
CKS2 Rev 
5’-GGAATTCATATGGCCCACAAGCAGATCTACTAC-3’ 
 
5’-GGAATTGGATCCTCATTTTTGTTGATCTTTTGGAAGAGG-3’ 
CDK1 F 
 
CDK1 Rev 
5’-GGAATTCATATGGAAGATTATACCAAAATAGAGAAAATTGG-3’ 
 
5’-GGAATTGGATCCCTACATCTTCTTAATCTGATTG-3’ 
CDK2 F 
 
CDK2 Rev 
5’-GGAATTCATATGGAGAACTTCCAAAAGGTGG-3’ 
 
5’-GGAATTGGATCCTCAGAGTCGAAGATGG-3’ 
The underlined nucleotides represent start and end of the sequence encoding the gene, and 
bold nucleotides represent the cutting sites recognized by NdeI and BamHI in forward and 
reverse primers, respectively. 
 
The nucleotides in bold, represent the cutting sites of NdeI and BamHI. Underlined 
nucleotides mark the start and end of the coding sequence for the genes. The forward 
primer will attach to the template strand at the 5’ end, and the reverse primer will 
attach to the complimentary strand at the 5’ end. In this position, the primer’s 3’ ends 
will point to each other. The forward primer, corresponding to the sequences 
upstream, and the reverse primer, corresponding to the sequences downstream from 
the region to be amplified, flanks the target DNA [68].  
 
Tm and GC-content were calculated by using the program OligoCalc (version 3.26) 
[69]. The gene-sequences were obtained from internet resources of the National 
Center for Biotechnology Information (NCBI) [70]. Primer lengths were between 16 
and 29 nucleotides (complimentary to the coding sequence), and all 3’ends were a G 
or a C. The GC content varied from 29-50 % for the six primers. Variation in Tm 
between forward and reverse primers did not exceed 1 °C. Tm for the CKS2 primers 
was a few degrees higher than Tms for the CDK1 and CDK2 primers. Because of 
equal value of Tm for CDK1- and CDK2 primers, PCR could be executed for both 
fragments with the same program. PCR for the CKS2 fragment was executed under 
different conditions. Reaction mixtures and cycling conditions are described in 
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appendix 3. The PfuUltra™ II Fusion HS DNA polymerase (Stratagene) was used. 
This polymerase minimizes potential misincorporations, and generates blunt-ended 
products [71]. By adding restriction sites to the 5’ terminal of the primers, cohesive 
ends can be generated later by cutting the PCR-products with restriction enzymes 
[58]. To facilitate restriction enzyme cleavage, all primers were extended at the 5’ end 
with the same randomly chosen sequence GGAATT.  
 
 
3.2 Preparing plasmids 
DH5α/pGADT7 and DH5α/pGBKT7 (provided by Ingvild Flåtten) were cultivated 
over night in liquid Luria-Broth (LB) medium (appendix 4), and with appropriate 
antibiotics as described in appendix 5. In order to retrieve the purified plasmids, 
overnight cultures were prepared the next day by using the kit JETSTAR (Genomed), 
as described in the producer’s protocol (appendix 6). The concentrations were 
measured by the use of Nanodrop, and the purified plasmids were cut with two 
restriction enzymes simultaneously (double digestion).  
 
3.2.1 Restriction endonucleases 
NdeI and BamHI (New England Biolabs) were selected as restriction endonucleases 
because both plasmids contain their restriction sites [61, 62]. To be sure that the 
restriction enzymes did not cut within the fragments of interest, the program 
Webcutter 2.0 [72] was used (appendix 7). In the latest experiments, BamHI was 
changed to BamHI-HF™,, which has the same specificity but reduced star activity.  
 
NdeI was originally isolated from Neisseria denitrificans and its recognition site is 
shown in figure 3.1.  
 
Figure 3.1: Recognition site NdeI [63]. 
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BamHI was originally isolated from Bacillus amyloliquefaciens. The recognition site 
of both BamHI and BamHI-HF™ is shown in figure 3.2.  
 
Figure 3.2: Recognition site BamHI and BamHI-HF™ [63]. 
 
Two restrictions enzymes can have different activity in the same buffer. The New 
England Biolabs internet resource [63], provides a tool (Double Digest Finder) that 
can be used to find the optimal reaction conditions for digestion. The tool will state 
the recommended buffer, and if bovine serum albumin (BSA) is required or not. Since 
NdeI only has 75 % activity compared to BamHI in the recommended buffer, NdeI 
needs more incubation time. NdeI and BamHI-HF on the other hand, have the same 
activity in the recommended buffer and can be added at the same time. Reaction 
conditions for double digestion with BamHI and NdeI, and BamHI-HF and NdeI are 
described in appendix 8.   
 
3.3 Analysis of products  
Gel electrophoresis was used to separate DNA fragments amplified by PCR and after 
digestion of plasmids, and to check for inserts after transformation in E. coli (3.5). In 
the first experiments, 0.5 x TBE buffer (appendix 4) was used and the gel was stained 
with ethidium bromide (Merck). This was later changed to 1 x TAE buffer (appendix 
4), and staining with GelRed (Biotium). After electrophoresis, the gel was immersed 
in the stain, examined by UV-light, and photographed by using ChemiGenius Bio 
Imaging System (VWR). GeneSnap (Syngene) was used as image-editing program. 
Gel electrophoresis and staining was carried out as described in appendix 9. 
 
In order to retrieve the PCR-products and digested plasmids, the bands of interest 
were cut out from the gel by using a scalpel. The gel pieces were then rinsed by using 
the kit Wizard® SV Gel and PCR Clean-Up System (Promega) as described in the 
producer’s protocol (appendix 10). The kit consists of reaction mixtures and 
disposable chromatography columns that absorb the DNA, and can after washing be 
eluted out. 
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Digested fragments were not rinsed by gel electrophoresis, but purified by using the 
kit QIAquick PCR Purification (QIAgen) as described in the producer’s protocol 
(appendix 11).  
 
 
3.4 Transformation 
CKS2 and CDK1AF could not be cloned directly into pGADT7 and pGBKT7, and 
was therefore subcloned as described in 3.4.1. The cloning of CDK2AF and CDK2F 
into pGADT7 and pGBKT7 could be done without subcloning.  
 
XL 10-Gold® Ultracompetent Cells (Stratagene) were used for transformation. These 
cells are tetracycline and chloramphenicol resistant [71]. Ligation mixtures were set 
up and the competent cells were transformed with the ligation mixtures. The 
procedures are described in appendix 12. The transformation mixtures were plated on 
solid LB plates containing the appropriate antibiotics (appendix 4), and incubated at 
37 °C overnight. Representative transformants were cultured over night in liquid LB 
medium with appropriate antibiotics. The next day, purified plasmids were prepared 
by using the kit Wizard Plus SV Minipreps DNA Purification System (Promega) as 
described in the producer’s protocol (appendix 13). To verify that cloning of 
fragments in respective plasmids was successful, purified plasmids were digested, and 
gel electrophoresis was performed (appendix 9). Gel profiles were analyzed, and 
appropriate clones were subjected to DNA sequence analysis at GATC Biotech 
(Germany). The clones subjected to DNA sequence analysis were cultured again 
overnight in liquid LB medium with appropriate antibiotics. Aliquots (1 ml) of each 
overnight bacterial culture were mixed with 300 µl of 87 % glycerol (Merck) and 
stored in Cryo tubes at -80 °C.  
 
3.4.1 pGEM®-T Easy Vector System  
The pGEM®-T Easy Vector System (Promega) was used for subcloning of the 
fragments CKS2 and CDK1AF. Before transformation, the blunt-ended fragments 
from PCR amplification had to be modified. By A-tailing the fragments, only one 
insert will be ligated into the vector as opposed to multiple insertions that can occur 
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with blunt-ended cloning [67]. Ligation mixtures were set up and transformed into 
JM109 High Efficiency Competent Cells (Promega). Indicator LB plates were 
prepared with ampicillin, IPTG and X-gal. The transformation mixtures were then 
plated and incubated at 37 °C overnight. All procedures were carried out by following 
the protocol in the technical manual provided by Promega. The protocol, reaction 
mixtures, and preparation of solutions and plates are described in appendix 1. 
Representative transformants were cultured overnight in liquid LB medium with 
ampicillin to a final concentration of 100 µg/ml. The overnight cultures were then 
prepared by using the kit Wizard Plus SV Minipreps DNA Purification System 
(Promega) as described in the producer’s protocol (appendix 13). To verify that 
cloning of fragments in respective plasmids was successful, purified plasmids were 
digested with EcoRI (New England Biolabs), and gel electrophoresis was performed. 
Gel profiles were analyzed, and appropriate clones were subjected to DNA sequence 
analysis at GATC Biotech. Aliquots (1 ml) of each overnight bacterial culture were 
mixed with 300 µl of 87 % glycerol and stored at -80 °C. After verification of inserted 
fragment and orientation of it, the fragments were cut from the pGEM-T Easy vectors 
by double digestion with NdeI and BamHI. The MCS of pGEM-T Easy vector 
contains, among others, the recognition site of NdeI. Because the recognition sites of 
NdeI and BamHI were added to the primers, a few possible fragments can result from 
the digestion. Still, only the fragment of interest will match the digested plasmids 
pGBKT7 and pGADT7 when ligation mixtures are set up.  
 
3.4.2 Sequencing 
The appropriate clones from transformations of pGBKT7 and pGADT7 with inserts, 
and subcloning of fragments into pGEM-T Easy vectors, were sent to GATC Biotech 
in Germany to be sequenced. The sequences from GATC Biotech were then 
compared to the original sequences by the use of Basic Local Alignment Search Tool 
(BLAST) on NCBI’s internet resources [70]. Appropriate primers were included in 
the shipment to GATC when necessary. These primers are described in appendix 14. 
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3.5 The S. cerevisiae two-hybrid analysis 
A small amount of S. cerevisiae AH 109 (Clontech) from the -80 °C glycerol stock 
was resuspended in 1 ml sterile 0.8 % saline. 100 µl of 10-1 and 10-2 dilutions were 
plated on solid medium containing a blend of yeast extract, peptone and dextrose 
(YPD) (appendix 4), and incubated at 30 °C for 3-4 days. After confirmation of the 
structures of the various plasmid constructs, the two-hybrid analysis was set up to 
score PPIs between CKS2 and the CDKs. Appropriate combinations of the plasmids 
isolated from E. coli were transformed into the yeast strain by a modified lithium 
acetate (LiAc) method [64, 73] as described in appendix 15.  For each S. cerevisiae 
two-hybrid analysis, eight transformations were conducted. An overview of the 
transformation combinations is outlined in figure 3.3.  
 
As a positive control, the plasmids pGADT7/hda and pGBKT7/dnaN (provided by 
Line Johnsen) were used. Previous work by Kurz et al. [74] has shown that the E. coli 
proteins hda (DnaA related protein) and dnaN (β-sliding clamp) directly interacts in 
vitro. For negative control, the plasmids pGADT7 and pGBKT7 without inserts were 
used. As seen in figure 3.3, a transformation of pGADT7 with insert and pBGKT7 
without insert, and opposite, was performed. These transformations were used as 
controls for toxicity and to screen out constructs that could auto activate the his-
reporter gene. The last two transformations were carried out with the intention to 
score PPI between CKS2 and the CDKs (CDK1 and CDK2 with two mutations, and 
CDK2 with the single mutation). To examine the three PPIs of interest, all four 
fragments were cloned as both bait and prey so the interactions could be tested in both 
directions. The same outline was performed for all three PPIs. 
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General layout:
pGAD/hda + pGBK/dnaN (+ ctr)
pGAD + pGBK (‐ ctr)
pGAD/X + pGBK
pGAD/Y + pGBK
pGBK/X + pGAD
pGBK/Y + pGAD
pGAD/X + pGBK/Y
pGAD/Y + pGBK/X
To check for 
auto activation
of the promotor
To score for PPI
Layout when Y = CDK1AF:
pGAD/hda + pGBK/dnaN
pGAD + pGBK
pGAD/CKS2 + pGBK
pGAD/CDK1AF + pGBK
pGBK/CKS2 + pGAD
pGBK/CDK1AF + pGAD
pGAD/CKS2 + pGBK/CDK1AF
pGAD/CDK1AF + pGBK/CKS2
Layout when Y = CDK2AF:
pGAD/hda + pGBK/dnaN
pGAD + pGBK
pGAD/CKS2 + pGBK
pGAD/CDK2AF + pGBK
pGBK/CKS2 + pGAD
pGBK/CDK2AF + pGAD
pGAD/CKS2 + pGBK/CDK2AF
pGAD/CDK2AF + pGBK/CKS2
Layout when Y = CDK2F:
pGAD/hda + pGBK/dnaN
pGAD + pGBK
pGAD/CKS2 + pGBK
pGAD/CDK2F + pGBK
pGBK/CKS2 + pGAD
pGBK/CDK2F + pGAD
pGAD/CKS2 + pGBK/CDK2F
pGAD/CDK2F + pGBK/CKS2  
Figure 3.3: An overview of the combinations of the various plasmid constructs 
transformed into S. cerevisiae AH 109 (Clontech). The upper layout shows the 
transformation combinations in general. As a positive (+ ctr) and negative (- ctr) control, 
pGAD/hda + pGBK/dnaN, and pGAD + pGBK respectively, were used. The same plasmids 
for + ctr and - ctr were used for all three S. cerevisiae two-hybrid analysis. Protein X = CKS2, 
and protein Y = CDKAF, CDK2AF or CDK2F. All four transformations with the 
combination plasmid/insert + plasmid (empty) were controls for toxicity and to screen out 
constructs that could auto activate the his-reporter gene. The last two transformations were 
used to score for PPI. To examine all the PPIs of interest, all four fragments were cloned as 
both bait and prey. 
 
 
Transformation mixtures were plated on solid synthetic dropout medium. The 
medium contained Minimal SD Base (SD) with added dropout supplement, DO 
Supplement (SD-DO) (both Clontech) (appendix 4). Plates were incubated at 30 °C 
until transformants appeared (3-5 days). Appropriate transformants were grown in 
liquid SD-DO medium lacking leucine and tryptophan (SD-DO –leu/-trp), 
supplemented with adenine and histidine (both Sigma-Aldrich) to final concentrations 
of 20 µg/ml, at 30 °C overnight. To test for interactions, overnight cell cultures were 
collected by centrifugation, washed twice with sterile 0.8 % saline, and adjusted to an 
optical density at 600 nm (OD600) of ~ 1.0. This was diluted 10, 100 and 1000 times 
for each sample. The S. cerevisiae two-hybrid analysis (appendix 16) was set up by 
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spotting 10 µl aliquots of each dilution (OD = 1, 10-1, 10-2, 10-3) onto solid SD-DO –
leu/-trp (control plate) or lacking leucine, tryptophan, and histidine (SD-DO –leu/-
trp/-his) (to score for PPI) (appendix 4). Plates were incubated at 30 °C for 3 days. 
AH109 cells transformed with both pGBKT7 (provides the cells with trp) and 
pGADT7 (provides the cells with leu) will grow on SD-DO –leu/-trp medium. Cells 
where PPI occur will activate the his-reporter gene, and grow on SD-DO –leu/-trp/-his 
medium. A general layout of the two-hybrid analysis is outlined in figure 3.4. For 
each of the three PPIs tested, the two-hybrid analyses were performed both ways, and 
two parallels were tested. The two-hybrid analyses were carried out at least twice for 
each PPI.  
 
 
1
2
3
4
1 10-3
5
10-1 10-2
6
 
Figure 3.4: An overview of the S. cerevisiae two-hybrid analysis. The analysis was set up 
by spotting 10 µl aliquots of each dilution (OD = 1, 10-1, 10-2, 10-3) of each sample onto solid 
SD-DO medium lacking leucine and tryptophan (SD-DO –leu/-trp) (control plate) or lacking 
leucine, tryptophan, and histidine (SD-DO –leu/-trp/-his) (to score for PPI). 1: positive 
control, 2: negative control, 3 and 4: test for auto activation, 5 and 6: screen for PPI (two 
parallels were screened from the same plate of transformants).  
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4 Results 
4.1 PCR and cloning of the CKS2 gene 
cDNA of CKS2 was amplified by PCR (see Methods section 3.1) using the primers 
CKS2 F and CKS2 Rev (table 3.1). CKS2 DNA fragments were purified by gel 
electrophoresis (figure 4.1). The fragments could be seen at around 300 bp on the gel, 
which is consistent with the size of CKS2 (240 bp, [70]). All the bands (marked in 
red) were cut out from the gel and purified as described in chapter 3.3. The PCR-
products of CKS2 were then digested with NdeI and Bam HI, purified, and included 
in ligation mixtures with pGBKT7 and pGADT7, also digested with NdeI and BamHI 
(3.4).  
 
 
300 bp
1  2   3  4   5  6   7  8   9
 
Figure 4.1: Gel electrophoresis of PCR-products of CKS2.  
1: 2 log ladder, 2-9: PCR-products of CKS2.   
 
 
Clones containing CKS2 could not be found after transformation of the ligation 
mixtures into XL 10-Gold® cells. Since CKS2 could not be cloned directly into 
pGBKT7 and pGADT7, subcloning of CKS2 into pGEM-T Easy Vector was 
performed (see chapter 3.4 for details on subcloning). Different clones were checked 
for inserts after subcloning by gel electrophoresis (3.3), and the result is shown in 
figure 4.2 A. Two and two lanes contained a sample from the same clone. The 
leftmost lane of the two contained plasmid digested with EcoRI, and was expected to 
yield two bands. The rightmost lane of the two contained the same plasmid but uncut. 
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The bands yielded by the two samples were compared, and so the uncut plasmid 
served as a control to determine whether the other plasmid had been cut or not. Bands 
for the CKS2 fragment should have appeared around 300 bp, but no clear bands could 
be seen, most likely because the concentration of CKS2 fragments were too low to be 
detected. All the bands for uncut plasmids had about the right size, which is 3015 bp 
for the pGEM-T Easy vector [67]. When compared to the respective, digested clone in 
the adjacent lane, neither of the clones seemed to be completely cut. The digested 
plasmids yielded several bands, most likely due to nicked circle, super coiled, 
undigested and some digested forms. Either of the clones could therefore contain the 
CKS2 fragment, and clone #4 was arbitrarily selected and sent to GATC Biotech to be 
sequenced. Comparison using BLAST computer software (appendix 17) of the 
original sequence and the sequence obtained from GATC Biotech showed that the 
plasmid in clone #4 contained the CKS2 gene in the right orientation. 
 
1  2   3  4   5  6   7  8   9
300 bp
3000 bp
A
3000 bp
300 bp
B
1  2  3  4  5  6   7  8  9 10
Figure 4.2: Analysis of subcloning of CKS2 by gel electrophoresis.  
A: Four clones were tested for CKS2 inserts in pGEM-T Easy vector. 1: 2 log ladder,  
2: Clone#1 cut, 3: Clone#1 uncut, 4: Clone#2 cut, 5: Clone#2 uncut, 6: Clone#3 cut,  
7: Clone#3 uncut, 8: Clone#4 cut (selected for sequencing), 9: Clone#4 uncut.  
B: After verification of Clone#4, CKS2 was cut out from pGEM-T Easy and analyzed by gel 
electrophoresis. 1: 2 log ladder, 2-9: digested pGEM-T Easy/CKS2, 10: pGEM-T Easy 
(empty).  
 
 
Figure 4.2 B shows gel electrophoresis of CKS2 cut from the pGEM-T Easy vector. 
Large amounts of clone #4 were digested with NdeI and BamHI, and the bands could 
therefore clearly be seen on the gel. Bands appeared two places on the gel, consistent 
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with the sizes of CKS2 and pGEM-T Easy vector. The bands for CKS2 (marked in 
red) were cut out from the gel and used further. pGEM-T Easy vector without insert 
was applied in lane 10 to compare the size of this band to bands yielded by the cut 
plasmids with fragments. 
  
pGBKT7 and pGADT7 were digested with NdeI and Bam HI, and purified by gel 
electrophoresis. The results from gel electrophoresis are shown for pGBKT7 and 
pGADT7 in figure 4.3 A and B respectively. pGBKT7 have a size of 7300 bp and 
pGADT7 have a size of 8000 bp [61, 62]. The bands that could be seen on the gel for 
both plasmids indicate that they have been cut. For each analysis, to give an indication 
of the size of the plasmid, an uncut sample of the plasmid was applied in lane 1. For 
pGBKT7, the uncut sample showed very weak bands. This was most likely due to too 
low amount of plasmid DNA, and could not be detected. The bands of interest 
(marked in red for both plasmids) were cut out and purified as described in section 
3.3. Ligation mixtures with digested and purified CKS2 fragment, pGBKT7 and 
pGADT7, were set up as described in 3.4. 
 
 
1  2   3  4   5  6   7  8   9
A
 
1  2   3  4   5  6   7  8   9
B
 
Figure 4.3: Digested pGBKT7 and pGADT7 analysed by gel electrophoresis.  
A: pGBKT7 was double digested with restriction enzymes. 1: Uncut pGBKT7. 2-9: Cut 
pGBKT7. 
B: pGADT7 was double digested with restriction enzymes. 1: Uncut pGADT7. 2-9: Cut 
pGADT7. 
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Different clones were tested for CKS2 inserts into pGBKT7 and pGADT7 by 
digestion with NdeI and BamHI (3.2.1), and analysis by gel electrophoresis (3.3). The 
results of gel electrophoresis is shown in figure 4.4 A and B. Figure 4.4 A shows that 
all clones seemed to contain the right fragment, and from figure 4.4 B one can see that 
only clone#3 and clone#6 of the tested clones seemed to contain a fragment of the 
right size. Even though the CKS2 fragments were sequenced and verified when 
inserted in the pGEM-T Easy vector, appropriate clones were also sequenced for 
inserts in pGBKT7 and pGADT7 as an additional control. Clone #1 (figure 4.4.A) and 
clone #3 (figure 4.4 B) were selected for verification of CKS2 insert in pGBKT7 and 
pGADT7, respectively (both marked in red). For the selected clones, the bands of the 
respective plasmids were consistent with the known sizes. Comparison of sequences 
by using BLAST (appendix 17), showed that the clones tested contained the right 
fragment. The plasmids with fragment (constructs) are from here on referred to as 
pGBK/CKS2 and pGAD/CKS2 and were used in the further analyses to test the 
interactions with CDK1AF, CDK2AF and CDK2F.  
 
 
300 bp
8000 bp
1  2   3   4   5   6   7   8   9  10 11  12 13 
A
 
8000 bp
300 bp
B
1  2   3   4   5   6   7   8   9  10 11  12 13 
 
Figure 4.4: Analysis of cloning of CKS2 by gel electrophoresis.  
A: Six clones were tested for CKS2 inserts in pGBKT7. 1: 2 log ladder, 2: Clone#1 cut 
(selected for sequencing), 3: Clone#1 uncut, 4: Clone#2 cut, 5: Clone#2 uncut, 6: Clone#3 
cut, 7: Clone#3 uncut, 8: Clone#4 cut, 9: Clone#4 uncut, 10: Clone#5 cut, 11: Clone#5 uncut, 
12: Clone#6 cut, 13: Clone#6 uncut.  
B: Six clones were tested for CKS2 inserts in pGADT7. 1: 2 log ladder, 2: Clone#1 cut,  
3: Clone#1 uncut, 4: Clone#2 cut, 5: Clone#2 uncut, 6: Clone#3 cut (selected for sequencing), 
7: Clone#3 uncut, 8: Clone#4 cut, 9: Clone#4 uncut, 10: Clone#5 cut, 11: Clone#5 uncut,  
12: Clone#6 cut, 13: Clone#6 uncut.  
The uncut clones serve as controls for the cut clones.  
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4.2 PPIs of CKS2 and CDK1AF 
4.2.1 PCR and cloning of the CDK1AF gene 
The primers CDK1 F and CDK1 Rev (table 3.1) were used to amplify cDNA of 
CDK1AF by PCR (3.1). Fragments were purified by gel electrophoresis, and the result 
is shown in figure 4.5. The fragments could be seen at around 900 bp on the gel, 
which is consistent with the size of CDK1 (894 bp, [70]). All the bands (marked in 
red) were cut out. Directly cloning of CDK1AF into pGBKT7 and pGADT7 was 
attempted but did not succeed. Therefore, subcloning into pGEM-T Easy Vector was 
also performed for CDK1AF, as for CKS2 (see Methods section 3.4).  
 
900 bp
1  2  3  4  5  6  7  8  9 10
 
Figure 4.5: Gel electrophoresis of PCR-products of CDK1AF.  
1: 2 log ladder, 2-10: PCR-products of CDK1AF. 
 
 
Gel electrophoresis for different clones tested after subcloning of CDK1AF in  
pGEM-T Easy, is shown in figure 4.6 A. Two adjacent lanes contained sample from 
the same clone. Lanes 2, 4, 6 and 8 contained plasmid cut with the restriction enzyme 
EcoRI. Lanes 3, 5, 7, and 9 contained the respective uncut plasmid so the sizes of cut 
and uncut plasmid could be compared. Two bands could barely be seen in the gel 
around 900 bp for clone#8. This was consistent with the size of CDK1. Clone#8 was 
sent to GATC Biotech to be sequenced. As for the other sequence results, the tool 
BLAST (appendix 17) was used for comparison of the sequences. The result showed 
that the plasmid in clone #8 contained CDK1AF in the right orientation.  
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900 bp
3000 bp
A
1  2   3  4   5  6   7  8   9
3000 bp
900 bp
B
1  2  3  4  5  6   7  8  9 10
Figure 4.6: Analysis of subcloning of CDK1AF by gel electrophoresis.  
A: Four clones were tested for CDK1AF inserts in pGEM-T Easy vector. 1: 2 log ladder,  
2: Clone#5 cut, 3: Clone#5 uncut, 4: Clone#6 cut, 5: Clone#6 uncut, 6: Clone#7 cut,  
7: Clone#7 uncut, 8: Clone#8 cut (selected for sequencing), 9: Clone#8 uncut.  
B: After verification of Clone#8, CDK1AF was cut out from pGem-T Easy. 1: 2 log ladder, 
2-9: digested pGEM-T Easy/CDK1AF, 10: pGEM-T Easy uncut.  
 
 
Figure 4.6 B shows gel electrophoresis of CDK1AF cut from the pGEM-T Easy 
vector with NdeI and BamHI. Bands appeared two places on the gel, consistent with 
the sizes of CDK1 and pGEM-T Easy vector. The bands for CDK1AF (marked in red) 
were cut out from the gel and purified. A sample of pGEM-T Easy vector without 
insert was applied in lane 10 for comparison of band sizes.  
 
Ligation mixtures with digested and purified CDK1 fragment, pGBKT7 and 
pGADT7, were set up and transformed into XL 10-Gold® cells as described in 3.4. 
Figure 4.7 A and B show the results of gel electrophoresis of different clones tested 
for CDK1AF inserts into pGBKT7 and pGADT7, respectively. Figure 4.7 A shows 
that only clone#11 seemed to contain a fragment of the right size in pGBKT7, and 
was sent to GATC Biotech for sequencing (marked in red). From figure 4.7 B, one 
can see that all but one of the tested clones seemed to contain the right fragment in 
pGADT7, and clone #7 was selected to be sequenced (marked in red). This 
sequencing, as for CKS2 in pGBKT7 and pGADT7, served as an additional control. 
For the selected clones, the bands for the respective plasmids were consistent with the 
known sizes. Sequences were compared by the use of BLAST (appendix 17), and 
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showed that the clones tested contained the right fragment. The constructs are from 
here on referred to as pGBK/CDK1AF and pGAD/CDK1AF.  
 
8000 bp
900 bp
A
1  2   3   4   5   6   7   8   9  10 11 12 13 
8000 bp
900 bp
B
1   2   3   4   5   6   7   8   9  10 11 12 13 
Figure 4.7: Analysis of cloning of CDK1AF by gel electrophoresis.  
A: Six clones were tested for CDK1AF inserts in pGBKT7. 1: 2 log ladder, 2: Clone#7 cut,  
3: Clone#7 uncut, 4: Clone#8 cut, 5: Clone#8 uncut, 6: Clone#9 cut, 7: Clone#9 uncut,  
8: Clone#10 cut, 9: Clone#10 uncut, 10: Clone#11 cut (selected for sequencing),  
11: Clone#11 uncut, 12: Clone#12 cut, 13: Clone#12 uncut.  
B: Six clones were tested for CDK1AF inserts in pGADT7. 1: 2 log ladder, 2: Clone#7 cut 
(selected for sequencing), 3: Clone#7 uncut, 4: Clone#8 cut, 5: Clone#8 uncut, 6: Clone#9 
cut, 7: Clone#9 uncut, 8: Clone#10 cut, 9: Clone#10 uncut, 10: Clone#11 cut, 11: Clone#11 
uncut, 12: Clone#12 cut, 13: Clone#12 uncut.  
The uncut clones serve as controls for the cut clones.  
 
4.2.2 S. cerevisiae two-hybrid analysis for PPIs of CKS2 and CDK1AF 
The transformations of plasmid constructs and the S. cerevisiae two-hybrid analyses 
for pGBK/CKS2 and pGAD/CDK1AF, and pGAD/CKS2 and pGBK/CDK1AF were 
carried out as described in 3.5. The results are shown figure 4.8 and 4.9. Similar 
results were obtained for all analyses of PPI between CKS2 and CDK1AF.  
 
All samples should grow on the control plate (-leu/-trp) indicating that the cells have 
taken up both pGBKT7 and pGADT7. The plate to the left (-leu/-trp/-his) scores for 
PPIs and should only show growth if cells contained plasmids with protein inserts that 
interacted, thereby were able themselves to produce histidine. Row 1 is the positive 
control and showed growth on both plates as expected, because the proteins hda and 
dnaN are known to interact in Y2H. The negative control in row 2 only showed 
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growth on the control plate. This was also as expected because the plasmids were 
empty. Rows 3 and 4 tests for auto activation, and therefore growth was only wanted 
on the control plate. The tests showed no growth on the -leu/-trp/-his plate, indicating 
that neither of the plasmids contained constructs that were able to auto-activate the 
promoter. The two rows at the bottom are tests scoring for PPI (in two parallels), and 
growth on the -leu/-trp/-his plate indicates PPI between the fused proteins. The test 
showed growth, indicating that CKS2 was interacting with CDK1AF when CKS2 was 
cloned as the bait protein (figure 4.8). Similar results were obtained when CDK1AF 
was cloned as the bait protein (figure 4.9).  
 
 
 
 
1: pGBK/hda +
pGAD/DnaN (+ctr)
2: pGBK +      
pGAD (-ctr)
3: pGAD/CDK1AF +    
pGBK
4: pGBK/CKS2 +   
pGAD
5: pGAD/CDK1AF + 
pGBK/CKS2 #1
6: pGAD/CDK1AF + 
pGBK/CKS2 #2
Interaction 
between CKS2 
and CDK1AF
1 10-1 10-2 10-3
–leu/–trp/–his –leu/–trp
1 10-1 10-2 10-3OD:
 
Figure 4.8: S. cerevisiae two-hybrid analysis of pGBK/CKS2 and pGAD/CDK1AF.  
The following construct combinations were transformed into AH109: 1: Positive control, 
pGBK/hda and pGAD/DnaN, 2: Negative control, pGBK and pGAD without inserts,  
3: Test for auto-activation, pGAD with insert and pGBK without insert, 4: Test for auto-
activation, pGBK with insert and pGAD without insert, 5: Score for PPI #1, pGAD/CDK1AF 
and pGBK/CKS2, 6: Score for PPI #2, pGAD/CDK1AF and pGBK/CKS2. Right panel shows 
the control plate (-leu/-trp). Left panel shows plate that scores for PPIs (-leu/-trp/-his).  
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Figure 4.9: S. cerevisiae two-hybrid analysis of pGAD/CKS2 and pGBK/CDK1AF.  
The following construct combinations were transformed into AH109: 1: Positive control, 
pGBK/hda and pGAD/DnaN, 2: Negative control, pGBK and pGAD without inserts,  
3: Test for auto-activation, pGAD with insert and pGBK without insert, 4: Test for auto-
activation, pGBK with insert and pGAD without insert, 5: Score for PPI #1, pGAD/CKS2 and 
pGBK/CDK1AF, 6: Score for PPI #2, pGAD/CKS2 and pGBK/CDK1AF. Right panel shows 
the control plate (-leu/-trp). Left panel shows plate that scores for PPIs (-leu/-trp/-his).   
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4.3 PPIs of CKS2 and CDK2AF 
4.3.1 PCR and cloning of the CDK2AF gene 
Amplification of cDNA of CDK2AF was given by the primers CDK2 F and CDK2 
Rev (table 3.1) and the use of PCR. Fragments were purified by gel electrophoresis, 
and the result is shown in figure 4.10. The fragments that could be seen on the gel 
were consistent with the size of CDK2 (897 bp, [70]). The bands of interest (marked 
in red) were cut out from the gel, purified and digested with NdeI and BamHI-HF, 
then included in ligation mixtures with cut pGBKT7 and pGADT7. Ligation mixtures 
were transformed into XL 10-Gold® cells (see sections 3.2-3.4 for details).  
 
900 bp
1  2  3  4  5  6  7  8  9 10
 
Figure 4.10: Gel electrophoresis of PCR-products of CDK2AF.  
1: 2 log ladder, 2-10: PCR-products of CDK2AF. 
 
Figure 4.11 A and B show the results of gel electrophoresis of different clones tested 
for CDK2AF inserts in pGBKT7 and pGADT7 respectively. Figure 4.11 A shows that 
all but clone #1 seemed to contain a fragment of the right size. Clone #4 was selected 
for sequencing (marked in red). From figure 4.11 B, one can see that clones #7, #9, 
#10 and #12 contained a fragment of the appropriate size. Clone #7 was sequenced 
(marked in red). For the selected clones, the bands of the respective plasmid were 
consistent with the known sizes. BLAST (appendix 17) was used to compare the 
sequences, and showed that the clones tested contained the right fragment. The 
constructs are from here on referred to as pGBK/CDK2AF and pGAD/CDK2AF. 
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Figure 4.11: Analysis of cloning of CDK2AF by gel electrophoresis.  
A: Six clones tested for CDK2AF inserts in pGBKT7. 1: 2 log ladder, 2: Clone#1 cut,  
3: Clone#1 uncut, 4: Clone#2 cut, 5: Clone#2 uncut, 6: Clone#3 cut, 7: Clone#3 uncut,  
8: Clone#4 cut (selected for sequencing), 9: Clone#4 uncut, 10: Clone#5 cut, 11: Clone#5 
uncut, 12: Clone#6 cut, 13: Clone#6 uncut.  
B: Six clones were tested for CDK2AF inserts in pGADT7. 1: 2 log ladder, 2: Clone#7 cut 
(selected for sequencing), 3: Clone#7 uncut, 4: Clone#8 cut, 5: Clone#8 uncut, 6: Clone#9 
cut, 7: Clone#9 uncut, 8: Clone#10 cut, 9: Clone#10 uncut, 10: Clone#11 cut, 11: Clone#11 
uncut, 12: Clone#12 cut, 13: Clone#12 uncut. 
The uncut clones serve as controls for the cut clones.   
 
 
 
4.3.2 S. cerevisiae two-hybrid analysis for PPIs of CKS2 and CDK2AF 
Figure 4.12 and 4.13 shows the results of the S. cerevisiae two-hybrid analysis for 
pGBK/CKS2 and pGAD/CDK2AF, and pGAD/CKS2 and pGBK/CDK2AF 
respectively (see 3.5 for details). The results obtained were similar to the results 
described for CKS2 interaction with CDK1AF. The control plate showed growth for 
all samples. The plate scoring for PPIs (-leu/-trp/-his) showed growth for the positive 
control and for the two parallels testing whether CKS2 interacted with CDK2AF or 
not. Rows 2, 3 and 4 showed no growth, indicating that neither of the constructs were 
able to auto-activate the promoter when not interacting with a protein. Both two 
hybrid analyses show that CKS2 interacts with CDK2AF regardless of whether CKS2 
(figure 4.12) or CDK2AF (figure 4.13) is cloned as the bait protein.  
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Figure 4.12: S. cerevisiae two-hybrid analysis of pGBK/CKS2 and pGAD/CDK2AF. 
The following construct combinations were transformed into AH109: 1: Positive control, 
pGBK/hda and pGAD/DnaN, 2: Negative control, pGBK and pGAD without inserts,  
3: Test for auto-activation, pGAD with insert and pGBK without insert, 4: Test for auto-
activation, pGBK with insert and pGAD without insert, 5: Score for PPI #1, pGAD/CDK2AF 
and pGBK/CKS2, 6: Score for PPI #2, pGAD/CDK2AF and pGBK/CKS2. Right panel shows 
the control plate (-leu/-trp). Left panel shows plate that scores for PPIs (-leu/-trp/-his).  
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Figure 4.13: S. cerevisiae two-hybrid analysis of pGAD/CKS2 and pGBK/CDK2AF. 
The following construct combinations were transformed into AH109: 1: Positive control, 
pGBK/hda and pGAD/DnaN, 2: Negative control, pGBK and pGAD without inserts,  
3: Test for auto-activation, pGAD with insert and pGBK without insert, 4: Test for auto-
activation, pGBK with insert and pGAD without insert, 5: Score for PPI #1, pGAD/CKS2 and 
pGBK/CDK2AF, 6: Score for PPI #2, pGAD/CKS2 and pGBK/CDK2AF. Right panel shows 
the control plate (-leu/-trp). Left panel shows plate that scores for PPIs (-leu/-trp/-his).  
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4.4 PPIs of CKS2 and CDK2F 
4.4.1 PCR and cloning of the CDK2F gene 
cDNA of CDK2F was amplified by PCR. The same primers as for CDK2AF were 
used (CDK2 F and CDK2 Rev, table 3.1). Fragments were purified by gel 
electrophoresis, and the result is shown in figure 4.14. The fragments that could be 
seen on the gel were consistent with the size of CDK2 (897bp, [70]). The bands of 
interest (marked in red), were used further as described for CDK2AF.    
 
900 bp
1  2  3  4  5  6  7 8  9 10
 
Figure 4.14: PCR-products of CDK2F.  
1: 2 log ladder, 2-10: PCR-products of CDK2F. 
 
 
Different clones were tested for CDK2F inserts in pGBKT7 and pGADT7, and 
analyzed by gel electrophoresis. The results are shown in figure 4.15 A and B 
respectively. Figure 4.15 A shows that clone #7 and #9 seemed to contain the right 
fragment. Figure 4.15 B shows that clone #1, #2 and #5 of the six clones tested, 
seemed to contain a fragment of the right size. Clone # 7 and clone #1 (both marked 
in red) were sequenced. Comparison of seqences by the use of BLAST (appendix 17) 
showed that the clones tested contained the right fragment. The constructs are from 
here on referred to as pGBK/CDK2F and pGAD/CDK2F.  
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Figure 4.15: Analysis of cloning of CDK2F by gel electrophoresis.  
A: Three clones were tested for CDK2F inserts in pGBKT7. 1: 2 log ladder, 2: Clone#7 cut 
(selected for sequencing), 3: Clone#7 uncut, 4: Clone#8 cut, 5: Clone#8 uncut, 6: Clone#9 
cut, 7: Clone#9 uncut, 8: Clone#10 cut, 9: Clone#10 uncut. 
B: Six clones were tested for CDK2F inserts in pGADT7. 1: 2 log ladder, 2: Clone#1 cut 
(selected for sequencing), 3: Clone#1 uncut, 4: Clone#2 cut, 5: Clone#2 uncut, 6: Clone#3 
cut, 7: Clone#3 uncut, 8: Clone#4 cut, 9: Clone#4 uncut, 10: Clone#5 cut, 11: Clone#5 uncut,  
12: Clone#6 cut, 13: Clone#6 uncut.  
The uncut clones serve as controls for the cut clones.  
 
 
 
 
4.4.2 S. cerevisiae two-hybrid analysis for interaction of CKS2 with 
CDK2F 
The results of the S. cerevisiae two-hybrid analysis for pGBK/CKS2 and 
pGAD/CDK2F, and pGAD/CKS2 and pGBK/CDK2F are shown in figures 4.16 and 
4.17, respectively. The results are similar to the results already described for 
CDK1AF and CDK2AF, but the control plate shows poor growth for pGAD/CDK2F. 
This indicates that CDK2F was mildly toxic to the yeast cells. However, the results 
show that CKS2 and CDK2F interacted regardless of whether CKS2 (figure 4.16) or 
CDK2F (figure 4.17) was cloned as the bait protein.  
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Figure 4.16: S. cerevisiae two-hybrid analysis of pGBK/CKS2 and pGAD/CDK2F. 
The following construct combinations were transformed into AH109: 1: Positive control, 
pGBK/hda and pGAD/DnaN, 2: Negative control, pGBK and pGAD without inserts,  
3: Test for auto-activation, pGAD with insert and pGBK without insert, 4: Test for auto-
activation, pGBK with insert and pGAD without insert, 5: Score for PPI #1, pGAD/CDK2F 
and pGBK/CKS2, 6: Score for PPI #2, pGAD/CDK2F and pGBK/CKS2. Right panel shows 
the control plate (-leu/-trp). Left panel shows plate that scores for PPIs (-leu/-trp/-his).  
 
 
 
 
 
 
 
 
 
1 10-1 10-2 10-3 1 10-1 10-2 10-3
1: pGBK/hda +
pGAD/DnaN (+ctr)
2: pGBK +      
pGAD (-ctr)
3: pGAD/CKS2 +    
pGBK
4: pGBK/CDK2F +   
pGAD
5: pGAD/CKS2 + 
pGBK/CDK2F #1
6: pGAD/CKS2 +  
pGBK/CDK2F #2
Interaction 
between CKS2 
and CDK2F
–leu/–trp/–his –leu/–trp
OD:
 
Figure 4.17: S. cerevisiae two-hybrid analysis of pGAD/CKS2 and pGBK/CDK2F. 
The following construct combinations were transformed into AH109: 1: Positive control, 
pGBK/hda and pGAD/DnaN, 2: Negative control, pGBK and pGAD without inserts,  
3: Test for auto-activation, pGAD with insert and pGBK without insert, 4: Test for auto-
activation, pGBK with insert and pGAD without insert, 5: Score for PPI #1, pGAD/CKS2 and 
pGBK/CDK2F, 6: Score for PPI #2, pGAD/CKS2 and pGBK/CDK2F. Right panel shows the 
control plate (-leu/-trp). Left panel shows plate that scores for PPIs (-leu/-trp/-his).  
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4.5 Summary of the S. cerevisiae two-hybrid analyses 
Table 4.1 summarizes the different PPI’s assessed with the S. cerevisiae two-hybrid 
analyses. The interaction of CKS2 with CDK1AF, CDK2AF and CDK2F could be 
shown both ways by the use of the Y2H system.  
 
 
Table 4.1: Overview of the PPI’s shown with the S. cerevisiae two-hybrid analysis.  
Plasmid pGBK/CDK1AF pGBK/CDK2AF pGBK/CDK2F 
 
pGAD/CKS2 
 
 
+ 
 
+ 
 
+ 
 
Plasmid pGAD/CDK1AF pGAD/CDK2AF pGAD/CDK2F 
 
pGBK/CKS2 
 
 
+ 
 
+ 
 
+ 
The positive symbol indicates that the interaction could be shown in the Y2H system. 
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5 Discussion  
5.1 Y2H can be used to identify CKS2 interactions with CDKs 
Egan and Solomon [15] explored the binding of CKS2 to CDKs. They found that 
CDKs with mutations in the gene sequence of the inhibitory phosphorylation sites, 
changing T14 to alanine and Y15 to phenylalanine, did not affect the binding of 
CKS2 to CDK1/CCNB. This was tested for both mutations individually (T14A and 
Y15F), or in combination (AF). This indicates that the dephosphorylated sites are only 
important for activation of CDKs [23, 35], and not for binding of CKS2. In this 
project, the CDK gene sequences used to investigate the binding to CKS2 had 
mutations in the inhibitory phosphorylation sites in order to simulate the 
dephosphorylated state in vivo. Binding was observed regardless of whether the T14A 
and Y15F mutations or the single Y15F mutation were used, indicating that the T14A 
mutation was not necessary for CKS2 binding, which is in agreement with findings by 
Egan and Solomon [15]. Egan and Solomon [15] also tested binding of CKS2 to 
CDK1 with a changed amino acid at the activating phosphorylation site, T161. They 
found that phosphorylation of T161 stimulated binding of CKS2. We used no 
mutations of T161 to simulate activating phosphorylation in this project, indicating 
that the yeast cells carried out the phosphorylations at T161 in the CDKs. 
Alternatively, T161 is not necessary for CKS2 binding.  
 
In a previous attempted Y2H study, where a different yeast strain and plasmids were 
used, yeast cells were not viable [18]. Others have also reported that CDK2 was 
mildly toxic in yeast cells [75]. In this study, plates with cells that were transformed 
with pGADT7 containing CDK1AF, CDK2AF or CDK2F often had to be incubated 
for 1-2 days longer than the other plates, indicating that some toxicity of the CDKs 
occurred. However, to avoid growth of spontaneously mutated yeast cells, incubation 
time never exceeded 5 days. With this incubation time, yeast cells grew sufficiently 
after transformations, so that PPIs could be measured. 
 
Generation of false positive and false negative PPIs is a common problem in Y2H. 
The use of two reporter genes in parallel can be used to increase the stringency of the 
analysis and avoid appearance of false positive signals [1]. In the conducted S. 
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cerevisiae two-hybrid analyses, the HIS3 reporter was used, which is of medium 
stringency [64]. Transformants tested in the analyses were carefully selected among 
homogenous colonies. Two parallels were tested for each PPI in each experiment. In 
some tests only one parallel produced growth. This was most likely due to false 
negatives. However, the majority of the tests produced growth, suggesting that the 
analyses were reliable.  
 
The S. cerevisiae two-hybrid analyses showed that CKS2 interacts with both CDK1 
and CDK2. These results are in agreement with previous studies, which have 
identified these interactions by the use of other methods, such as immunoprecipitation 
[8, 14, 15, 17]. The results show that Y2H can be used for assessing CKS2 
interactions with both CDK1 and CDK2, and it is likely that the established 
interactions can be used in further screens.   
 
5.2 Future prospects for use of Y2H 
The development of different screens with CKS2 would be a next step towards 
developing targets of the CKS2/CDK interactions. The established CKS2/CDK1 
and/or CKS2/CDK2 interaction can be tested in a reverse screen to detect small 
molecule compounds able to break the interaction. The URA3 reporter, often used in 
reverse screens, is more difficult to activate than the HIS3 reporter, leading to a higher 
risk of missing the PPIs (false negatives) [1, 64]. Therefore, the robustness of the 
CKS2 interactions have to be further investigated for a rY2H screen. However, we 
conclude that the obtained results are promising and indicate that the CKS2/CDKs 
interactions may be suited for such a screen. Small molecule compounds detected in a 
rY2H screen would be candidates for possible drugs in CKS2 interaction targeted 
therapy.  
 
If the established interactions proved difficult to use in a rY2H screen, other 
interactions obtained from a cDNA-library screen could then be investigated. The 
cDNA-library (cloned as prey) screened for interactions with CKS2 (cloned as bait) 
would reveal possible CKS2 interacting partners present in the library [2, 3, 55]. Such 
a screen would also contribute to a better understanding of CKS2 function, which is 
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not fully clarified, and would be of importance for interpretation of the results from 
the clinical CKS2 studies.  
 
Since our results showed that CKS2 interacted with both CDK1 and CDK2, it would 
be of interest to identify the CDK/cyclin complex that binds CKS2, and the cell cycle 
phase in which CKS2 is active. The cyclins are synthesized and degraded at specific 
phases in the cell cycle, and CDK1 and CDK2 are known to bind to cyclins A, B and 
E [6, 36, 37]. It has previously been shown that CKS2 is present in all phases of the 
cell cycle [76]. It should therefore be possible for CKS2 to bind CDK1 and CDK2 in 
all cell cycle phases, although further investigations are necessary to clarify this. Such 
knowledge would be of importance for understanding the function of CKS2, and why 
overexpression of the protein is associated with aggressive tumors.  
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Appendix 1 
Procedure for subcloning 
 
 
pGEM®-T Easy Vector System from Promega.  
Modified protocol from technical manual, 2007. 
 
The vector map of pGEM®-T Easy Vector is shown in figure A1.1.  
 
 
Figure A1.1: pGEM®-T Easy Vector map. The MCS lies within the coding region of β-
galactosidase, contains several recognition sites for restriction enzymes, and is flanked by the 
RNA polymerases T7 and SP6. The vector also contains an ampicillin resistance gene. 
 
 
An overview of A-tailing is outlined in figure A1.2.  
 
Start with 1-7 µl of purified PCR fragment generated by 
a proofreading polymerase (e.g., Pfu DNA polymerase)
Add 1 µl Taq DNA polymerase 10X Reaction Buffer with 
MgCl2
Add dATP to a final concentration of 0.2 mM
Add 5 units of Taq DNA polymerase
Add deionized water to a final reaction volume of 10 µl
Incubate at 70 °C for 30 minutes
Use 1-2 µl in a ligation reaction with Promega’s T-vector  
Figure A1.2: A-tailing procedure for blunt-ended PCR fragments. The pGEM-T Easy 
vector is equipped with single 3’-T overhangs at the insertion site, and this will greatly 
improve the efficiency of ligation. 
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Calculating Insert:Vector Molar Ratios: 
 
Ratios from 3:1 to 1:3 provide good initial parameters. The T-vector is approximately 
3 kb and is supplied at 50 ng/µl. To calculate the appropriate amount of PCR product 
(insert) to include in the ligation reaction, use the following equation. 
 
ng of vector × kb size of insert
kb size of vector
× insert:vector molar ratio = ng of insert
 
 
For CKS2 (16 ng/µl), the following parameters were used: 
 
2
1
50 ng × 0.240 kbp
3.0 kb
× = 8 ng
 
 
Total volume is 10 µl: 
8 ng/µl × 10 µl = 80 ng 
 
16 ng/µl × X µl = 80 ng 
X = 5 µl 
 
For CDK1 (48.7 ng/µl), the following parameters were used: 
 
2
1
50 ng × 0.90 kbp
3.0 kb
× = 30 ng
 
 
Total volume is 10 µl: 
30 ng/µl × 10 µl = 300 ng 
 
30 ng/µl × X µl = 300 ng 
X = 6.2 µl 
 
 
Reaction mixtures for A-tailing: 
 
CKS2 CDK1 
CKS2 PCR product 
dATP 2 mM 
Taq DNA polymerase (5 u/µl) 
Taq DNA polymerase rxn 
buffer (10×) 
Deionized water 
  5.0 µl 
  1.0 µl 
  1.0 µl 
  1.0 µl 
   
  2.0 µl 
 CKS2 PCR product 
dATP 2 mM 
Taq DNA polymerase (5 u/µl) 
Taq DNA polymerase rxn 
buffer (10×) 
Deionized water 
  6.2 µl 
  1.0 µl 
  1.0 µl 
  1.0 µl 
   
  0.8 µl 
Total 10.0 µl  Total 10.0 µl 
Incubate at 70 °C for 30 minutes.  
 
 
 
Protocol for ligation of fragment into pGEM-T Easy vector 
 
1. Briefly centrifuge T-vector to collect content at the bottom of the tube. 
2. Set up ligation reactions as described below: 
2× Rapid Ligation Buffer, T4 DNA Ligase       5.0 µl 
pGEM®-T Easy Vector (50 ng)       1.0 µl 
PCR product             µl 
T4 DNA Ligase (3 Weiss units/µl)       1.0 µl 
Deionized water   to 10.0 µl 
 Note: vortex the 2× Rapid Ligation Buffer vigorously before each use. 
3. Mix the reactions by pipetting. Incubate the reactions overnight at 4 °C. 
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Protocol for transformation of JM109 High Efficiency Competent E. coli cells 
 
1. Prepare two LB/ampicillin/IPTG/X-Gal plates for each ligation reaction (see 
below). Equilibrate the plates to room temperature prior to plating (Step 10). 
2. Centrifuge the tubes containing the ligation reactions to collect contents at the 
bottom of the tube. Add 2 µl of each ligation reaction to a sterile 1.5 ml 
microcentrifuge tube on ice. 
3. Remove tubes of frozen JM109 High Efficiency Competent Cells from storage 
and place in an ice bath until just thawed (about 5 minutes). Mix the cells by 
gently flicking the tube. Note: avoid excessive pipetting, as the competent 
cells are extremely fragile.  
4. Carefully transfer 50 µl of cells into each tube prepared in step 2.  
5. Gently flick the tubes to mix and place them on ice for 20 minutes. 
6. Heat-shock the cells for 45-50 seconds in a water bath at exactly 42 °C (Do 
not shake). 
7. Immediately return the tubes to ice for 2 minutes.  
8. Add 950 µl room temperature LB medium to the tubes. 
9. Incubate for 1.5 hours at 37 °C with shaking. 
10. Plate 100 µl of each transformation culture onto one LB/ampicillin/IPTG/     
X-Gal plate.  
11. Spin down the rest of the transformation culture at 13 000 rpm for 2 minutes, 
remove the supernatant and resuspend in 100 µl LB. Repeat step 10. 
12. Incubate the plates overnight at 37 °C.  
 
White colonies generally contain inserts; however, inserts may also be present in blue 
colonies.  
 
 
 
 
Composition of Buffers and Solutions: 
 
IPTG stock solution (0.1 M) X-Gal (50 mg/ml) 
IPTG 1.2 g  X-Gal 100 mg 
dH2O to 50 ml  N,N´-dimethyl-formamide 2 ml 
Filtersterilize and store at 4°C   Dissolve, cover with aluminum foil 
and store at -20 °C  
 
LB plates with ampicillin/IPTG/X-Gal: 
 
Melt LB agar in the microwave, and pour onto a 50 ml tube (gives 2 plates). Allow 
the medium to cool to 50 °C before adding ampicillin to a final concentration of 100 
µg/ml. Supplement with 0.5 mM IPTG and 80 µg/ml X-Gal. Pour 25 ml of medium 
into 90 mm petri dishes. Let the agar harden. Store at 4 °C for up to 1 month, or at 
room temperature for up to 1 week.  
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Appendix 2 
Protocol for reverse transcription to synthesize cDNA 
 
 
Illumina® TotalPrep RNA Amplification Kit from Ambion 
Modified from protocol following steps II.C. – II.E.* 
 
 
 
C. Reverse Transcription to Synthesize First Strand cDNA 
1. Bring RNA samples to 11 µl with nuclease-free water in a 0.5 ml 
microcentrifuge tube. 
2. Add 9 µl of Reverse Transcription Master Mix (table A2.1) to the RNA 
sample. Mix thoroughly by pipetting up and down 2-3 times, then flicking the 
tube 3-4 times, and centrifuge briefly to collect the reaction in the bottom of 
the tube. 
 
Table A2.1: Reverse Transcription Master Mix (for one single 20 µl reaction)  
Amount Component 
1 µl T7 Oligo(dT) Primer 
2 µl 10X First Strand Buffer 
4 µl dNTP Mix 
1 µl RNase Inhibitor 
1 µl ArrayScript 
  
3. Place the sample in the thermal cycler, and incubate for 2 hours at 42 °C.   
4. After incubation, centrifuge for about 5 seconds to collect the reaction mixture 
at the bottom of the tube. Place the tubes on ice and immediately proceed to 
section D. 
 
 
 
D. Second Strand cDNA Synthesis 
5. Add 80 µl of Second Strand Master Mix (table A2.2) to the sample, mix 
thoroughly by pipetting up and down 2-3 times, then flicking the tube 3-4 
times, and centrifuge briefly to collect the reaction in the bottom of the tube. 
 
Table A2.2: Second Strand Master Mix (for one single 100 µl reaction)  
Amount Component 
63 µl Nuclease-free Water 
10 µl 10X Second Strand Buffer 
  4 µl dNTP Mix 
  2 µl DNA Polymerase 
  1 µl RNase H 
 Note: to be prepared on ice 
6. Place the sample in the thermal cycler, and incubate for 2 hours at 16 °C. 
7. Place the sample tube on ice and freeze immediately or proceed to section E. 
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E. cDNA Purification 
8. Preheat a minimum of 20 µl of nuclease-free water to 55 °C. 
9. Add 250 µl cDNA Binding Buffer to the sample, and mix thoroughly by 
pipetting up and down 2-3 times, then flicking the tube 3-4 times. Centrifuge 
the sample briefly to collect the mixture in the bottom of the tube. 
10. Put the cDNA Filter Cartridge in the wash tube and pass the sample from step 
9 onto to the centre of the filter. 
11. Centrifuge for 1 minute at 10 000 rpm. 
12. Discard the flow-through and replace the filter in the wash tube. 
13. Apply 500 µl Wash Buffer onto the filter (make sure that ethanol has been 
added to the Wash Buffer). 
14. Centrifuge for 1 minute at 10 000 rpm. 
15. Discard the flow-through and centrifuge the filter for an additional minute to 
remove trace amounts of Wash Buffer. 
16. Transfer the filter to a clean tube. 
17. Apply 20 µl of nuclease-free water holding about 55 °C (colder water or more 
than 58 °C may result in reduced cDNA yield) to the centre of the filter. 
18. Incubate at room temperature for 2 minutes and then centrifuge for 1 minute at 
10 000 rpm. The double stranded cDNA will now be in the eluate 
(approximately 17,5 µl). 
19. Measure the concentration by using the NanoDrop, and store at – 20 °C.  
 
 
 
* The protocol proceeds with In Vitro Transcription to Synthesize cRNA and cRNA 
Purification. The purpose here was to synthesize cDNA, and therefore the procedure 
was stopped after cDNA Purification.  
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Appendix 3 
PCR-protocols for CDK1, CDK2 and CKS2 
 
Materials provided by Stratagene: 
PfuUltra™ II Fusion HS DNA Polymerase  
10× PfuUltra™ II Reaction Buffer 
 
 
Mastermix for CDK1: 
Component 1 reaction 5 reactions 
Distilled  water 40,5 µl 202.5 µl 
10× PfuUltra™ II Reaction Buffer*   5,0 µl   25.0 µl 
dNTP mix (25 mM each dNTP)   0,5 µl     2.5 µl 
DNA template, CDK1AF (100 ng/µl)   1,0 µl**     5.0 µl 
Primer CDK1F (10 µM)   1,0 µl     5.0 µl 
Primer CDK1Rev (10 µM)   1,0 µl     5.0 µl 
PfuUltra™ II Fusion HS DNA Polymerase   1,0 µl     5.0 µl 
Total reaction volume 50,0 µl 250.0 µl 
 
 
 
Mastermix for CDK2: 
Component 1 reaction 5 reactions 
Distilled  water 40,5 µl 202.5 µl 
10× PfuUltra™ II Reaction Buffer*   5,0 µl   25.0 µl 
dNTP mix (25 mM each dNTP)   0,5 µl     2.5 µl 
DNA template, CDK2F or CDK2AF   1,0 µl**     5.0 µl 
Primer CDK2F (10 µM)   1,0 µl     5.0 µl 
Primer CDK2Rev (10 µM)   1,0 µl     5.0 µl 
PfuUltra™ II Fusion HS DNA Polymerase   1,0 µl     5.0 µl 
Total reaction volume 50,0 µl 250.0 µl 
 
 
 
Mastermix for CKS2: 
Component 1 reaction 5 reactions 
Distilled  water 39,5 µl 197.5 µl 
10× PfuUltra™ II Reaction Buffer*   5,0 µl   25.0 µl 
dNTP mix (25 mM each dNTP)   0,5 µl     2.5 µl 
DNA template, cDNA CKS2 (15 ng/µl)   2,0 µl**   10.0 µl 
Primer CKS2F (10 µM)   1,0 µl     5.0 µl 
Primer CKS2Rev (10 µM)   1,0 µl     5.0 µl 
PfuUltra™ II Fusion HS DNA Polymerase   1,0 µl     5.0 µl 
Total reaction volume 50,0 µl 250.0 µl 
 
 
Transfer 50 µl mastermix to each PCR tube and run the appropriate programme. 
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Cycling Parameters for CDK1 and CDK1:  
Segment Number of cycles Temperature Duration (cDNA) 
1 1 95 °C 2 minutes 
95 °C 20 seconds 
Primer Tm-5 °C  20 seconds 
 
2 
 
30 
72 °C 15 seconds for targets ≤ 1 kb  
3 1 72 °C 3 minutes 
Primer Tm CDK1 = CDK2 = 50 °C 
CDK1 = 894 bp  
CDK2 = 897 bp 
 
 
 
PCR cycling parameters for CKS2:  
Segment Number of cycles Temperature Duration (cDNA) 
1 1 95 °C 1 minute 
95 °C 20 seconds 
Primer Tm-5 °C  20 seconds 
 
2 
 
40 
72 °C 30 seconds for targets ≤ 1 kb  
3 1 72 °C 3 minutes 
Primer Tm CKS2 = 53 °C 
CKS2 = 240 bp 
 
 
Analyze the PCR amplification products on a 0.8 % agarose gel.  
 
 
* The 10× buffer provides a final 1 × Mg2+ concentration of 2mM 
** The amount of DNA template required varies depending on the type of DNA being 
amplified. Generally 100 ng of genomic DNA template is recommended. Less DNA 
template should be used for amplification of lambda or vector (5-30 ng) PCR targets.  
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Appendix 4  
Growth media, buffers and solutions 
 
Table A4.1: Growth media for E. coli  
 
LB (Luria Broth) 
  
Tryptone 10 g  
Yeast extract 5 g  
NaCl 10 g  
dH2O to 1000 ml  
Autoclave  
 
 
 
LB agar  
LB medium with 0.5 %  Bacto agar  
Autoclave  
 
 
 
LB medium to plate  
LB agar with ampicillin and chloramphenicol to final concentrations of 100 µg/ml 
and 30 µg/ml, respectively (pGADT7) 
 
LB agar with kanamycin and chloramphenicol to final concentrations of 50 µg/ml 
and 30 µg/ml, respectively (pGBKT7) 
 
LB agar with ampicillin, IPTG and X-Gal to final concentrations of 100 µg/ml, 0.5 
mM, and 80 µg/ml, respectively (pGEM-T Easy Vector) 
 
 
 
Table A4.2: Buffers and solutions  
 
5 × TBE buffer 
  
Tris base 54 g  
Boric acid 27.5 g  
0.5 M EDTA (pH 8.0) 20 ml  
dH2O to 1000 ml  
The agarose gels were run in 0.5 × TBE  
  
50 × TAE buffer   
Tris base 242 g  
Glacial acetic acid 57.1 ml  
0.5 M EDTA (pH 8.0) 100 ml  
 to 1000 ml  
   
0.8 % NaCl   
Sodium chloride 1.6 g  
dH2O 
 
to 200 ml  
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Table A4.3: Growth media for S. cerevisiae  
 
YPD 
  
YPD 20 g  
dH2O to 400 ml  
Autoclave  
 
 
 
YPD agar   
YPD  20 g  
Add some dH2O and let it dissolve under stirring   
Adjust pH ~ 6.0 with NaOH  
Bacto agar 8 g  
Complete with dH2O to 400 ml  
Autoclave  
 
 
 
SD-DO  
Minimal SD Base 10.7 g  
DO supplement (-ade/-his/-leu/-trp) 0.24 g  
Add some dH2O and let it dissolve under stirring  
Adjust pH ~ 6.0 with NaOH  
Complete with dH2O to 400 ml  
Autoclave   
 
 
  
SD-DO medium to plate   
SD-DO medium supplemented with adenine to a final concentration of  20 µg/ml (to score 
for PPI) 
 
SD-DO medium supplemented with adenine and histidine to final concentrations of  20 
µg/ml (control) 
 
Pour plates in aseptic conditions 
 
 
  
One-step buffer    
Lithium Acetate 1M (pH 7.5) 20 ml  
PEG 3350 (or PEG 4000) 40 g  
Add some dH2O and let it dissolve under stirring  
Complete with dH2O  to 100 ml  
Sterilize the solution by 3 cycles of warming for 30 minutes at 65 °C (one cycle per day, 
let the solution at room temperature between each cycle) 
Store the sterilized solution at 4 °C 
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Appendix 5 
Protocol for preparing bacterial culture 
 
 
 
1. In a 250 ml tubes, add 50 ml LB medium. 
2. Add appropriate antibiotics (table A5.1). 
3. Add a small amount of the appropriate -80 stock of bacterial culture to the 
tube. 
4. Incubate at 37 °C overnight in a swirling water bath. 
 
 
 
 
Table A5.1: Type and final concentration of antibiotics added to bacterial culture before 
incubation overnight.  
 Plasmid 
 pGBKT7  pGADT7  
 
Antibiotics 
 
Kanamycin (50 mg/ml) 
50 µg/ml 
 
 
Ampicillin (100 mg/ml) 
100 µg/ml 
 
Concentrations of stock-solutions are shown in brackets. 
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Appendix 6 
Protocol for plasmid purification, midi 
 
JETSTAR Plasmid Purification Kit from Genomed.  
 
Modified  from JETSTAR 2.0 Plasmid Mini/Midi/ Maxi-Protocol 
Follow the steps stated for Midi which is suitable for low copy plasmids (0.2-1 µg 
DNA/ml LB medium). Culture volume is 25-100 ml and gives DNA yield of  5-100 
µg 
 
1. Column equilibration: add 10 ml of solution E4. Allow the column to empty 
by gravity flow, do not force out remaining solution. 
2. Harvesting bacterial cells: spin down the cell culture (centrifuging at 4 °C, 
850×10 rpm for 10 minutes). Remove all traces of LB medium.  
3. Cell resuspension: dissolve the pellet with 4 ml of solution E1. 
4. Cell lysis: add 4 ml of solution E2. Do not vortex, just gently mix by inverting 
the tube until the lysate appears to be homogenous. Incubate at room 
temperature for 5 minutes. 
5. Neutralization: add 4 ml of solution E3 and mix immediately by multiple 
inverting. Do not vortex. Then centrifuge at room temperature, 850×10 rpm 
for 10 minutes.  
6. Column loading: apply the supernatant from step 5 to the column, and allow 
the lysate to run by gravity flow. 
7. Column washing: add 10 ml of solution E5, and allow to empty by gravity 
flow. Repeat step 7. Do not force out remaining solution. 
8. Plasmid elution: switch tube under the column. Add 5 ml of solution E6 to the 
column and allow to run by gravity flow. Do not force out remaining solution.  
9. Plasmid precipitation: precipitate the DNA with 3.5 ml isopropanol and 
centrifuge at 4 °C, 850×10 rpm for 30 minutes. Remove the supernatant.  
10. Wash the plasmid DNA with 70 % ethanol and transfer everything to a 
eppendorf tube. Centrifuge at 14 000 rpm for 30 minutes. Remove the ethanol 
by using a pipette connected to water suction. 
11. Air dry the DNA pellet for at least 10 minutes. 
12. Redissolve the DNA pellet in 100 µl nuclease-free water. Measure the 
concentration and store at -20 °C.  
 
 
 
 
Solutions supplied with the kit: 
 
Solution E1 (Cell Resuspending) Store at RT 
50 mM  Tris  
10 mM  EDTA  
 HCl ad pH 8.0  
The RNase-containing solution E1 must be stored at 4°C. 
   
Solution E2  (Cell Lysis) Store at RT 
200 mM  NaOH  
1.0 %  SDS (w/v)  
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Solution E3 (Neutralization) Store at RT 
3.1 M  potassium acetate  
 acetic acid ad pH 5.5  
   
Solution E4 (Column Equilibration) Store at RT 
600 mM  NaCl  
100 mM  sodium acetate  
0.15 %  TritonX-100  
 acetic acid ad pH 5.0  
   
Solution E5 (Column Washing) Store at RT 
800 mM  NaCl  
100 mM  sodium acetate  
 acetic acid ad pH 5.0  
   
Solution E6 (DNA Elution) Store at RT 
1250 mM  NaCl  
100 mM  Tris  
 HCl ad pH 8.5  
  RT = room temperature 
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Appendix 7 
Restriction enzymes that cut and do not cut the CDK1, CDK2 and CKS2 nucleotide 
seuences. The analysis was performed using Webcutter.  
 
CKS2 
240 base pairs 
Graphic map | Table by enzyme name  
 
              XhoII                                                         
              MflI                Eco255I               Bse118I             
              BstYI               Acc113I               BssAI   NspI        
atggcccacaagcagatctactactcggacaagtacttcgacgaacactacgagtaccggcatgttatgttaccc base pairs 
taccgggtgttcgtctagatgatgagcctgttcatgaagctgcttgtgatgctcatggccgtacaatacaatggg 1 to 75 
              BstX2I              ScaI                  BsrFI               
              BglII                                     Cfr10I              
                                                                            
  
                                                   BseRI        AspEI       
                                                Ksp632I         EclHKI      
                                              Eco57I       BseRI            
agagaactttccaaacaagtacctaaaactcatctgatgtctgaagaggagtggaggagacttggtgtccaacag base pairs 
tctcttgaaaggtttgttcatggattttgagtagactacagacttctcctcacctcctctgaaccacaggttgtc 76 to 150 
                                                Eam1104I        AhdI        
                                                EarI            Eam1105I    
                                                                            
  
                                                                            
                                                                      EarI  
                           BspHI                                      Eam11 
agtctaggctgggttcattacatgattcatgagccagaaccacatattcttctctttagacgacctcttccaaaa base pairs 
tcagatccgacccaagtaatgtactaagtactcggtcttggtgtataagaagagaaatctgctggagaaggtttt 151 to 225 
                           RcaI                                       Ksp63 
                                                                            
                                                                            
  
                  
                  
04I               
gatcaacaaaaatga  base pairs 
ctagttgtttttact  226 to 240 
2I                
                                   
 
The following endonucleases were selected but don't cut this sequence: 
AatI, AatII, Acc16I, Acc65I, AccB1I, AccB7I, AccBSI, AccI, AccIII, AclNI,  
AcsI, AcyI, AfeI, AflII, AflIII, AgeI, Alw21I, Alw44I, AlwNI, Ama87I, AocI,  
Aor51HI, ApaI, ApaLI, ApoI, AscI, AseI, AsnI, Asp700I, Asp718I, AspHI,  
AspI, AtsI, AvaI, AviII, AvrII, BalI, BamHI, BanI, BanII, BanIII, BbeI,  
BbiII, BbrPI, BbsI, BbuI, Bbv12I, Bbv16II, BcgI, BclI, BcoI, BfrI, BglI,  
BlnI, BlpI, BpiI, BpmI, Bpu1102I, Bpu14I, BpuAI, Bsa29I, BsaAI, BsaBI,  
BsaHI, BsaI, BsaMI, BsaOI, BsaWI, BscI, Bse21I, Bse8I, BseAI, BseCI, BsePI,  
BsgI, Bsh1285I, Bsh1365I, BshNI, BsiEI, BsiHKAI, BsiI, BsiMI, BsiWI, BsmBI,  
BsmI, BsoBI, Bsp106I, Bsp119I, Bsp120I, Bsp13I, Bsp1407I, Bsp143II, Bsp1720I,  
Bsp19I, Bsp68I, BspCI, BspDI, BspEI, BspLU11I, BspMI, BspTI, BspXI, BsrBI,  
BsrBRI, BsrDI, BsrGI, BssHII, BssSI, BssT1I, Bst1107I, Bst98I, BstBI, BstD102I,  
BstDSI, BstEII, BstH2I, BstI, BstMCI, BstPI, BstSFI, BstSNI, BstXI, BstZI,  
Bsu15I, Bsu36I, CciNI, CelII, Cfr42I, Cfr9I, CfrI, ClaI, CpoI, Csp45I,  
CspI, CvnI, DraI, DraII, DraIII, DrdI, DsaI, EaeI, EagI, Ecl136II, EclXI,  
Eco105I, Eco130I, Eco147I, Eco24I, Eco31I, Eco32I, Eco47III, Eco52I, Eco64I,  
Eco72I, Eco81I, Eco88I, Eco91I, EcoICRI, EcoNI, EcoO109I, EcoO65I, EcoRI,  
EcoRV, EcoT14I, EcoT22I, EheI, ErhI, Esp1396I, Esp3I, FauNDI, FbaI, FriOI,  
FseI, FspI, GsuI, HaeII, Hin1I, HincII, HindII, HindIII, HpaI, Hsp92I,  
KasI, Kpn2I, KpnI, Ksp22I, KspI, LspI, MamI, MfeI, MluI, MluNI, Mph1103I,  
MroI, MroNI, MscI, MslI, Msp17I, MspA1I, MspCI, MunI, Mva1269I, NaeI, NarI,  
NcoI, NdeI, NgoAIV, NgoMI, NheI, NotI, NruI, NsiI, NspBII, NspV, PacI,  
PaeI, PaeR7I, Pfl23II, PflMI, PinAI, Ple19I, PmaCI, Pme55I, PmeI, PmlI,  
Ppu10I, PpuMI, PshAI, PshBI, Psp124BI, Psp1406I, Psp5II, PspAI, PspALI,  
PspEI, PspLI, PspOMI, PstI, PstNHI, PvuI, PvuII, RsrII, SacI, SacII, SalI,  
SapI, SbfI, SexAI, SfcI, SfiI, Sfr274I, Sfr303I, SfuI, SgfI, SgrAI, SmaI,  
SmiI, SnaBI, SpeI, SphI, SplI, SrfI, Sse8387I, SseBI, SspBI, SspI, SstI,  
SstII, StuI, StyI, SunI, SwaI, Tth111I, Van91I, Vha464I, VneI, VspI, XbaI,  
XcmI, XhoI, XmaI, XmaIII, XmnI, Zsp2I 
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CDK1 
894 base pairs 
Graphic map | Table by enzyme name  
 
                                     BshNI                                  
                                     Asp718I                                
                                     Eco64I                    AccI       SfcI 
atggaagattataccaaaatagagaaaattggagaaggtacctatggagttgtgtataagggtagacacaaaact base pairs 
taccttctaatatggttttatctcttttaacctcttccatggatacctcaacacatattcccatctgtgttttga 1 to 75 
                                     BanI KpnI                            BstSFI 
                                     Acc65I                                 
                                     AccB1I                                 
  
                                                                            
                                                EarI Asp700I   Eco255I      
                                                Eam1104I       Acc113I      
acaggtcaagtggtagccatgaaaaaaatcagactagaaagtgaagaggaaggggttcctagtactgcaattcgg base pairs 
tgtccagttcaccatcggtactttttttagtctgatctttcacttctccttccccaaggatcatgacgttaagcc 76 to 150 
                                                Ksp632I        ScaI         
                                                     XmnI                   
                                                                            
  
                                                   Eco57I                   
                                                 BbsI                       
  AcsI                                           BpuAI                      
gaaatttctctattaaaggaacttcgtcatccaaatatagtcagtcttcaggatgtgcttatgcaggattccagg base pairs 
ctttaaagagataatttccttgaagcagtaggtttatatcagtcagaagtcctacacgaatacgtcctaaggtcc 151 to 225 
  ApoI                                           Bbv16II                    
                                                 BpiI                       
                                                                            
  
                          NcoI Bsp19I                                       
                          StyI DsaI XhoII                                   
                          Eco130I BstX2I                                    
ttatatctcatctttgagtttctttccatggatctgaagaaatacttggattctatccctcctggtcagtacatg base pairs 
aatatagagtagaaactcaaagaaaggtacctagacttctttatgaacctaagatagggaggaccagtcatgtac 226 to 300 
                          ErhI BstDSI  Eco57I                               
                          BssT1I BstYI                                      
                          EcoT14I MflI                                      
  
                                                                            
                                                                      EarI  
                                     SfcI                    XbaI     Eam11 
gattcttcacttgttaagagttatttataccaaatcctacaggggattgtgttttgtcactctagaagagttctt base pairs 
ctaagaagtgaacaattctcaataaatatggtttaggatgtcccctaacacaaaacagtgagatcttctcaagaa 301 to 375 
                                     BstSFI                           Ksp63 
                                                                            
                                                                            
  
                                                                            
                                                                            
04I                                                                         
cacagagacttaaaacctcaaaatctcttgattgatgacaaaggaacaattaaactggctgattttggccttgcc base pairs 
gtgtctctgaattttggagttttagagaactaactactgtttccttgttaatttgaccgactaaaaccggaacgg 376 to 450 
2I                                                                          
                                                                            
                                                                            
  
                                                          XhoII             
                                                          MflI              
                                                          BstYI    GsuI     
agagcttttggaatacctatcagagtatatacacatgaggtagtaacactctggtacagatctccagaagtattg base pairs 
tctcgaaaaccttatggatagtctcatatatgtgtactccatcattgtgagaccatgtctagaggtcttcataac 451 to 525 
                                                          BstX2I   BpmI     
                                                          BglII             
                                                                            
  
                                XcmI                                        
                              HincII          BshNI                         
                            GsuI              Eco64I                        
ctggggtcagctcgttactcaactccagttgacatttggagtataggcaccatatttgctgaactagcaactaag base pairs 
gaccccagtcgagcaatgagttgaggtcaactgtaaacctcatatccgtggtataaacgacttgatcgttgattc 526 to 600 
                            BpmI              BanI                          
                              HindII          AccB1I                        
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            NcoI Bsp19I                                                     
            StyI DsaI         Ksp22I      EarI                              
            Eco130I           FbaI        Eam1104I                          
aaaccacttttccatggggattcagaaattgatcaactcttcaggattttcagagctttgggcactcccaataat base pairs 
tttggtgaaaaggtacccctaagtctttaactagttgagaagtcctaaaagtctcgaaacccgtgagggttatta 601 to 675 
            ErhI BstDSI       BclI        Ksp632I                           
            BssT1I                          Eco57I                          
            EcoT14I                                                         
  
         BalI                                                               
         MscI                                                               
       EaeI                                                                 
gaagtgtggccagaagtggaatctttacaggactataagaatacatttcccaaatggaaaccaggaagcctagca base pairs 
cttcacaccggtcttcaccttagaaatgtcctgatattcttatgtaaagggtttacctttggtccttcggatcgt 676 to 750 
       CfrI                                                                 
         MluNI                                                              
                                                                            
  
                                                                            
                                                                            
                                                                          AcsI 
tcccatgtcaaaaacttggatgaaaatggcttggatttgctctcgaaaatgttaatctatgatccagccaaacga base pairs 
agggtacagtttttgaacctacttttaccgaacctaaacgagagcttttacaattagatactaggtcggtttgct 751 to 825 
                                                                          ApoI 
                                                                            
                                                                            
  
                                                                        
                                                                        
                                                                        
atttctggcaaaatggcactgaatcatccatattttaatgatttggacaatcagattaagaagatgtag  base pairs 
taaagaccgttttaccgtgacttagtaggtataaaattactaaacctgttagtctaattcttctacatc  826 to 894 
                                                                        
 
 
The following endonucleases were selected but don't cut this sequence: 
AatI, AatII, Acc16I, AccB7I, AccBSI, AccIII, AclNI, AcyI, AfeI, AflII,  
AflIII, AgeI, AhdI, Alw21I, Alw44I, AlwNI, Ama87I, AocI, Aor51HI, ApaI,  
ApaLI, AscI, AseI, AsnI, AspEI, AspHI, AspI, AtsI, AvaI, AviII, AvrII,  
BamHI, BanII, BanIII, BbeI, BbiII, BbrPI, BbuI, Bbv12I, BcgI, BcoI, BfrI,  
BglI, BlnI, BlpI, Bpu1102I, Bpu14I, Bsa29I, BsaAI, BsaBI, BsaHI, BsaI,  
BsaMI, BsaOI, BsaWI, BscI, Bse118I, Bse21I, Bse8I, BseAI, BseCI, BsePI,  
BseRI, BsgI, Bsh1285I, Bsh1365I, BsiEI, BsiHKAI, BsiI, BsiMI, BsiWI, BsmBI,  
BsmI, BsoBI, Bsp106I, Bsp119I, Bsp120I, Bsp13I, Bsp1407I, Bsp143II, Bsp1720I,  
Bsp68I, BspCI, BspDI, BspEI, BspHI, BspLU11I, BspMI, BspTI, BspXI, BsrBI,  
BsrBRI, BsrDI, BsrFI, BsrGI, BssAI, BssHII, BssSI, Bst1107I, Bst98I, BstBI,  
BstD102I, BstEII, BstH2I, BstI, BstMCI, BstPI, BstSNI, BstXI, BstZI, Bsu15I,  
Bsu36I, CciNI, CelII, Cfr10I, Cfr42I, Cfr9I, ClaI, CpoI, Csp45I, CspI,  
CvnI, DraI, DraII, DraIII, DrdI, EagI, Eam1105I, Ecl136II, EclHKI, EclXI,  
Eco105I, Eco147I, Eco24I, Eco31I, Eco32I, Eco47III, Eco52I, Eco72I, Eco81I,  
Eco88I, Eco91I, EcoICRI, EcoNI, EcoO109I, EcoO65I, EcoRI, EcoRV, EcoT22I,  
EheI, Esp1396I, Esp3I, FauNDI, FriOI, FseI, FspI, HaeII, Hin1I, HindIII,  
HpaI, Hsp92I, KasI, Kpn2I, KspI, LspI, MamI, MfeI, MluI, Mph1103I, MroI,  
MroNI, MslI, Msp17I, MspA1I, MspCI, MunI, Mva1269I, NaeI, NarI, NdeI, NgoAIV,  
NgoMI, NheI, NotI, NruI, NsiI, NspBII, NspI, NspV, PacI, PaeI, PaeR7I,  
Pfl23II, PflMI, PinAI, Ple19I, PmaCI, Pme55I, PmeI, PmlI, Ppu10I, PpuMI,  
PshAI, PshBI, Psp124BI, Psp1406I, Psp5II, PspAI, PspALI, PspEI, PspLI,  
PspOMI, PstI, PstNHI, PvuI, PvuII, RcaI, RsrII, SacI, SacII, SalI, SapI,  
SbfI, SexAI, SfiI, Sfr274I, Sfr303I, SfuI, SgfI, SgrAI, SmaI, SmiI, SnaBI,  
SpeI, SphI, SplI, SrfI, Sse8387I, SseBI, SspBI, SspI, SstI, SstII, StuI,  
SunI, SwaI, Tth111I, Van91I, Vha464I, VneI, VspI, XhoI, XmaI, XmaIII, Zsp2I 
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CDK2 
897 base pairs 
Graphic map | Table by enzyme name  
 
                                         BsiWI                              
                  Esp1396I               PspLI       BsrGI                  
                  AccB7I                 SplI        SspBI                HincII 
atggagaacttccaaaaggtggaaaagatcggagagggcacgtacggagttgtgtacaaagccagaaacaagttg base pairs 
tacctcttgaaggttttccaccttttctagcctctcccgtgcatgcctcaacacatgtttcggtctttgttcaac 1 to 75 
                  PflMI                  BsaAI       Bsp1407I             HindII 
                  Van91I                 Pfl23II                            
                                         SunI                               
  
                   AflII BfrI                                               
                   BspTI MspCI                                 Eco255I      
                   Bsp143II                                    Acc113I      
acgggagaggtggtggcgcttaagaaaatccgcctggacactgagactgagggtgtgcccagtactgccatccga base pairs 
tgccctctccaccaccgcgaattcttttaggcggacctgtgactctgactcccacacgggtcatgacggtaggct 76 to 150 
                   HaeII Vha464I                               ScaI         
                   BstH2I                                                   
                   Bst98I                                                   
  
  XhoII      MspCI                                                          
  MflI       Bst98I                                                         
  BstYI      BspTI                  SspI                                    
gagatctctctgcttaaggagcttaaccatcctaatattgtcaagctgctggatgtcattcacacagaaaataaa base pairs 
ctctagagagacgaattcctcgaattggtaggattataacagttcgacgacctacagtaagtgtgtcttttattt 151 to 225 
  BstX2I     AflII                                                          
  BglII      Vha464I                                                        
             BfrI                                                           
  
                              BglII                                         
                              BstX2I                                     BsaMI 
     SexAI      AcsI       BsgI         AcsI                             BsmI 
ctctacctggtttttgaatttctgcaccaagatctcaagaaattcatggatgcctctgctctcactggcattcct base pairs 
gagatggaccaaaaacttaaagacgtggttctagagttctttaagtacctacggagacgagagtgaccgtaagga 226 to 300 
                ApoI          BstYI     ApoI                             Mva1269I 
                              MflI                                          
                              XhoII                                         
  
                                                                            
    Ksp632I                   MspA1I   BpmI                       DraII     
    Eam1104I                  PvuII    EcoO109I                   PpuMI     
cttcccctcatcaagagctatctgttccagctgctccagggcctagctttctgccattctcatcgggtcctccac base pairs 
gaaggggagtagttctcgatagacaaggtcgacgaggtcccggatcgaaagacggtaagagtagcccaggaggtg 301 to 375 
                              NspBII   GsuI                       EcoO109I  
    EarI                               DraII                      Psp5II    
                                                                            
  
                                                                            
                                                                            
       Eco31I        AlwNI                         NheI                     
cgagaccttaaacctcagaatctgcttattaacacagagggggccatcaagctagcagactttggactagccaga base pairs 
gctctggaatttggagtcttagacgaataattgtgtctcccccggtagttcgatcgtctgaaacctgatcggtct 376 to 450 
       BsaI                                        PstNHI                   
                                                                            
                                                                            
  
                                       Eco91I     Acc65I    Eco24I SstI     
                                    Esp1396I      BanI KpnI AspHI FriOI     
                                    AccB7I EcoO65I AccB1I Ecl136II BanII    
gcttttggagtccctgttcgtacttacacccatgaggtggtgaccctgtggtaccgagctcctgaaatcctcctg base pairs 
cgaaaacctcagggacaagcatgaatgtgggtactccaccactgggacaccatggctcgaggactttaggaggac 451 to 525 
                                    PflMI BstPI   Eco64I  EcoICRI SacI      
                                    Van91I PspEI  Asp718I   Bbv12I Alw21I   
                                       BstEII     BshNI     Psp124BI BsiHKAI 
  
                        BstXI                                               
                      NspBII                                                
          SspI        PvuII           GsuI                                Bsp12 
ggctgcaaatattattccacagctgtggacatctggagcctgggctgcatctttgctgagatggtgactcgccgg base pairs 
ccgacgtttataataaggtgtcgacacctgtagacctcggacccgacgtagaaacgactctaccactgagcggcc 526 to 600 
                      MslI            BpmI                                PspOM 
                      MspA1I                                                
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   Eco24I                             BsaWI SapI BstYI                      
EcoO109I                              MroI Bsp13I XhoII    DraII            
    0I          GsuI                  BspEI BsiMI BstX2I   PpuMI            
gccctattccctggagattctgagattgaccagctcttccggatctttcggactctggggaccccagatgaggtg base pairs 
cgggataagggacctctaagactctaactggtcgagaaggcctagaaagcctgagacccctggggtctactccac 601 to 675 
    I BanII     BpmI                  AccIII EarI MflI     EcoO109I         
DraII ApaI                            Kpn2I Eam1104I       Psp5II           
   FriOI                              BseAI Ksp632I                         
  
      BalI                                               BanII              
      MscI                                               Eco24I             
    EaeI                                             Bsp120I                
gtgtggccaggagttacttctatgcctgattacaagccaagtttccccaagtgggcccggcaagattttagtaaa base pairs 
cacaccggtcctcaatgaagatacggactaatgttcggttcaaaggggttcacccgggccgttctaaaatcattt 676 to 750 
    CfrI                                             PspOMI                 
      MluNI                                              FriOI              
                                                         ApaI               
  
                                                                            
                                                                            
                                                      BsgI                  
gttgtacctcccctggatgaagatggacggagcttgttatcgcaaatgctgcactacgaccctaacaagcggatt base pairs 
caacatggaggggacctacttctacctgcctcgaacaatagcgtttacgacgtgatgctgggattgttcgcctaa 751 to 825 
                                                                            
                                                                            
                                                                            
  
     StyI                                                                  
     Eco130I                                                               
  EaeI EcoT14I                                                             
tcggccaaggcagccctggctcaccctttcttccaggatgtgaccaagccagtaccccatcttcgactctga  base pairs 
agccggttccgtcgggaccgagtgggaaagaaggtcctacactggttcggtcatggggtagaagctgagact  826 to 897 
  CfrI      XcmI                                                           
     ErhI                                                                  
     BssT1I                                                                
  
 
 
 
The following endonucleases were selected but don't cut this sequence: 
AatI, AatII, Acc16I, AccBSI, AccI, AclNI, AcyI, AfeI, AflIII, AgeI, AhdI,  
Alw44I, Ama87I, AocI, Aor51HI, ApaLI, AscI, AseI, AsnI, Asp700I, AspEI,  
AspI, AtsI, AvaI, AviII, AvrII, BamHI, BanIII, BbeI, BbiII, BbrPI, BbsI,  
BbuI, Bbv16II, BcgI, BclI, BcoI, BglI, BlnI, BlpI, BpiI, Bpu1102I, Bpu14I,  
BpuAI, Bsa29I, BsaBI, BsaHI, BsaOI, BscI, Bse118I, Bse21I, Bse8I, BseCI,  
BsePI, BseRI, Bsh1285I, Bsh1365I, BsiEI, BsiI, BsmBI, BsoBI, Bsp106I, Bsp119I,  
Bsp1720I, Bsp19I, Bsp68I, BspCI, BspDI, BspHI, BspLU11I, BspMI, BspXI,  
BsrBI, BsrBRI, BsrDI, BsrFI, BssAI, BssHII, BssSI, Bst1107I, BstBI, BstD102I,  
BstDSI, BstI, BstMCI, BstSFI, BstSNI, BstZI, Bsu15I, Bsu36I, CciNI, CelII,  
Cfr10I, Cfr42I, Cfr9I, ClaI, CpoI, Csp45I, CspI, CvnI, DraI, DraIII, DrdI,  
DsaI, EagI, Eam1105I, EclHKI, EclXI, Eco105I, Eco147I, Eco32I, Eco47III,  
Eco52I, Eco57I, Eco72I, Eco81I, Eco88I, EcoNI, EcoRI, EcoRV, EcoT22I, EheI,  
Esp3I, FauNDI, FbaI, FseI, FspI, Hin1I, HindIII, HpaI, Hsp92I, KasI, Ksp22I,  
KspI, LspI, MamI, MfeI, MluI, Mph1103I, MroNI, Msp17I, MunI, NaeI, NarI,  
NcoI, NdeI, NgoAIV, NgoMI, NotI, NruI, NsiI, NspI, NspV, PacI, PaeI, PaeR7I,  
PinAI, Ple19I, PmaCI, Pme55I, PmeI, PmlI, Ppu10I, PshAI, PshBI, Psp1406I,  
PspAI, PspALI, PstI, PvuI, RcaI, RsrII, SacII, SalI, SbfI, SfcI, SfiI,  
Sfr274I, Sfr303I, SfuI, SgfI, SgrAI, SmaI, SmiI, SnaBI, SpeI, SphI, SrfI,  
Sse8387I, SseBI, SstII, StuI, SwaI, Tth111I, VneI, VspI, XbaI, XhoI, XmaI,  
XmaIII, XmnI, Zsp2I 
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Appendix 8 
Protocol for double digestion with restriction enzymes NdeI and BamHI, and NdeI 
and BamHI-HF 
 
 
Table A8.1 and table A8.2 show reaction conditions for double digestion with NdeI 
and BamHI, and NdeI and BamHI-HF respectively.  
 
 
 
Table A8.1: Double digestion with NdeI and BamHI  
Component Amount per reaction 
DNA   4 µg* or 1 µg**    
Buffer 3   5 µl 
BSA (10 × dilution)   5 µl 
Nuclease-free water (ad 45 µl)      µl 
NdeI   3 µl Æ incubate at 37 °C for 2 hours 
BamHI   2 µl Æ incubate at 37 °C for 1.5 hour 
Total volume   50 µl 
* when digesting plasmids without inserted fragment. 
** when digesting plasmids with inserted fragment. 
 
 
Table A8.2: Double digestion with NdeI and BamHI-HF 
Component Amount per reaction 
DNA   4 µg* or 1 µg**  
Buffer 4   5 µl 
Nuclease-free water (ad 46µl)      µl 
NdeI   2 µl 
BamHI-HF   2 µl Æ incubate at 37 °C for 2 hours 
Total volume  50 µl 
Before gel electrophoresis, add 2.5 µl 10 % SDS to each tube 
* when digesting plasmids without inserted fragment. 
** when digesting plasmids with inserted fragment.  
 
After double digestion, the cutting mixtures were either used further or stored at -20 
°C.  
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Appendix 9 
Protocol for analysis by gel electrophoresis 
 
To all DNA samples including the DNA marker, 2 log ladder (New England Biolabs 
Inc.), add Loading Dye Blue (6×, New England Biolabs Inc.).  
 
1. Add 0.5 g agarose and 60 ml buffer* to a 250 ml bottle. Heat the mixture in the 
microwave to the boiling point until a clear, transparent solution is achieved. 
2. Let the mixture cool down and pour it into a gel mold. 
3. Apply an appropriate comb for forming the sample wells in the gel.  
4. Allow the gel to set completely at room temperature (25-30 minutes).  
5. Remove the comb and transfer the gel to an electrophoresis tank containing 
enough buffer* to cover the gel. 
6. Apply the DNA marker and the DNA samples to separate wells. 
7. Apply a voltage of 100 V and run for 1.5 to 2.5 hours, depending on the size of 
the samples. 
8. Immerse the gel in stain** and allow to stain for 15-30 minutes. 
9. Examine the gel by UV light and photograph the gel (when appropriate, cut out 
the gel pieces with a scalpel).  
 
* 0.5 x TBE or 1 x TAE 
** 100 ml dH2O and 10 μl 1 % ethidium bromide, or 100 ml dH2O and 30 µl GelRed 
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Appendix 10 
Protocol for purification of PCR products 
 
 
Wizard® SV Gel and PCR Clean-Up System from Promega. 
 
 
Modified from Quick Protocol, following the steps for DNA purification by 
centrifugation. 
 
 
Gel slice preparation 
Dissolving the gel slice 
1. Following electrophoresis, excise DNA band from gel and place gel slice in a 
1.5 ml microcentrifuge tube. 
2. Add 10 µl membrane binding solution per 10 mg of gel slice. Vortex and 
incubate at 50-65 °C until gel slice is completely dissolved. From time to time, 
invert tube. 
 
Binding of DNA 
1. Insert the minicolumn into the collection tube. 
2. Transfer dissolved gel mixture to the minicolumn assembly. Incubate at room 
temperature for 1 minute (the column can only take 700 µl, if there is not 
room for all the gel mixture, do steps 2 and 3 again). 
3. Centrifuge at 13 000 rpm for 1 minute. Discard the flow-through and reinsert 
the minicolumn into the collection tube. 
 
Washing 
4. Add 700 µl membrane wash solution (ethanol added). Centrifuge at 13 000 
rpm for 1 minute. Discard flow-through and reinsert the minicolumn into the 
collection tube. 
5. Repeat step 4 with 500 µl membrane wash solution. Centrifuge at 13 000 rpm 
for 5 minutes. 
6. Empty the collection tube and recentrifuge the column assembly at 13 000 rpm 
for an additional 1 minute.  
 
Elution 
7. Carefully transfer the minicolumn to a clean 1.5 ml microcentrifuge tube. 
8. Add 30 µl of nuclease-free water to the minicolumn. Incubate at room 
temperature for 1 minute. Centrifuge at 13 000 rpm for 1 minute 
9. Discard the minicolumn, measure the concentration of the DNA. Store at 4°C 
or – 20 °C 
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Appendix 11 
Protocol for purification of DNA fragments from PCR and other enzymatic reactions  
 
 
QIAquick PCR Purification Kit from QIAgen 
 
Modified from Bench Protocol: QIAquick PCR Purification, follow the steps for 
microcentrifuge 
 
1. Add 5 volumes of Buffer PB to 1 volume of the sample and mix. 
2. Place a QIAquick spin column in a provided 2 ml collection tube. 
3. To bind DNA, apply the sample to the QIAquick column and centrifuge at 
13 000 rpm for 60 seconds. Discard flow-through and place the QIAquick 
column back into the same tube. 
4. To wash, add 0.75 ml Buffer PE to the QIAquick column and centrifuge at 
13 000 rpm for 60 seconds. Discard flow-through and place the QIAquick 
column back in the same tube. 
5. Centrifuge the column for an additional 60 seconds (13 000 rpm).  
6. Place the QIAquick column in a clean 1.5 ml microcentrifuge tube 
7. To elute DNA, add 30 µl nuclease-free water to the center of the QIAquick 
membrane. Incubate for 60 seconds and centrifuge the column at 13 000 rpm 
for 60 seconds 
8. Measure the concentration and store at -20 °C  
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Appendix 12 
Protocols for ligation mixtures and transfomations of XL 10-Gold® Ultracompetent E. 
coli cells 
 
 
Protocol for ligation of fragment into plasmid 
 
1. Add appropriate amount of digested fragment to a 1.5 ml tube. 
2. Add appropriate amount of digested plasmid. 
3. Add 2 µl of T4 DNA Ligase Buffer (New England Biolabs Inc). 
4. Add 1 µl of T4 DNA Ligase (New England Biolabs Inc). 
5. Incubate tubes at 16 °C overnight, and store at -20 °C.  
 
Total DNA should be 1-10 ng/µl. The insert:vector molar ratio formula is used to 
calculate the appropriate amount of digested PCR product (insert) and plasmid to 
include in the ligation reaction:  
ng insert
bp insert
ng vector
bp vector
= 2-6
Optimal ratio
 
The optimal amount of DNA give insert:vector molar ratios between two and six. 
Ratios below 2:1 gives poorer ligation efficiency and ratios above 6:1 promote 
multiple inserts (product information, New England Biolabs Inc). 
 
 
Protocol for transformation of XL 10-Gold® Ultracompetent E. coli (modified 
protocol provided by Stratagene) 
 
1. Pre-chill tubes on ice. Preheat LB medium to 42 °C. 
2. Thaw the XL 10 Gold® cells on ice. 
3. When thawed, gently mix the cells by pipetting, and aliquot 100 µl to each 
tube. 
4. Add 4 µl β-Mercaptoethanol (β-ME, Strategene) to each tube and incubate on 
ice for 10 minutes, swirling gently every 2 minutes.  
5. Add 4 µl of ligation mixture to the appropriate tube, swirl gently and incubate 
on ice for 30 minutes. 
6. Heat-shock the tubes at 42 °C for 30 seconds (duration is critical).  
7. Incubate the tubes on ice for 2 minutes. 
8. Add 900 µl preheated (42 °C) LB to each tube, and incubate at 37 °C for 1 
hour with shaking.  
9. Plate 100 µl of the transformation mixture on LB plates containing appropriate 
antibiotics.  
10. Pellet the rest of the transformation mixture at 13 000 rpm for 2 minutes. 
Remove the supernatant and resuspend the cell pellet in 100 µl LB. Repeat 
step 9. 
11. Incubate the plates at 37 °C overnight. 
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Appendix 13 
Protocol for plasmid purification, mini 
 
 
Wizard® Plus SV Minipreps DNA Purification System from Promega 
 
Modified from Quick Protocol, following the steps for centrifugation protocol. 
 
 
Production of cleared lysate 
1. Pellet 1-10 ml overnight culture of E. coli cells containing plasmid at 13 000 
rpm for 3 minutes, and remove the supernatant. 
2. Thoroughly resuspend pellet with 250 µl cell resuspension solution. 
3. Add 250 µl cell lysis solution to each sample; invert 4 times to mix. 
4. Add 10 µl alkaline protease solution; invert 4 times to mix. Incubate 5 minutes 
at room temperature. 
5. Add 350 µl neutralization solution; invert 4 times to mix. 
6. Centrifuge at 13 000 rpm for 10 minutes at room temperature. 
 
Binding of plasmid DNA 
7. Insert spin column into collection tube. 
8. Decant cleared lysate into spin column. 
9. Centrifuge at 13 000 rpm for 1 minute at room temperature. Discard 
flowthrough and reinsert column into collection tube. 
 
Washing 
10. Add 750 µl wash solution (with ethanol added). Centrifuge at 13 000 rpm for 
1 minute. Discard flowthrough and reinsert column into collection tube. 
11. Repeat step 10 with 250 µl wash solution.  
12. Centrifuge at 13 000 rpm for 2 minutes at room temperature. 
 
Elution 
13. Transfer spin column to a sterile 1.5 ml microcentrifuge tube, being careful 
not to transfer any of the column wash solution with the spin column. 
14. Add 50 µl of nuclease-free water to the spin column. Centrifuge at 13 000 rpm 
for 1 minute.  
15. Discard column, measure the concentration of DNA and store at -20 °C.  
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Appendix 14  
List of materials used 
 
Table A14.1: Bacterial strains and plasmids 
Strain name Relevant features Plasmid Source 
XL 10-Gold TetrΔ(mrcA)183Δ(mrcCB-hsdSMR-mrr)173 
endA1 supE44 thi-1 recA1 gyrA96 relA1 lac Hte 
[F´ proAB lac1qZ ΔM15 Tn10 (Tetr) Amy Camr] 
     -   Stratagene 
JM109 endA1, recA1, gyrA96, thi, hsdR17 (rk–, mk+), 
relA1, supE44, Δ( lac-proAB), [F´ traD36, 
proAB, laqIqZΔM15]  
     - Promega 
DH5α supE44, ΔlacU169(φ80lacZΔM15), hsdR17, 
recA1, endA1, gyrA96, thi-1, relA1 
     - Walter Messer  
Y2H 01 DH5α pGADT7 Ingvild Flåtten 
Y2H 03 DH5α pGBKT7 Ingvild Flåtten 
 
 
   
Plasmid  Relevant features Selection/ 
nutritional marker 
Source 
pCMV-HA/CDK1AF PCMV IE, pUC ori, SV 40 splice donor/splice 
acceptor, HA epitope tag, bearing CDK1AF 
Amp Randi Syljuåsen 
pCMV-HA/CDK2F PCMV IE, pUC ori, SV 40 splice donor/splice 
acceptor, HA epitope tag, bearing CDK2F 
Amp Randi Syljuåsen 
pGADT7 PADH1, pUC ori, 2 μ ori; yeast two-hybrid vector 
bearing the GAL4 activation domain 
Amp/ LEU2 Clontech 
pGAD/CDK1AF pGADT7 bearing CDK1AF Amp/ LEU2 This work 
pGAD/CDK2F pGADT7 bearing CDK2F Amp/ LEU2 This work 
pGAD/CDK2AF pGADT7 bearing CDK2AF Amp/ LEU2 This work 
pGAD/CKS2 pGADT7 bearing CKS2 Amp/ LEU2 This work 
pGAD/hda pGADT7 bearing hda Amp/ LEU2 Line Johnsen 
pGBKT7 PADH1, pUC ori, 2 μ ori; yeast two-hybrid vector 
bearing the GAL4 DNA binding domain 
Kan/ TRP1 Clontech 
pGBK/CDK1AF pGBKT7 bearing CDK1AF Kan/ TRP1 This work 
pGBK/CDK2F pGBKT7 bearing CDK2F Kan/ TRP1 This work 
pGBK/CDK2AF pGBKT7 bearing CDK2AF Kan/ TRP1 This work 
pGBK/CKS2 pGBKT7 bearing CKS2 Kan/ TRP1 This work  
pGBK/dnaN pGBKT7 bearing dnaN Kan/ TRP1 Line Johnsen 
pGEM-T Easy Vector T7 and SP6 RNA Polymerase promotors, ori, f1 
ori, lacZ; vector used for subcloningx 
Amp Promega 
pGEM/CDK1AF pGEM bearing CDK1AF Amp This work 
pGEM/CKS2 pGEM bearing CKS2 Amp This work 
pSM/CDK2AF Unknown vector bearing CDK2AF Amp David Morgan 
    
 
 
  
Table A14.2: Primers   
Primers Nucleotide sequence Producer 
Primer AD 5’-AGATGGTGCACGATGCACAG-3’ Eurogentec S.A. 
Primer BD 5’-TTTTCGTTTTAAAACCTAAGAGTC-3’ Eurogentec S.A. 
CDK1F 5’-GGAATTCATATGGAAGATTATACCAAAATAGAGAAAATTGG-3’ Eurogentec S.A. 
CDK1Rev 5’-GGAATTGGATCCCTACATCTTCTTAATCTGATTG-3’ Eurogentec S.A. 
CDK2F 5’-GGAATTCATATGGAGAACTTCCAAAAGGTGG-3’ Eurogentec S.A. 
CDK2Rev 5’-GGAATTGGATCCTCAGAGTCGAAGATGG-3’ Eurogentec S.A. 
CKS2F 5’-GGAATTCATATGGCCCACAAGCAGATCTACTAC-3’ Eurogentec S.A. 
CKS2Rev 5’-GGAATTGGATCCTCATTTTTGTTGATCTTTTGGAAGAGG-3’ Eurogentec S.A. 
Primer T7 5’-TAATACGACTCACTATAGGG-3’ GATC Biotech 
Primer SP6 5’-ATTTAGGTGACACTATAGAA-3’ GATC Biotech 
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Table A14.3: Restriction enzymes  
Enzyme Restriction site Buffer Producer 
Bam HI    (20 000 u/ml) 5’…GGATCC…3’ NEBuffer3 + BSA New England Biolabs 
Bam HI-HF    (20 000 u/ml) 5’…GGATCC…3’ NEBuffer 4 New England Biolabs 
EcoRI    (20 000 u/ml) 5’…GAATTC…3’ NEBuffer EcoRI New England Biolabs 
NdeI    (20 000 u/ml) 5’…CATATG…3’ NEBuffer 4 New England Biolabs 
    
 
 
 
Table A14.4: Other enzymes and proteins    
Enzyme/protein Buffer Producer 
BSA (10 mg/ml)  New England Biolabs 
PfuUltra™ II fusion HS DNA 
Polymerase 
10 × PfuUltra™ II reaction buffer Stratagene 
T4 DNA Ligase  T4 DNA Ligase Reaction Buffer New England Biolabs 
T4 DNA Ligase  2× Rapid Ligation Buffer Promega 
Taq DNA Polymerase  Taq DNA Polymerase 10× Reaction Buffer Promega 
   
  
Table A14.5: Stock solutions of antibiotics   
Antibiotic Stock solution Producer 
Ampicillin 100 mg/ml in dH2O Bristol-Meyers Squibb 
Cloramphenicol   30 mg/ml in dH2O Sigma-Aldrich 
Kanamycin   50 mg/ml in dH2O  Sigma-Aldrich  
  
    
  
Table A14.6: Other chemicals and reagents for molecular biology 
Chemical/Reagent Concentration Producer 
2-Log DNA Ladder (marker) 1000 µg/ml New England Biolabs 
5-bromo-4-chloro-3-indolyl-β-D-galactoside (X-Gal) 50 mg/ml Sigma-Aldrich  
Adenine 2 mg/ml in dH2O Sigma-Aldrich 
Agarose, Type I  Sigma-Aldrich 
β-mercaptoethanol  Stratagene 
cDNA ref RNA (for CKS2) 100 ng/µl This work  
dATP 100 mM Promega 
Dithiothreitol (DTT) 1 M Sigma-ALdrich 
dNTP mix 25 mM each dNTP AB 
Ethidium Bromide 1 % Merck 
Gel Loading Dye, Blue 6× New England Biolabs 
GelRed  Biotium 
Glyserol 99 % Merck 
Histidine 2 mg/ml in dH2O Sigma-Aldrich 
Isopropyl- β-D-galactosidase (IPTG) 100 mM Sigma-Aldrich  
Nuclease-Free Water  QIAgen 
Sodium Chloride 0.8 % in dH2O Merck 
Sodium dodecyl sulfate (SDS) 10 %  VWR International  
       
 
Table A14.7: Commercial kits 
Kit Producer 
Illumina® TotalPrep RNA Amplification Kit Ambion Inc 
Wizard® SV Gel and PCR Clean-Up System Promega 
QIAquick PCR Purification Kit Protocol QIAGEN 
Wizard® Plus SV Minipreps DNA Purification System Promega 
JetStar (Midi-prep) Genomed 
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Table A14.8: List of materials and reagents used for Y2H 
Name Relevant features Producer 
AH 109 MATa, trp1-901, leu2-3, 112, ura3-52, his3-200, 
gal4Δ, gal80Δ, LYS2::GAL1TATA-HIS3, GAL2UAS-
GAL2TATA-ADE2, URA3::MEL1UAS-Mel1TATA-lacZ 
Clontech 
Bacto agar  BD 
DO Supplement  Clontech 
Glass beads 4 mm Merck 
Herring Testes Carrier DNA  Clontech 
Minimal SD Base   Clontech 
YPD  Clontech 
   
 
 
Table A14.9: Equipment 
Equipment Model Producer 
Centrifues 5900 Kubota 
 MIKRO 200R Hettich Zentrifugen 
Electric power supply Power Pac 300 BioRad 
Gel elctrophoresis tank  OWI 
Heating block QBD2 Grant 
Imaging system Chemi Genius VWR International 
Incubation cabinet  Fermaks 
Nanodrop 1000 Thermo Scientific 
PCR machine PTC-100 MJ Research, Inc. 
Pipettes Pipetboy comfort IBS Integra Biosciences 
 100-1000, 10-100, 10-20 and 0.5-5 µl Termo Scientific 
Shaking incubator Thermomixer comfort 2 ml Eppendorf 
Vortexer MS3 digital IKA 
Water bath shaker Innova 3100 New Brunswick Scientific 
UV spectrophotometer UV-1800 Shimadzu 
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Appendix 15 
Protocol for transformation in S. cerevisiae AH109 by the LiAc method (modified) 
 
 
 
1. Mix 100 µl of one-step buffer (appendix 4) with 10 µl of sterile 1M 
dithiothreitol (DTT) (vortex DTT if cloudy). 
2. Resuspend three AH109 colonies from the YPD plate in this solution by 
gently vortexing (if colonies are < 2 mm, use several colonies). 
3. In separate tubes, add ~ 500 ng of each plasmid DNA and 1 µl Herring Testes 
Carrier DNA (Clontech). The total volume DNA can be max 10 µl and 
approximately 1 µg.  
4. Add one tube of mixture from step 2 to each tube containing the DNA (from 
step 3).  
5. Vortex gently. 
6. Incubate for 30 minutes at 45 °C. 
7. Apply all the cells in each tube onto solid SD-DO –leu/-trp medium and use 5-
7 glass beads to promote even spreading of the cells.  
8. Shake the plate back and forth until the transformation mixture is spread over 
the agar surface and has been absorbed. Incubate the plates at 30 °C until 
transformants appear (3-5 days).  
 
 
When transforming simultaneous cotransformations, the bait plasmid (pGBKT7) must 
be used in excess and the pGADT7 plasmid must be limiting. 
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Appendix 16 
Protocol for S. cerevisiae two-hybrid analysis 
 
 
 
1. Transfer appropriate transformants from their solid SD-DO –leu/-trp plate to a 
separate Falcon tube containing 2 ml liquid SD-DO –leu/-trp medium. 
2. Incubate at 30 °C overnight in a swirling water bath. 
3. Mix aliquots (500 µl) of each overnight yeast culture with 200 µl of 87 % 
glycerol and store at -80 °C. 
4. Pellet the rest from each culture from 3 at 13 000 rpm for 3 minutes, and 
remove the supernatant. 
5. Resuspend the cell pellet in 1 ml sterile 0.8 % saline, pellet at 13 000 rpm and 
remove the supernatant. 
6. Repeat step 5.  
7. Resuspend the cell pellet in an appropriate amount of sterile 0.8 % saline 
(depending on the size of the pellet). 
8. Take out 100 µl from each culture in step 7, and dilute with 900 µl of sterile 
0.8 % saline. 
9. Measure optical density (OD) at 600 nm and adjust with sterile 0.8 % saline to 
OD ~ 1.0.  
10. Prepare 10-1, 10-2, and 10-3 dilutions with sterile 0.8 % saline for each sample. 
11. Spot 10 µl aliquots of each dilution (OD = 1, 10-1, 10-2, 10-3) onto solid SD-
DO –leu/-trp medium (control plate) or SD-DO –leu/-trp/-his medium (to 
score for PPI). 
12. Allow the plates to dry completely and incubate at 30 °C for 3 days. 
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Appendix 17 
Sequencing. Comparisons of all cloned fragments sequenced by GATC Biotech with 
the known gene sequence. The computer tool BLAST was used for all the cloned 
fragments. T7 is forward primer, and SP6, BD and AD are revers primers used for 
sequencing. 
 
 
BLAST for CKS2 cloned into pGEM-T Easy-T7 
>lcl|34845  
Length=1022 
 
 Score =  444 bits (240),  Expect = 4e-129 
 Identities = 240/240 (100%), Gaps = 0/240 (0%) 
 Strand=Plus/Plus 
 
Query  1    ATGGCCCACAAGCAGATCTACTACTCGGACAAGTACTTCGACGAACACTACGAGTACCGG  60               
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  45   ATGGCCCACAAGCAGATCTACTACTCGGACAAGTACTTCGACGAACACTACGAGTACCGG  104 
 
Query  61   CATGTTATGTTACCCAGAGAACTTTCCAAACAAGTACCTAAAACTCATCTGATGTCTGAA  120            
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  105  CATGTTATGTTACCCAGAGAACTTTCCAAACAAGTACCTAAAACTCATCTGATGTCTGAA  164 
   
Query  121  GAGGAGTGGAGGAGACTTGGTGTCCAACAGAGTCTAGGCTGGGTTCATTACATGATTCAT  180             
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  165  GAGGAGTGGAGGAGACTTGGTGTCCAACAGAGTCTAGGCTGGGTTCATTACATGATTCAT  224 
   
Query  181  GAGCCAGAACCACATATTCTTCTCTTTAGACGACCTCTTCCAAAAGATCAACAAAAATGA  240             
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  225  GAGCCAGAACCACATATTCTTCTCTTTAGACGACCTCTTCCAAAAGATCAACAAAAATGA  284 
 
 
 
 
 
 
BLAST for CKS2 cloned into pGEM-T Easy-SP6 
>lcl|5649  
Length=1035 
 
 Score =  444 bits (240),  Expect = 4e-129 
 Identities = 240/240 (100%), Gaps = 0/240 (0%) 
 Strand=Plus/Minus 
 
Query  1    ATGGCCCACAAGCAGATCTACTACTCGGACAAGTACTTCGACGAACACTACGAGTACCGG  60              
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  313  ATGGCCCACAAGCAGATCTACTACTCGGACAAGTACTTCGACGAACACTACGAGTACCGG  254 
 
Query  61   CATGTTATGTTACCCAGAGAACTTTCCAAACAAGTACCTAAAACTCATCTGATGTCTGAA  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  253  CATGTTATGTTACCCAGAGAACTTTCCAAACAAGTACCTAAAACTCATCTGATGTCTGAA  194 
 
Query  121  GAGGAGTGGAGGAGACTTGGTGTCCAACAGAGTCTAGGCTGGGTTCATTACATGATTCAT  180              
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  193  GAGGAGTGGAGGAGACTTGGTGTCCAACAGAGTCTAGGCTGGGTTCATTACATGATTCAT  134 
 
Query  181  GAGCCAGAACCACATATTCTTCTCTTTAGACGACCTCTTCCAAAAGATCAACAAAAATGA  240             
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  133  GAGCCAGAACCACATATTCTTCTCTTTAGACGACCTCTTCCAAAAGATCAACAAAAATGA  74 
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BLAST for CDK1AF cloned into pGEM-T Easy-T7 
>lcl|29787  
Length=1036 
 
 Score = 1626 bits (880),  Expect = 0.0 
 Identities = 887/892 (99%), Gaps = 0/892 (0%) 
 Strand=Plus/Plus 
 
Query  1    ATGGAAGATTATACCAAAATAGAGAAAATTGGAGAAGGTACCTATGGAGTTGTGTATAAG  60 
            ||||||||||||||||||||||||||||||||||||||| ||| |||||||||||||||| 
Sbjct  45   ATGGAAGATTATACCAAAATAGAGAAAATTGGAGAAGGTGCCTTTGGAGTTGTGTATAAG  104 
 
Query  61   GGTAGACACAAAACTACAGGTCAAGTGGTAGCCATGaaaaaaaTCAGACTAGAAAGTGAA  120                            
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||   
Sbjct  105  GGTAGACACAAAACTACAGGTCAAGTGGTAGCCATGAAAAAAATCAGACTAGAAAGTGAA  164 
 
Query  121  GAGGAAGGGGTTCCTAGTACTGCAATTCGGGAAATTTCTCTATTAAAGGAACTTCGTCAT  180              
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  165  GAGGAAGGGGTTCCTAGTACTGCAATTCGGGAAATTTCTCTATTAAAGGAACTTCGTCAT  224 
   
Query  181  CCAAATATAGTCAGTCTTCAGGATGTGCTTATGCAGGATTCCAGGTTATATCTCATCTTT  240              
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  225  CCAAATATAGTCAGTCTTCAGGATGTGCTTATGCAGGATTCCAGGTTATATCTCATCTTT  284 
 
Query  241  GAGTTTCTTTCCATGGATCTGAAGAAATACTTGGATTCTATCCCTCCTGGTCAGTACATG  300             
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  285  GAGTTTCTTTCCATGGATCTGAAGAAATACTTGGATTCTATCCCTCCTGGTCAGTACATG  344 
 
Query  301  GATTCTTCACTTGTTAAGAGTTATTTATACCAAATCCTACAGGGGATTGTGTTTTGTCAC  360             
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  345  GATTCTTCACTTGTTAAGAGTTATTTATACCAAATCCTACAGGGGATTGTGTTTTGTCAC  404 
 
Query  361  TCTAGAAGAGTTCTTCACAGAGACTTAAAACCTCAAAATCTCTTGATTGATGACAAAGGA  420             
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  405  TCTAGAAGAGTTCTTCACAGAGACTTAAAACCTCAAAATCTCTTGATTGATGACAAAGGA  464 
 
Query  421  ACAATTAAACTGGCTGATTTTGGCCTTGCCAGAGCTTTTGGAATACCTATCAGAGTATAT  480             
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  465  ACAATTAAACTGGCTGATTTTGGCCTTGCCAGAGCTTTTGGAATACCTATCAGAGTATAT  524 
 
Query  481  ACACATGAGGTAGTAACACTCTGGTACAGATCTCCAGAAGTATTGCTGGGGTCAGCTCGT  540             
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  525  ACACATGAGGTAGTAACACTCTGGTACAGATCTCCAGAAGTATTGCTGGGGTCAGCTCGT  584 
   
Query  541  TACTCAACTCCAGTTGACATTTGGAGTATAGGCACCATATTTGCTGAACTAGCAACTAAG  600             
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  585  TACTCAACTCCAGTTGACATTTGGAGTATAGGCACCATATTTGCTGAACTAGCAACTAAG  644 
 
Query  601  AAACCACTTTTCCATGGGGATTCAGAAATTGATCAACTCTTCAGGATTTTCAGAGCTTTG  660             
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  645  AAACCACTTTTCCATGGGGATTCAGAAATTGATCAACTCTTCAGGATTTTCAGAGCTTTG  704 
 
Query  661  GGCACTCCCAATAATGAAGTGTGGCCAGAAGTGGAATCTTTACAGGACTATAAGAATACA  720             
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  705  GGCACTCCCAATAATGAAGTGTGGCCAGAAGTGGAATCTTTACAGGACTATAAGAATACA  764 
 
Query  721  TTTCCCAAATGGAAACCAGGAAGCCTAGCATCCCATGTCAAAAACTTGGATGAAAATGGC  780             
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  765  TTTCCCAAATGGAAACCAGGAAGCCTAGCATCCCATGTCAAAAACTTGGATGAAAATGGC  824 
 
Query  781  TTGGATTTGCTCTCGAAAATGTTAATCTATGATCCAGCCAAACGAATTTCTGGCAAAATG  840             
            ||| |||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  825  TTGNATTTGCTCTCGAAAATGTTAATCTATGATCCAGCCAAACGAATTTCTGGCAAAATG  884 
 
Query  841  GCACTGAATCATCCATATTTTAATGATTTGGACAATCAGATTAAGAAGATGT  892 
            |||||||||||||||||||||||||||||||||||||| |||||||| |||| 
Sbjct  885  GCACTGAATCATCCATATTTTAATGATTTGGACAATCANATTAAGAANATGT  936 
 
 
 
 
 
 90
BLAST for CDK1AF cloned into pGEM-T Easy-SP6 
>lcl|57635  
Length=1025 
 
 Score = 1637 bits (886),  Expect = 0.0 
 Identities = 891/894 (99%), Gaps = 0/894 (0%) 
 Strand=Plus/Minus 
 
Query  1    ATGGAAGATTATACCAAAATAGAGAAAATTGGAGAAGGTACCTATGGAGTTGTGTATAAG  60 
            ||||||||||||||||||||||||||||||||||||||| ||| |||||||||||||||| 
Sbjct  964  ATGGAAGATTATACCAAAATAGAGAAAATTGGAGAAGGTGCCTTTGGAGTTGTGTATAAG  905 
 
Query  61   GGTAGACACAAAACTACAGGTCAAGTGGTAGCCATGaaaaaaaTCAGACTAGAAAGTGAA  120 
            |||||||||||||||||||||||||||||||||||||||||| ||||||||||||||||| 
Sbjct  904  GGTAGACACAAAACTACAGGTCAAGTGGTAGCCATGAAAAAANTCAGACTAGAAAGTGAA  845 
 
Query  121  GAGGAAGGGGTTCCTAGTACTGCAATTCGGGAAATTTCTCTATTAAAGGAACTTCGTCAT  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  844  GAGGAAGGGGTTCCTAGTACTGCAATTCGGGAAATTTCTCTATTAAAGGAACTTCGTCAT  785 
 
Query  181  CCAAATATAGTCAGTCTTCAGGATGTGCTTATGCAGGATTCCAGGTTATATCTCATCTTT  240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  784  CCAAATATAGTCAGTCTTCAGGATGTGCTTATGCAGGATTCCAGGTTATATCTCATCTTT  725 
 
Query  241  GAGTTTCTTTCCATGGATCTGAAGAAATACTTGGATTCTATCCCTCCTGGTCAGTACATG  300 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  724  GAGTTTCTTTCCATGGATCTGAAGAAATACTTGGATTCTATCCCTCCTGGTCAGTACATG  665 
 
Query  301  GATTCTTCACTTGTTAAGAGTTATTTATACCAAATCCTACAGGGGATTGTGTTTTGTCAC  360 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  664  GATTCTTCACTTGTTAAGAGTTATTTATACCAAATCCTACAGGGGATTGTGTTTTGTCAC  605 
 
Query  361  TCTAGAAGAGTTCTTCACAGAGACTTAAAACCTCAAAATCTCTTGATTGATGACAAAGGA  420 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  604  TCTAGAAGAGTTCTTCACAGAGACTTAAAACCTCAAAATCTCTTGATTGATGACAAAGGA  545 
 
Query  421  ACAATTAAACTGGCTGATTTTGGCCTTGCCAGAGCTTTTGGAATACCTATCAGAGTATAT  480 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  544  ACAATTAAACTGGCTGATTTTGGCCTTGCCAGAGCTTTTGGAATACCTATCAGAGTATAT  485 
 
Query  481  ACACATGAGGTAGTAACACTCTGGTACAGATCTCCAGAAGTATTGCTGGGGTCAGCTCGT  540 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  484  ACACATGAGGTAGTAACACTCTGGTACAGATCTCCAGAAGTATTGCTGGGGTCAGCTCGT  425 
 
Query  541  TACTCAACTCCAGTTGACATTTGGAGTATAGGCACCATATTTGCTGAACTAGCAACTAAG  600 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  424  TACTCAACTCCAGTTGACATTTGGAGTATAGGCACCATATTTGCTGAACTAGCAACTAAG  365 
 
Query  601  AAACCACTTTTCCATGGGGATTCAGAAATTGATCAACTCTTCAGGATTTTCAGAGCTTTG  660 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  364  AAACCACTTTTCCATGGGGATTCAGAAATTGATCAACTCTTCAGGATTTTCAGAGCTTTG  305 
 
Query  661  GGCACTCCCAATAATGAAGTGTGGCCAGAAGTGGAATCTTTACAGGACTATAAGAATACA  720 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  304  GGCACTCCCAATAATGAAGTGTGGCCAGAAGTGGAATCTTTACAGGACTATAAGAATACA  245 
 
Query  721  TTTCCCAAATGGAAACCAGGAAGCCTAGCATCCCATGTCAAAAACTTGGATGAAAATGGC  780 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  244  TTTCCCAAATGGAAACCAGGAAGCCTAGCATCCCATGTCAAAAACTTGGATGAAAATGGC  185 
 
Query  781  TTGGATTTGCTCTCGAAAATGTTAATCTATGATCCAGCCAAACGAATTTCTGGCAAAATG  840 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  184  TTGGATTTGCTCTCGAAAATGTTAATCTATGATCCAGCCAAACGAATTTCTGGCAAAATG  125 
 
Query  841  GCACTGAATCATCCATATTTTAATGATTTGGACAATCAGATTAAGAAGATGTAG  894 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  124  GCACTGAATCATCCATATTTTAATGATTTGGACAATCAGATTAAGAAGATGTAG  71 
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BLAST for CKS2 cloned into pGADT7 #3-T7 
 
>lcl|65297  
Length=1190 
 
 Score =  440 bits (238),  Expect = 6e-128 
 Identities = 239/240 (99%), Gaps = 0/240 (0%) 
 Strand=Plus/Plus 
 
Query  1    ATGGCCCACAAGCAGATCTACTACTCGGACAAGTACTTCGACGAACACTACGAGTACCGG  60 
            ||||||||| |||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  26   ATGGCCCACNAGCAGATCTACTACTCGGACAAGTACTTCGACGAACACTACGAGTACCGG  85 
 
Query  61   CATGTTATGTTACCCAGAGAACTTTCCAAACAAGTACCTAAAACTCATCTGATGTCTGAA  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  86   CATGTTATGTTACCCAGAGAACTTTCCAAACAAGTACCTAAAACTCATCTGATGTCTGAA  145 
 
Query  121  GAGGAGTGGAGGAGACTTGGTGTCCAACAGAGTCTAGGCTGGGTTCATTACATGATTCAT  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  146  GAGGAGTGGAGGAGACTTGGTGTCCAACAGAGTCTAGGCTGGGTTCATTACATGATTCAT  205 
 
Query  181  GAGCCAGAACCACATATTCTTCTCTTTAGACGACCTCTTCCAAAAGATCAACAAAAATGA  240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  206  GAGCCAGAACCACATATTCTTCTCTTTAGACGACCTCTTCCAAAAGATCAACAAAAATGA  265 
 
 
 
 
 
 
BLAST for CKS2 cloned into pGADT7 #3-AD 
 
>lcl|52233  
Length=968 
 
 Score =  444 bits (240),  Expect = 4e-129 
 Identities = 240/240 (100%), Gaps = 0/240 (0%) 
 Strand=Plus/Minus 
 
Query  1    ATGGCCCACAAGCAGATCTACTACTCGGACAAGTACTTCGACGAACACTACGAGTACCGG  60 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  275  ATGGCCCACAAGCAGATCTACTACTCGGACAAGTACTTCGACGAACACTACGAGTACCGG  216 
 
Query  61   CATGTTATGTTACCCAGAGAACTTTCCAAACAAGTACCTAAAACTCATCTGATGTCTGAA  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  215  CATGTTATGTTACCCAGAGAACTTTCCAAACAAGTACCTAAAACTCATCTGATGTCTGAA  156 
 
Query  121  GAGGAGTGGAGGAGACTTGGTGTCCAACAGAGTCTAGGCTGGGTTCATTACATGATTCAT  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  155  GAGGAGTGGAGGAGACTTGGTGTCCAACAGAGTCTAGGCTGGGTTCATTACATGATTCAT  96 
 
Query  181  GAGCCAGAACCACATATTCTTCTCTTTAGACGACCTCTTCCAAAAGATCAACAAAAATGA  240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  95   GAGCCAGAACCACATATTCTTCTCTTTAGACGACCTCTTCCAAAAGATCAACAAAAATGA  36 
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BLAST for CKS2 cloned into pGBKT7 #1-T7 
 
>lcl|58465  
Length=1137 
 
 Score =  429 bits (232),  Expect = 1e-124 
 Identities = 236/240 (98%), Gaps = 0/240 (0%) 
 Strand=Plus/Plus 
 
Query  1    ATGGCCCACAAGCAGATCTACTACTCGGACAAGTACTTCGACGAACACTACGAGTACCGG  60 
            |||||||||| ||||||||||||||||||||   |||||||||||||||||||||||||| 
Sbjct  26   ATGGCCCACANGCAGATCTACTACTCGGACANNNACTTCGACGAACACTACGAGTACCGG  85 
 
Query  61   CATGTTATGTTACCCAGAGAACTTTCCAAACAAGTACCTAAAACTCATCTGATGTCTGAA  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  86   CATGTTATGTTACCCAGAGAACTTTCCAAACAAGTACCTAAAACTCATCTGATGTCTGAA  145 
 
Query  121  GAGGAGTGGAGGAGACTTGGTGTCCAACAGAGTCTAGGCTGGGTTCATTACATGATTCAT  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  146  GAGGAGTGGAGGAGACTTGGTGTCCAACAGAGTCTAGGCTGGGTTCATTACATGATTCAT  205 
 
Query  181  GAGCCAGAACCACATATTCTTCTCTTTAGACGACCTCTTCCAAAAGATCAACAAAAATGA  240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  206  GAGCCAGAACCACATATTCTTCTCTTTAGACGACCTCTTCCAAAAGATCAACAAAAATGA  265 
 
 
 
 
 
 
 
 
BLAST for CKS2 cloned into pGBKT7 #1-BD 
 
>lcl|20179  
Length=1134 
 
 Score =  444 bits (240),  Expect = 5e-129 
 Identities = 240/240 (100%), Gaps = 0/240 (0%) 
 Strand=Plus/Minus 
 
Query  1    ATGGCCCACAAGCAGATCTACTACTCGGACAAGTACTTCGACGAACACTACGAGTACCGG  60 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  398  ATGGCCCACAAGCAGATCTACTACTCGGACAAGTACTTCGACGAACACTACGAGTACCGG  339 
 
Query  61   CATGTTATGTTACCCAGAGAACTTTCCAAACAAGTACCTAAAACTCATCTGATGTCTGAA  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  338  CATGTTATGTTACCCAGAGAACTTTCCAAACAAGTACCTAAAACTCATCTGATGTCTGAA  279 
 
Query  121  GAGGAGTGGAGGAGACTTGGTGTCCAACAGAGTCTAGGCTGGGTTCATTACATGATTCAT  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  278  GAGGAGTGGAGGAGACTTGGTGTCCAACAGAGTCTAGGCTGGGTTCATTACATGATTCAT  219 
 
Query  181  GAGCCAGAACCACATATTCTTCTCTTTAGACGACCTCTTCCAAAAGATCAACAAAAATGA  240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  218  GAGCCAGAACCACATATTCTTCTCTTTAGACGACCTCTTCCAAAAGATCAACAAAAATGA  159 
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BLAST for CDK1AF cloned into pGADT7 #1-T7  
 
>lcl|9073  
Length=1023 
 
 Score = 1629 bits (882),  Expect = 0.0 
 Identities = 889/894 (99%), Gaps = 0/894 (0%) 
 Strand=Plus/Plus 
 
Query  1    ATGGAAGATTATACCAAAATAGAGAAAATTGGAGAAGGTACCTATGGAGTTGTGTATAAG  60 
            |||| ||||||||||||| ||||||||||||||||| || ||| |||||||||||||||| 
Sbjct  7    ATGGNAGATTATACCAAANTAGAGAAAATTGGAGAANGTGCCTTTGGAGTTGTGTATAAG  66 
 
Query  61   GGTAGACACAAAACTACAGGTCAAGTGGTAGCCATGaaaaaaaTCAGACTAGAAAGTGAA  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  67   GGTAGACACAAAACTACAGGTCAAGTGGTAGCCATGAAAAAAATCAGACTAGAAAGTGAA  126 
 
Query  121  GAGGAAGGGGTTCCTAGTACTGCAATTCGGGAAATTTCTCTATTAAAGGAACTTCGTCAT  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  127  GAGGAAGGGGTTCCTAGTACTGCAATTCGGGAAATTTCTCTATTAAAGGAACTTCGTCAT  186 
 
Query  181  CCAAATATAGTCAGTCTTCAGGATGTGCTTATGCAGGATTCCAGGTTATATCTCATCTTT  240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  187  CCAAATATAGTCAGTCTTCAGGATGTGCTTATGCAGGATTCCAGGTTATATCTCATCTTT  246 
 
Query  241  GAGTTTCTTTCCATGGATCTGAAGAAATACTTGGATTCTATCCCTCCTGGTCAGTACATG  300 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  247  GAGTTTCTTTCCATGGATCTGAAGAAATACTTGGATTCTATCCCTCCTGGTCAGTACATG  306 
 
Query  301  GATTCTTCACTTGTTAAGAGTTATTTATACCAAATCCTACAGGGGATTGTGTTTTGTCAC  360 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  307  GATTCTTCACTTGTTAAGAGTTATTTATACCAAATCCTACAGGGGATTGTGTTTTGTCAC  366 
 
Query  361  TCTAGAAGAGTTCTTCACAGAGACTTAAAACCTCAAAATCTCTTGATTGATGACAAAGGA  420 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  367  TCTAGAAGAGTTCTTCACAGAGACTTAAAACCTCAAAATCTCTTGATTGATGACAAAGGA  426 
 
Query  421  ACAATTAAACTGGCTGATTTTGGCCTTGCCAGAGCTTTTGGAATACCTATCAGAGTATAT  480 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  427  ACAATTAAACTGGCTGATTTTGGCCTTGCCAGAGCTTTTGGAATACCTATCAGAGTATAT  486 
 
Query  481  ACACATGAGGTAGTAACACTCTGGTACAGATCTCCAGAAGTATTGCTGGGGTCAGCTCGT  540 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  487  ACACATGAGGTAGTAACACTCTGGTACAGATCTCCAGAAGTATTGCTGGGGTCAGCTCGT  546 
 
Query  541  TACTCAACTCCAGTTGACATTTGGAGTATAGGCACCATATTTGCTGAACTAGCAACTAAG  600 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  547  TACTCAACTCCAGTTGACATTTGGAGTATAGGCACCATATTTGCTGAACTAGCAACTAAG  606 
 
Query  601  AAACCACTTTTCCATGGGGATTCAGAAATTGATCAACTCTTCAGGATTTTCAGAGCTTTG  660 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  607  AAACCACTTTTCCATGGGGATTCAGAAATTGATCAACTCTTCAGGATTTTCAGAGCTTTG  666 
 
Query  661  GGCACTCCCAATAATGAAGTGTGGCCAGAAGTGGAATCTTTACAGGACTATAAGAATACA  720 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  667  GGCACTCCCAATAATGAAGTGTGGCCAGAAGTGGAATCTTTACAGGACTATAAGAATACA  726 
 
Query  721  TTTCCCAAATGGAAACCAGGAAGCCTAGCATCCCATGTCAAAAACTTGGATGAAAATGGC  780 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  727  TTTCCCAAATGGAAACCAGGAAGCCTAGCATCCCATGTCAAAAACTTGGATGAAAATGGC  786 
 
Query  781  TTGGATTTGCTCTCGAAAATGTTAATCTATGATCCAGCCAAACGAATTTCTGGCAAAATG  840 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  787  TTGGATTTGCTCTCGAAAATGTTAATCTATGATCCAGCCAAACGAATTTCTGGCAAAATG  846 
 
Query  841  GCACTGAATCATCCATATTTTAATGATTTGGACAATCAGATTAAGAAGATGTAG  894 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  847  GCACTGAATCATCCATATTTTAATGATTTGGACAATCAGATTAAGAAGATGTAG  900 
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BLAST for CDK1AF cloned into pGADT7 #1-AD 
 
>lcl|12121  
Length=1002 
 
 Score = 1618 bits (876),  Expect = 0.0 
 Identities = 888/895 (99%), Gaps = 1/895 (0%) 
 Strand=Plus/Minus 
 
Query  1    ATGGAAGATTATACCAAAATAGAGAAAATTGGAGAAGGTACCTATGGAGTTGTGTATAAG  60 
            ||||||||||||||||||||||||||||||||||||||| ||| |||||||||||||||| 
Sbjct  924  ATGGAAGATTATACCAAAATAGAGAAAATTGGAGAAGGTGCCTTTGGAGTTGTGTATAAG  865 
 
Query  61   GGTAGACACAAAACTACAGGTCAAGTGGTAGCCATGaaaaaaaTCAGACTAGAAAGTGAA  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  864  GGTAGACACAAAACTACAGGTCAAGTGGTAGCCATGAAAAAAATCAGACTAGAAAGTGAA  805 
 
Query  121  GAGGAAGGGGTTCCTAGTACTGCAATTCGGGAAATTTCTCTATTAAAGGAACTTCGTCAT  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  804  GAGGAAGGGGTTCCTAGTACTGCAATTCGGGAAATTTCTCTATTAAAGGAACTTCGTCAT  745 
 
Query  181  CCAAATATAGTCAGTCTTCAGGATGTGCTTATGCAGGATTCCAGGTTATATCTCATCTTT  240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  744  CCAAATATAGTCAGTCTTCAGGATGTGCTTATGCAGGATTCCAGGTTATATCTCATCTTT  685 
 
Query  241  GAGTTTCTTTCCATGGATCTGAAGAAATACTTGGATTCTATCCCTCCTGGTCAGTACATG  300 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  684  GAGTTTCTTTCCATGGATCTGAAGAAATACTTGGATTCTATCCCTCCTGGTCAGTACATG  625 
 
Query  301  GATTCTTCACTTGTTAAGAGTTATTTATACCAAATCCTACAGGGGATTGTGTTTTGTCAC  360 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  624  GATTCTTCACTTGTTAAGAGTTATTTATACCAAATCCTACAGGGGATTGTGTTTTGTCAC  565 
 
Query  361  TCTAGAAGAGTTCTTCACAGAGACTTAAAACCTCAAAATCTCTTGATTGATGACAAAGGA  420 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  564  TCTAGAAGAGTTCTTCACAGAGACTTAAAACCTCAAAATCTCTTGATTGATGACAAAGGA  505 
 
Query  421  ACAATTAAACTGGCTGATTTTGGCCTTGCCAGAGCTTTTGGAATACCTATCAGAGTATAT  480 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  504  ACAATTAAACTGGCTGATTTTGGCCTTGCCAGAGCTTTTGGAATACCTATCAGAGTATAT  445 
 
Query  481  ACACATGAGGTAGTAACACTCTGGTACAGATCTCCAGAAGTATTGCTGGGGTCAGCTCGT  540 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  444  ACACATGAGGTAGTAACACTCTGGTACAGATCTCCAGAAGTATTGCTGGGGTCAGCTCGT  385 
 
Query  541  TACTCAACTCCAGTTGACATTTGGAGTATAGGCACCATATTTGCTGAACTAGCAACTAAG  600 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  384  TACTCAACTCCAGTTGACATTTGGAGTATAGGCACCATATTTGCTGAACTAGCAACTAAG  325 
 
Query  601  AAACCACTTTTCCATGGGGATTCAGAAATTGATCAACTCTTCAGGATTTTCAGAGCTTTG  660 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  324  AAACCACTTTTCCATGGGGATTCAGAAATTGATCAACTCTTCAGGATTTTCAGAGCTTTG  265 
 
Query  661  GGCACTCCCAATAATGAAGTGTGGCCAGAAGTGGAATCTTTACAGGACTATAAGAATACA  720 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  264  GGCACTCCCAATAATGAAGTGTGGCCAGAAGTGGAATCTTTACAGGACTATAAGAATACA  205 
 
Query  721  TTTCCCAAATGGAAACCAGGAAGCCTAGCATCCCATGTCAAAAACTTGGATGAAAATGGC  780 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  204  TTTCCCAAATGGAAACCAGGAAGCCTAGCATCCCATGTCAAAAACTTGGATGAAAATGGC  145 
 
Query  781  TTGGATTTGCTCTCGAAAATGTTAATCTATGATCCAGCCAAACGAATTTCTGGCAAAATG  840 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  144  TTGGATTTGCTCTCGAAAATGTTAATCTATGATCCAGCCAAACGAATTTCTGGCAAAATG  85 
 
Query  841  GCACTGAATCATCCATATTTTAATGATTTGGACAATCA-GATTAAGAAGATGTAG  894 
            ||||||||||||||||||||||||||||||| |||    |||||||||||||||| 
Sbjct  84   GCACTGAATCATCCATATTTTAATGATTTGGNCAANGNNGATTAAGAAGATGTAG  30 
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BLAST for CDK1AF cloned into pGBKT7 #11-T7 
 
>lcl|59131  
Length=1156 
 
 Score = 1629 bits (882),  Expect = 0.0 
 Identities = 889/894 (99%), Gaps = 0/894 (0%) 
 Strand=Plus/Plus 
 
Query  1    ATGGAAGATTATACCAAAATAGAGAAAATTGGAGAAGGTACCTATGGAGTTGTGTATAAG  60 
            |||| ||||||||||||||||||||||||||  |||||| ||| |||||||||||||||| 
Sbjct  7    ATGGNAGATTATACCAAAATAGAGAAAATTGNNGAAGGTGCCTTTGGAGTTGTGTATAAG  66 
 
Query  61   GGTAGACACAAAACTACAGGTCAAGTGGTAGCCATGaaaaaaaTCAGACTAGAAAGTGAA  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  67   GGTAGACACAAAACTACAGGTCAAGTGGTAGCCATGAAAAAAATCAGACTAGAAAGTGAA  126 
 
Query  121  GAGGAAGGGGTTCCTAGTACTGCAATTCGGGAAATTTCTCTATTAAAGGAACTTCGTCAT  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  127  GAGGAAGGGGTTCCTAGTACTGCAATTCGGGAAATTTCTCTATTAAAGGAACTTCGTCAT  186 
 
Query  181  CCAAATATAGTCAGTCTTCAGGATGTGCTTATGCAGGATTCCAGGTTATATCTCATCTTT  240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  187  CCAAATATAGTCAGTCTTCAGGATGTGCTTATGCAGGATTCCAGGTTATATCTCATCTTT  246 
 
Query  241  GAGTTTCTTTCCATGGATCTGAAGAAATACTTGGATTCTATCCCTCCTGGTCAGTACATG  300 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  247  GAGTTTCTTTCCATGGATCTGAAGAAATACTTGGATTCTATCCCTCCTGGTCAGTACATG  306 
 
Query  301  GATTCTTCACTTGTTAAGAGTTATTTATACCAAATCCTACAGGGGATTGTGTTTTGTCAC  360 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  307  GATTCTTCACTTGTTAAGAGTTATTTATACCAAATCCTACAGGGGATTGTGTTTTGTCAC  366 
 
Query  361  TCTAGAAGAGTTCTTCACAGAGACTTAAAACCTCAAAATCTCTTGATTGATGACAAAGGA  420 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  367  TCTAGAAGAGTTCTTCACAGAGACTTAAAACCTCAAAATCTCTTGATTGATGACAAAGGA  426 
 
Query  421  ACAATTAAACTGGCTGATTTTGGCCTTGCCAGAGCTTTTGGAATACCTATCAGAGTATAT  480 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  427  ACAATTAAACTGGCTGATTTTGGCCTTGCCAGAGCTTTTGGAATACCTATCAGAGTATAT  486 
 
Query  481  ACACATGAGGTAGTAACACTCTGGTACAGATCTCCAGAAGTATTGCTGGGGTCAGCTCGT  540 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  487  ACACATGAGGTAGTAACACTCTGGTACAGATCTCCAGAAGTATTGCTGGGGTCAGCTCGT  546 
 
Query  541  TACTCAACTCCAGTTGACATTTGGAGTATAGGCACCATATTTGCTGAACTAGCAACTAAG  600 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  547  TACTCAACTCCAGTTGACATTTGGAGTATAGGCACCATATTTGCTGAACTAGCAACTAAG  606 
 
Query  601  AAACCACTTTTCCATGGGGATTCAGAAATTGATCAACTCTTCAGGATTTTCAGAGCTTTG  660 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  607  AAACCACTTTTCCATGGGGATTCAGAAATTGATCAACTCTTCAGGATTTTCAGAGCTTTG  666 
 
Query  661  GGCACTCCCAATAATGAAGTGTGGCCAGAAGTGGAATCTTTACAGGACTATAAGAATACA  720 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  667  GGCACTCCCAATAATGAAGTGTGGCCAGAAGTGGAATCTTTACAGGACTATAAGAATACA  726 
 
Query  721  TTTCCCAAATGGAAACCAGGAAGCCTAGCATCCCATGTCAAAAACTTGGATGAAAATGGC  780 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  727  TTTCCCAAATGGAAACCAGGAAGCCTAGCATCCCATGTCAAAAACTTGGATGAAAATGGC  786 
 
Query  781  TTGGATTTGCTCTCGAAAATGTTAATCTATGATCCAGCCAAACGAATTTCTGGCAAAATG  840 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  787  TTGGATTTGCTCTCGAAAATGTTAATCTATGATCCAGCCAAACGAATTTCTGGCAAAATG  846 
 
Query  841  GCACTGAATCATCCATATTTTAATGATTTGGACAATCAGATTAAGAAGATGTAG  894 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  847  GCACTGAATCATCCATATTTTAATGATTTGGACAATCAGATTAAGAAGATGTAG  900 
 96
BLAST for CDK1AF cloned into pGBKT7 #11-BD 
 
>lcl|62571  
Length=1152 
 
 Score = 1640 bits (888),  Expect = 0.0 
 Identities = 892/894 (99%), Gaps = 0/894 (0%) 
 Strand=Plus/Minus 
 
Query  1     ATGGAAGATTATACCAAAATAGAGAAAATTGGAGAAGGTACCTATGGAGTTGTGTATAAG  60 
             ||||||||||||||||||||||||||||||||||||||| ||| |||||||||||||||| 
Sbjct  1053  ATGGAAGATTATACCAAAATAGAGAAAATTGGAGAAGGTGCCTTTGGAGTTGTGTATAAG  994 
 
Query  61    GGTAGACACAAAACTACAGGTCAAGTGGTAGCCATGaaaaaaaTCAGACTAGAAAGTGAA  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  993   GGTAGACACAAAACTACAGGTCAAGTGGTAGCCATGAAAAAAATCAGACTAGAAAGTGAA  934 
 
Query  121   GAGGAAGGGGTTCCTAGTACTGCAATTCGGGAAATTTCTCTATTAAAGGAACTTCGTCAT  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  933   GAGGAAGGGGTTCCTAGTACTGCAATTCGGGAAATTTCTCTATTAAAGGAACTTCGTCAT  874 
 
Query  181   CCAAATATAGTCAGTCTTCAGGATGTGCTTATGCAGGATTCCAGGTTATATCTCATCTTT  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  873   CCAAATATAGTCAGTCTTCAGGATGTGCTTATGCAGGATTCCAGGTTATATCTCATCTTT  814 
 
Query  241   GAGTTTCTTTCCATGGATCTGAAGAAATACTTGGATTCTATCCCTCCTGGTCAGTACATG  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  813   GAGTTTCTTTCCATGGATCTGAAGAAATACTTGGATTCTATCCCTCCTGGTCAGTACATG  754 
 
Query  301   GATTCTTCACTTGTTAAGAGTTATTTATACCAAATCCTACAGGGGATTGTGTTTTGTCAC  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  753   GATTCTTCACTTGTTAAGAGTTATTTATACCAAATCCTACAGGGGATTGTGTTTTGTCAC  694 
 
Query  361   TCTAGAAGAGTTCTTCACAGAGACTTAAAACCTCAAAATCTCTTGATTGATGACAAAGGA  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  693   TCTAGAAGAGTTCTTCACAGAGACTTAAAACCTCAAAATCTCTTGATTGATGACAAAGGA  634 
 
Query  421   ACAATTAAACTGGCTGATTTTGGCCTTGCCAGAGCTTTTGGAATACCTATCAGAGTATAT  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  633   ACAATTAAACTGGCTGATTTTGGCCTTGCCAGAGCTTTTGGAATACCTATCAGAGTATAT  574 
 
Query  481   ACACATGAGGTAGTAACACTCTGGTACAGATCTCCAGAAGTATTGCTGGGGTCAGCTCGT  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  573   ACACATGAGGTAGTAACACTCTGGTACAGATCTCCAGAAGTATTGCTGGGGTCAGCTCGT  514 
 
Query  541   TACTCAACTCCAGTTGACATTTGGAGTATAGGCACCATATTTGCTGAACTAGCAACTAAG  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  513   TACTCAACTCCAGTTGACATTTGGAGTATAGGCACCATATTTGCTGAACTAGCAACTAAG  454 
 
Query  601   AAACCACTTTTCCATGGGGATTCAGAAATTGATCAACTCTTCAGGATTTTCAGAGCTTTG  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  453   AAACCACTTTTCCATGGGGATTCAGAAATTGATCAACTCTTCAGGATTTTCAGAGCTTTG  394 
 
Query  661   GGCACTCCCAATAATGAAGTGTGGCCAGAAGTGGAATCTTTACAGGACTATAAGAATACA  720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  393   GGCACTCCCAATAATGAAGTGTGGCCAGAAGTGGAATCTTTACAGGACTATAAGAATACA  334 
 
Query  721   TTTCCCAAATGGAAACCAGGAAGCCTAGCATCCCATGTCAAAAACTTGGATGAAAATGGC  780 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  333   TTTCCCAAATGGAAACCAGGAAGCCTAGCATCCCATGTCAAAAACTTGGATGAAAATGGC  274 
 
Query  781   TTGGATTTGCTCTCGAAAATGTTAATCTATGATCCAGCCAAACGAATTTCTGGCAAAATG  840 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  273   TTGGATTTGCTCTCGAAAATGTTAATCTATGATCCAGCCAAACGAATTTCTGGCAAAATG  214 
 
Query  841   GCACTGAATCATCCATATTTTAATGATTTGGACAATCAGATTAAGAAGATGTAG  894 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  213   GCACTGAATCATCCATATTTTAATGATTTGGACAATCAGATTAAGAAGATGTAG  160 
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BLAST for CDK2AF cloned into pGADT7 #7-T7 
 
>lcl|22439  
Length=1152 
 
 Score = 1635 bits (885),  Expect = 0.0 
 Identities = 892/897 (99%), Gaps = 0/897 (0%) 
 Strand=Plus/Plus 
 
Query  1    ATGGAGAACTTCCAAAAGGTGGAAAAGATCGGAGAGGGCACGTACGGAGTTGTGTACAAA  60 
            |||||| |||||| ||||||||||||||||||||||||| | | |||||||||||||||| 
Sbjct  18   ATGGAGNACTTCCNAAAGGTGGAAAAGATCGGAGAGGGCNCCTTCGGAGTTGTGTACAAA  77 
 
Query  61   GCCAGAAACAAGTTGACGGGAGAGGTGGTGGCGCTTAAGAAAATCCGCCTGGACACTGAG  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  78   GCCAGAAACAAGTTGACGGGAGAGGTGGTGGCGCTTAAGAAAATCCGCCTGGACACTGAG  137 
 
Query  121  ACTGAGGGTGTGCCCAGTACTGCCATCCGAGAGATCTCTCTGCTTAAGGAGCTTAACCAT  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  138  ACTGAGGGTGTGCCCAGTACTGCCATCCGAGAGATCTCTCTGCTTAAGGAGCTTAACCAT  197 
 
Query  181  CCTAATATTGTCAAGCTGCTGGATGTCATTCACACAGAAAATAAACTCTACCTGGTTTTT  240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  198  CCTAATATTGTCAAGCTGCTGGATGTCATTCACACAGAAAATAAACTCTACCTGGTTTTT  257 
 
Query  241  GAATTTCTGCACCAAGATCTCAAGAAATTCATGGATGCCTCTGCTCTCACTGGCATTCCT  300 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  258  GAATTTCTGCACCAAGATCTCAAGAAATTCATGGATGCCTCTGCTCTCACTGGCATTCCT  317 
 
Query  301  CTTCCCCTCATCAAGAGCTATCTGTTCCAGCTGCTCCAGGGCCTAGCTTTCTGCCATTCT  360 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  318  CTTCCCCTCATCAAGAGCTATCTGTTCCAGCTGCTCCAGGGCCTAGCTTTCTGCCATTCT  377 
 
Query  361  CATCGGGTCCTCCACCGAGACCTTAAACCTCAGAATCTGCTTATTAACACAGAGGGGGCC  420 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  378  CATCGGGTCCTCCACCGAGACCTTAAACCTCAGAATCTGCTTATTAACACAGAGGGGGCC  437 
 
Query  421  ATCAAGCTAGCAGACTTTGGACTAGCCAGAGCTTTTGGAGTCCCTGTTCGTACTTACACC  480 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  438  ATCAAGCTAGCAGACTTTGGACTAGCCAGAGCTTTTGGAGTCCCTGTTCGTACTTACACC  497 
 
Query  481  CATGAGGTGGTGACCCTGTGGTACCGAGCTCCTGAAATCCTCCTGGGCTGCAAATATTAT  540 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  498  CATGAGGTGGTGACCCTGTGGTACCGAGCTCCTGAAATCCTCCTGGGCTGCAAATATTAT  557 
 
Query  541  TCCACAGCTGTGGACATCTGGAGCCTGGGCTGCATCTTTGCTGAGATGGTGACTCGCCGG  600 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  558  TCCACAGCTGTGGACATCTGGAGCCTGGGCTGCATCTTTGCTGAGATGGTGACTCGCCGG  617 
 
Query  601  GCCCTATTCCCTGGAGATTCTGAGATTGACCAGCTCTTCCGGATCTTTCGGACTCTGGGG  660 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  618  GCCCTATTCCCTGGAGATTCTGAGATTGACCAGCTCTTCCGGATCTTTCGGACTCTGGGG  677 
 
Query  661  ACCCCAGATGAGGTGGTGTGGCCAGGAGTTACTTCTATGCCTGATTACAAGCCAAGTTTC  720 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  678  ACCCCAGATGAGGTGGTGTGGCCAGGAGTTACTTCTATGCCTGATTACAAGCCAAGTTTC  737 
 
Query  721  CCCAAGTGGGCCCGGCAAGATTTTAGTAAAGTTGTACCTCCCCTGGATGAAGATGGACGG  780 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  738  CCCAAGTGGGCCCGGCAAGATTTTAGTAAAGTTGTACCTCCCCTGGATGAAGATGGACGG  797 
 
Query  781  AGCTTGTTATCGCAAATGCTGCACTACGACCCTAACAAGCGGATTTCGGCCAAGGCAGCC  840 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  798  AGCTTGTTATCGCAAATGCTGCACTACGACCCTAACAAGCGGATTTCGGCCAAGGCAGCC  857 
 
Query  841  CTGGCTCACCCTTTCTTCCAGGATGTGACCAAGCCAGTACCCCATCTTCGACTCTGA  897 
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  858  CTGGCTCACCCTTTCTTCCAGGATGTGACCAAGCCAGTACCCCATCTTCGACTCTGA  914 
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BLAST for CDK2AF cloned into pGADT7 #7-AD 
 
>lcl|14991  
Length=1048 
 
 Score = 1637 bits (886),  Expect = 0.0 
 Identities = 893/897 (99%), Gaps = 0/897 (0%) 
 Strand=Plus/Minus 
 
Query  1    ATGGAGAACTTCCAAAAGGTGGAAAAGATCGGAGAGGGCACGTACGGAGTTGTGTACAAA  60 
            ||||||||||||||||||||||||||||||||||||||| | | |||||||||||||||| 
Sbjct  928  ATGGAGAACTTCCAAAAGGTGGAAAAGATCGGAGAGGGCGCCTTCGGAGTTGTGTACAAA  869 
 
Query  61   GCCAGAAACAAGTTGACGGGAGAGGTGGTGGCGCTTAAGAAAATCCGCCTGGACACTGAG  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  868  GCCAGAAACAAGTTGACGGGAGAGGTGGTGGCGCTTAAGAAAATCCGCCTGGACACTGAG  809 
 
Query  121  ACTGAGGGTGTGCCCAGTACTGCCATCCGAGAGATCTCTCTGCTTAAGGAGCTTAACCAT  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  808  ACTGAGGGTGTGCCCAGTACTGCCATCCGAGAGATCTCTCTGCTTAAGGAGCTTAACCAT  749 
 
Query  181  CCTAATATTGTCAAGCTGCTGGATGTCATTCACACAGAAAATAAACTCTACCTGGTTTTT  240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  748  CCTAATATTGTCAAGCTGCTGGATGTCATTCACACAGAAAATAAACTCTACCTGGTTTTT  689 
 
Query  241  GAATTTCTGCACCAAGATCTCAAGAAATTCATGGATGCCTCTGCTCTCACTGGCATTCCT  300 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  688  GAATTTCTGCACCAAGATCTCAAGAAATTCATGGATGCCTCTGCTCTCACTGGCATTCCT  629 
 
Query  301  CTTCCCCTCATCAAGAGCTATCTGTTCCAGCTGCTCCAGGGCCTAGCTTTCTGCCATTCT  360 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  628  CTTCCCCTCATCAAGAGCTATCTGTTCCAGCTGCTCCAGGGCCTAGCTTTCTGCCATTCT  569 
 
Query  361  CATCGGGTCCTCCACCGAGACCTTAAACCTCAGAATCTGCTTATTAACACAGAGGGGGCC  420 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  568  CATCGGGTCCTCCACCGAGACCTTAAACCTCAGAATCTGCTTATTAACACAGAGGGGGCC  509 
 
Query  421  ATCAAGCTAGCAGACTTTGGACTAGCCAGAGCTTTTGGAGTCCCTGTTCGTACTTACACC  480 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  508  ATCAAGCTAGCAGACTTTGGACTAGCCAGAGCTTTTGGAGTCCCTGTTCGTACTTACACC  449 
 
Query  481  CATGAGGTGGTGACCCTGTGGTACCGAGCTCCTGAAATCCTCCTGGGCTGCAAATATTAT  540 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  448  CATGAGGTGGTGACCCTGTGGTACCGAGCTCCTGAAATCCTCCTGGGCTGCAAATATTAT  389 
 
Query  541  TCCACAGCTGTGGACATCTGGAGCCTGGGCTGCATCTTTGCTGAGATGGTGACTCGCCGG  600 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  388  TCCACAGCTGTGGACATCTGGAGCCTGGGCTGCATCTTTGCTGAGATGGTGACTCGCCGG  329 
 
Query  601  GCCCTATTCCCTGGAGATTCTGAGATTGACCAGCTCTTCCGGATCTTTCGGACTCTGGGG  660 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  328  GCCCTATTCCCTGGAGATTCTGAGATTGACCAGCTCTTCCGGATCTTTCGGACTCTGGGG  269 
 
Query  661  ACCCCAGATGAGGTGGTGTGGCCAGGAGTTACTTCTATGCCTGATTACAAGCCAAGTTTC  720 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  268  ACCCCAGATGAGGTGGTGTGGCCAGGAGTTACTTCTATGCCTGATTACAAGCCAAGTTTC  209 
 
Query  721  CCCAAGTGGGCCCGGCAAGATTTTAGTAAAGTTGTACCTCCCCTGGATGAAGATGGACGG  780 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  208  CCCAAGTGGGCCCGGCAAGATTTTAGTAAAGTTGTACCTCCCCTGGATGAAGATGGACGG  149 
 
Query  781  AGCTTGTTATCGCAAATGCTGCACTACGACCCTAACAAGCGGATTTCGGCCAAGGCAGCC  840 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  148  AGCTTGTTATCGCAAATGCTGCACTACGACCCTAACAAGCGGATTTCGGCCAAGGCAGCC  89 
 
Query  841  CTGGCTCACCCTTTCTTCCAGGATGTGACCAAGCCAGTACCCCATCTTCGACTCTGA  897 
            ||||||||||||||||||||||||||||||||||||| ||||||||||||||||||| 
Sbjct  88   CTGGCTCACCCTTTCTTCCAGGATGTGACCAAGCCAGNACCCCATCTTCGACTCTGA  32 
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BLAST for CDK2AF cloned into pGBKT7 #4-T7 
 
>lcl|38089  
Length=1107 
 
 Score = 1613 bits (873),  Expect = 0.0 
 Identities = 888/897 (98%), Gaps = 1/897 (0%) 
 Strand=Plus/Plus 
 
Query  1    ATGGAGAACTTCCAAAAGGTGGAAAAGATCGGAGAGGGCACGTACGGAGTTGTGTACAAA  60 
            |||||| ||||||  ||||||||||||||||||   ||| | | |||||||||||||||| 
Sbjct  6    ATGGAGNACTTCC-NAAGGTGGAAAAGATCGGACNNGGCGCCTTCGGAGTTGTGTACAAA  64 
 
Query  61   GCCAGAAACAAGTTGACGGGAGAGGTGGTGGCGCTTAAGAAAATCCGCCTGGACACTGAG  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  65   GCCAGAAACAAGTTGACGGGAGAGGTGGTGGCGCTTAAGAAAATCCGCCTGGACACTGAG  124 
 
Query  121  ACTGAGGGTGTGCCCAGTACTGCCATCCGAGAGATCTCTCTGCTTAAGGAGCTTAACCAT  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  125  ACTGAGGGTGTGCCCAGTACTGCCATCCGAGAGATCTCTCTGCTTAAGGAGCTTAACCAT  184 
 
Query  181  CCTAATATTGTCAAGCTGCTGGATGTCATTCACACAGAAAATAAACTCTACCTGGTTTTT  240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  185  CCTAATATTGTCAAGCTGCTGGATGTCATTCACACAGAAAATAAACTCTACCTGGTTTTT  244 
 
Query  241  GAATTTCTGCACCAAGATCTCAAGAAATTCATGGATGCCTCTGCTCTCACTGGCATTCCT  300 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  245  GAATTTCTGCACCAAGATCTCAAGAAATTCATGGATGCCTCTGCTCTCACTGGCATTCCT  304 
 
Query  301  CTTCCCCTCATCAAGAGCTATCTGTTCCAGCTGCTCCAGGGCCTAGCTTTCTGCCATTCT  360 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  305  CTTCCCCTCATCAAGAGCTATCTGTTCCAGCTGCTCCAGGGCCTAGCTTTCTGCCATTCT  364 
 
Query  361  CATCGGGTCCTCCACCGAGACCTTAAACCTCAGAATCTGCTTATTAACACAGAGGGGGCC  420 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  365  CATCGGGTCCTCCACCGAGACCTTAAACCTCAGAATCTGCTTATTAACACAGAGGGGGCC  424 
 
Query  421  ATCAAGCTAGCAGACTTTGGACTAGCCAGAGCTTTTGGAGTCCCTGTTCGTACTTACACC  480 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  425  ATCAAGCTAGCAGACTTTGGACTAGCCAGAGCTTTTGGAGTCCCTGTTCGTACTTACACC  484 
 
Query  481  CATGAGGTGGTGACCCTGTGGTACCGAGCTCCTGAAATCCTCCTGGGCTGCAAATATTAT  540 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  485  CATGAGGTGGTGACCCTGTGGTACCGAGCTCCTGAAATCCTCCTGGGCTGCAAATATTAT  544 
 
Query  541  TCCACAGCTGTGGACATCTGGAGCCTGGGCTGCATCTTTGCTGAGATGGTGACTCGCCGG  600 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  545  TCCACAGCTGTGGACATCTGGAGCCTGGGCTGCATCTTTGCTGAGATGGTGACTCGCCGG  604 
 
Query  601  GCCCTATTCCCTGGAGATTCTGAGATTGACCAGCTCTTCCGGATCTTTCGGACTCTGGGG  660 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  605  GCCCTATTCCCTGGAGATTCTGAGATTGACCAGCTCTTCCGGATCTTTCGGACTCTGGGG  664 
 
Query  661  ACCCCAGATGAGGTGGTGTGGCCAGGAGTTACTTCTATGCCTGATTACAAGCCAAGTTTC  720 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  665  ACCCCAGATGAGGTGGTGTGGCCAGGAGTTACTTCTATGCCTGATTACAAGCCAAGTTTC  724 
 
Query  721  CCCAAGTGGGCCCGGCAAGATTTTAGTAAAGTTGTACCTCCCCTGGATGAAGATGGACGG  780 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  725  CCCAAGTGGGCCCGGCAAGATTTTAGTAAAGTTGTACCTCCCCTGGATGAAGATGGACGG  784 
 
Query  781  AGCTTGTTATCGCAAATGCTGCACTACGACCCTAACAAGCGGATTTCGGCCAAGGCAGCC  840 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  785  AGCTTGTTATCGCAAATGCTGCACTACGACCCTAACAAGCGGATTTCGGCCAAGGCAGCC  844 
 
Query  841  CTGGCTCACCCTTTCTTCCAGGATGTGACCAAGCCAGTACCCCATCTTCGACTCTGA  897 
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  845  CTGGCTCACCCTTTCTTCCAGGATGTGACCAAGCCAGTACCCCATCTTCGACTCTGA  901 
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BLAST for CDK2AF cloned into pGBKT7 #4-BD 
 
>lcl|63797  
Length=1162 
 
 Score = 1640 bits (888),  Expect = 0.0 
 Identities = 894/897 (99%), Gaps = 0/897 (0%) 
 Strand=Plus/Minus 
 
Query  1     ATGGAGAACTTCCAAAAGGTGGAAAAGATCGGAGAGGGCACGTACGGAGTTGTGTACAAA  60 
             ||||||||||||||||||||||||||||||||||||||| | | |||||||||||||||| 
Sbjct  1055  ATGGAGAACTTCCAAAAGGTGGAAAAGATCGGAGAGGGCGCCTTCGGAGTTGTGTACAAA  996 
 
Query  61    GCCAGAAACAAGTTGACGGGAGAGGTGGTGGCGCTTAAGAAAATCCGCCTGGACACTGAG  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  995   GCCAGAAACAAGTTGACGGGAGAGGTGGTGGCGCTTAAGAAAATCCGCCTGGACACTGAG  936 
 
Query  121   ACTGAGGGTGTGCCCAGTACTGCCATCCGAGAGATCTCTCTGCTTAAGGAGCTTAACCAT  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  935   ACTGAGGGTGTGCCCAGTACTGCCATCCGAGAGATCTCTCTGCTTAAGGAGCTTAACCAT  876 
 
Query  181   CCTAATATTGTCAAGCTGCTGGATGTCATTCACACAGAAAATAAACTCTACCTGGTTTTT  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  875   CCTAATATTGTCAAGCTGCTGGATGTCATTCACACAGAAAATAAACTCTACCTGGTTTTT  816 
 
Query  241   GAATTTCTGCACCAAGATCTCAAGAAATTCATGGATGCCTCTGCTCTCACTGGCATTCCT  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  815   GAATTTCTGCACCAAGATCTCAAGAAATTCATGGATGCCTCTGCTCTCACTGGCATTCCT  756 
 
Query  301   CTTCCCCTCATCAAGAGCTATCTGTTCCAGCTGCTCCAGGGCCTAGCTTTCTGCCATTCT  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  755   CTTCCCCTCATCAAGAGCTATCTGTTCCAGCTGCTCCAGGGCCTAGCTTTCTGCCATTCT  696 
 
Query  361   CATCGGGTCCTCCACCGAGACCTTAAACCTCAGAATCTGCTTATTAACACAGAGGGGGCC  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  695   CATCGGGTCCTCCACCGAGACCTTAAACCTCAGAATCTGCTTATTAACACAGAGGGGGCC  636 
 
Query  421   ATCAAGCTAGCAGACTTTGGACTAGCCAGAGCTTTTGGAGTCCCTGTTCGTACTTACACC  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  635   ATCAAGCTAGCAGACTTTGGACTAGCCAGAGCTTTTGGAGTCCCTGTTCGTACTTACACC  576 
 
Query  481   CATGAGGTGGTGACCCTGTGGTACCGAGCTCCTGAAATCCTCCTGGGCTGCAAATATTAT  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  575   CATGAGGTGGTGACCCTGTGGTACCGAGCTCCTGAAATCCTCCTGGGCTGCAAATATTAT  516 
 
Query  541   TCCACAGCTGTGGACATCTGGAGCCTGGGCTGCATCTTTGCTGAGATGGTGACTCGCCGG  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  515   TCCACAGCTGTGGACATCTGGAGCCTGGGCTGCATCTTTGCTGAGATGGTGACTCGCCGG  456 
 
Query  601   GCCCTATTCCCTGGAGATTCTGAGATTGACCAGCTCTTCCGGATCTTTCGGACTCTGGGG  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  455   GCCCTATTCCCTGGAGATTCTGAGATTGACCAGCTCTTCCGGATCTTTCGGACTCTGGGG  396 
 
Query  661   ACCCCAGATGAGGTGGTGTGGCCAGGAGTTACTTCTATGCCTGATTACAAGCCAAGTTTC  720 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  395   ACCCCAGATGAGGTGGTGTGGCCAGGAGTTACTTCTATGCCTGATTACAAGCCAAGTTTC  336 
 
Query  721   CCCAAGTGGGCCCGGCAAGATTTTAGTAAAGTTGTACCTCCCCTGGATGAAGATGGACGG  780 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  335   CCCAAGTGGGCCCGGCAAGATTTTAGTAAAGTTGTACCTCCCCTGGATGAAGATGGACGG  276 
 
Query  781   AGCTTGTTATCGCAAATGCTGCACTACGACCCTAACAAGCGGATTTCGGCCAAGGCAGCC  840 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  275   AGCTTGTTATCGCAAATGCTGCACTACGACCCTAACAAGCGGATTTCGGCCAAGGCAGCC  216 
 
Query  841   CTGGCTCACCCTTTCTTCCAGGATGTGACCAAGCCAGTACCCCATCTTCGACTCTGA  897 
             ||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  215   CTGGCTCACCCTTTCTTCCAGGATGTGACCAAGCCAGTACCCCATCTTCGACTCTGA  159 
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BLAST for CDK2F cloned into pGADT7 #1-T7 
 
>lcl|8891  
Length=776 
 
 Score = 1354 bits (733),  Expect = 0.0 
 Identities = 759/776 (97%), Gaps = 3/776 (0%) 
 Strand=Plus/Plus 
 
Query  2    TGGAGAACTTCCAAAAGGTGGAAAAGATCGGAGAGGG--CACGTACGGAGTTGTGTACAA  59 
            ||||| |||||||||||||||||||||||||||||||  | | |    |||||||||||| 
Sbjct  1    TGGAGNACTTCCAAAAGGTGGAAAAGATCGGAGAGGGCCCCCTTNNANAGTTGTGTACAA  60 
 
Query  60   AGCCAGAAACAAGTTGACGGGAGAGGTGGTGGCGCTTAAGAAAATCCGCCTGGACACTGA  119 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  61   AGCCAGAAACAAGTTGACGGGAGAGGTGGTGGCGCTTAAGAAAATCCGCCTGGACACTGA  120 
 
Query  120  GACTGAGGGTGTGCCCAGTACTGCCATCCGAGAGATCTCTCTGCTTAAGGAGCTTAACCA  179 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  121  GACTGAGGGTGTGCCCAGTACTGCCATCCGAGAGATCTCTCTGCTTAAGGAGCTTAACCA  180 
 
Query  180  TCCTAATATTGTCAAGCTGCTGGATGTCATTCACACAGAAAATAAACTCTACCTGGTTTT  239 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  181  TCCTAATATTGTCAAGCTGCTGGATGTCATTCACACAGAAAATAAACTCTACCTGGTTTT  240 
 
Query  240  TGAATTTCTGCACCAAGATCTCAAGAAATTCATGGATGCCTCTGCTCTCACTGGCATTCC  299 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  241  TGAATTTCTGCACCAAGATCTCAAGAAATTCATGGATGCCTCTGCTCTCACTGGCATTCC  300 
 
Query  300  TCTTCCCCTCATCAAGAGCTATCTGTTCCAGCTGCTCCAGGGCCTAGCTTTCTGCCATTC  359 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  301  TCTTCCCCTCATCAAGAGCTATCTGTTCCAGCTGCTCCAGGGCCTAGCTTTCTGCCATTC  360 
 
Query  360  TCATCGGGTCCTCCACCGAGACCTTAAACCTCAGAATCTGCTTATTAACACAGAGGGGGC  419 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  361  TCATCGGGTCCTCCACCGAGACCTTAAACCTCAGAATCTGCTTATTAACACAGAGGGGGC  420 
 
Query  420  CATCAAGCTAGCAGACTTTGGACTAGCCAGAGCTTTTGGAGTCCCTGTTCGTACTTACAC  479 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  421  CATCAAGCTAGCAGACTTTGGACTAGCCAGAGCTTTTGGAGTCCCTGTTCGTACTTACAC  480 
 
Query  480  CCATGAGGTGGTGACCCTGTGGTACCGAGCTCCTGAAATCCTCCTGGGCTGCAAATATTA  539 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  481  CCATGAGGTGGTGACCCTGTGGTACCGAGCTCCTGAAATCCTCCTGGGCTGCAAATATTA  540 
 
Query  540  TTCCACAGCTGTGGACATCTGGAGCCTGGGCTGCATCTTTGCTGAGATGGTGACTCGCCG  599 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  541  TTCCACAGCTGTGGACATCTGGAGCCTGGGCTGCATCTTTGCTGAGATGGTGACTCGCCG  600 
 
Query  600  GGCCCTATTCCCTGGAGATTCTGAGATTGACCAGCTCTTCCGGATCTTTCGGACTCTGGG  659 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  601  GGCCCTATTCCCTGGAGATTCTGAGATTGACCAGCTCTTCCGGATCTTTCGGACTCTGGG  660 
 
Query  660  GACCCCAGATGAGGTGGTGTGGCCAGGAGTTACTTCTATGCCTGATTACAAGCCAAGTTT  719 
            ||| |||||||||||||||||||||||||||||||||||||||||||||||  ||   || 
Sbjct  661  GACNCCAGATGAGGTGGTGTGGCCAGGAGTTACTTCTATGCCTGATTACAANNCANNNTT  720 
 
Query  720  CCCCAAGTGGGCCCGGCAAGATTTTAGTAAAGTTGTACCTCCCC-TGGATGAAGAT  774 
            |||||||||||||||||||||||||||||||||||||||||||| || |||||||| 
Sbjct  721  CCCCAAGTGGGCCCGGCAAGATTTTAGTAAAGTTGTACCTCCCCCTGAATGAAGAT  776 
 
 
 
GATC Biotech could not provide the reverse sequence, but the ab1 and fas files were 
analyzed. The inserted fragment in pGADT7 was CDK2F. 
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BLAST for CDK2F cloned into pGBKT7 #7-T7 
 
>lcl|30645  
Length=891 
 
 Score = 1578 bits (854),  Expect = 0.0 
 Identities = 860/865 (99%), Gaps = 0/865 (0%) 
 Strand=Plus/Plus 
 
Query  1    ATGGAGAACTTCCAAAAGGTGGAAAAGATCGGAGAGGGCACGTACGGAGTTGTGTACAAA  60 
            ||||||||||||||||||||||||||||||||||||||||||| |||||||||||||||| 
Sbjct  25   ATGGAGAACTTCCAAAAGGTGGAAAAGATCGGAGAGGGCACGTTCGGAGTTGTGTACAAA  84 
 
Query  61   GCCAGAAACAAGTTGACGGGAGAGGTGGTGGCGCTTAAGAAAATCCGCCTGGACACTGAG  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  85   GCCAGAAACAAGTTGACGGGAGAGGTGGTGGCGCTTAAGAAAATCCGCCTGGACACTGAG  144 
 
Query  121  ACTGAGGGTGTGCCCAGTACTGCCATCCGAGAGATCTCTCTGCTTAAGGAGCTTAACCAT  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  145  ACTGAGGGTGTGCCCAGTACTGCCATCCGAGAGATCTCTCTGCTTAAGGAGCTTAACCAT  204 
 
Query  181  CCTAATATTGTCAAGCTGCTGGATGTCATTCACACAGAAAATAAACTCTACCTGGTTTTT  240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  205  CCTAATATTGTCAAGCTGCTGGATGTCATTCACACAGAAAATAAACTCTACCTGGTTTTT  264 
 
Query  241  GAATTTCTGCACCAAGATCTCAAGAAATTCATGGATGCCTCTGCTCTCACTGGCATTCCT  300 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  265  GAATTTCTGCACCAAGATCTCAAGAAATTCATGGATGCCTCTGCTCTCACTGGCATTCCT  324 
 
Query  301  CTTCCCCTCATCAAGAGCTATCTGTTCCAGCTGCTCCAGGGCCTAGCTTTCTGCCATTCT  360 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  325  CTTCCCCTCATCAAGAGCTATCTGTTCCAGCTGCTCCAGGGCCTAGCTTTCTGCCATTCT  384 
 
Query  361  CATCGGGTCCTCCACCGAGACCTTAAACCTCAGAATCTGCTTATTAACACAGAGGGGGCC  420 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  385  CATCGGGTCCTCCACCGAGACCTTAAACCTCAGAATCTGCTTATTAACACAGAGGGGGCC  444 
 
Query  421  ATCAAGCTAGCAGACTTTGGACTAGCCAGAGCTTTTGGAGTCCCTGTTCGTACTTACACC  480 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  445  ATCAAGCTAGCAGACTTTGGACTAGCCAGAGCTTTTGGAGTCCCTGTTCGTACTTACACC  504 
 
Query  481  CATGAGGTGGTGACCCTGTGGTACCGAGCTCCTGAAATCCTCCTGGGCTGCAAATATTAT  540 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  505  CATGAGGTGGTGACCCTGTGGTACCGAGCTCCTGAAATCCTCCTGGGCTGCAAATATTAT  564 
 
Query  541  TCCACAGCTGTGGACATCTGGAGCCTGGGCTGCATCTTTGCTGAGATGGTGACTCGCCGG  600 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  565  TCCACAGCTGTGGACATCTGGAGCCTGGGCTGCATCTTTGCTGAGATGGTGACTCGCCGG  624 
 
Query  601  GCCCTATTCCCTGGAGATTCTGAGATTGACCAGCTCTTCCGGATCTTTCGGACTCTGGGG  660 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  625  GCCCTATTCCCTGGAGATTCTGAGATTGACCAGCTCTTCCGGATCTTTCGGACTCTGGGG  684 
 
Query  661  ACCCCAGATGAGGTGGTGTGGCCAGGAGTTACTTCTATGCCTGATTACAAGCCAAGTTTC  720 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  685  ACCCCAGATGAGGTGGTGTGGCCAGGAGTTACTTCTATGCCTGATTACAAGCCAAGTTTC  744 
 
Query  721  CCCAAGTGGGCCCGGCAAGATTTTAGTAAAGTTGTACCTCCCCTGGATGAAGATGGACGG  780 
            |||||||||||||||||||||||||||||||||||||||||||||   |||||||||||| 
Sbjct  745  CCCAAGTGGGCCCGGCAAGATTTTAGTAAAGTTGTACCTCCCCTGNNNGAAGATGGACGG  804 
 
Query  781  AGCTTGTTATCGCAAATGCTGCACTACGACCCTAACAAGCGGATTTCGGCCAAGGCAGCC  840 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  805  AGCTTGTTATCGCAAATGCTGCACTACGACCCTAACAAGCGGATTTCGGCCAAGGCAGCC  864 
 
Query  841  CTGGCTCACCCTTTCTTCCAGGATG  865 
            |||| |||||||||||||||||||| 
Sbjct  865  CTGGNTCACCCTTTCTTCCAGGATG  889 
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BLAST for CDK2F cloned into pGBKT7 #7-BD 
 
>lcl|35035  
Length=873 
 
 Score = 1317 bits (713),  Expect = 0.0 
 Identities = 714/715 (99%), Gaps = 0/715 (0%) 
 Strand=Plus/Minus 
 
Query  183  TAATATTGTCAAGCTGCTGGATGTCATTCACACAGAAAATAAACTCTACCTGGTTTTTGA  242 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  873  TAATATTGTCAAGCTGCTGGATGTCATTCACACAGAAAATAAACTCTACCTGGTTTTTGA  814 
 
Query  243  ATTTCTGCACCAAGATCTCAAGAAATTCATGGATGCCTCTGCTCTCACTGGCATTCCTCT  302 
            |||||||| ||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  813  ATTTCTGCNCCAAGATCTCAAGAAATTCATGGATGCCTCTGCTCTCACTGGCATTCCTCT  754 
 
Query  303  TCCCCTCATCAAGAGCTATCTGTTCCAGCTGCTCCAGGGCCTAGCTTTCTGCCATTCTCA  362 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  753  TCCCCTCATCAAGAGCTATCTGTTCCAGCTGCTCCAGGGCCTAGCTTTCTGCCATTCTCA  694 
 
Query  363  TCGGGTCCTCCACCGAGACCTTAAACCTCAGAATCTGCTTATTAACACAGAGGGGGCCAT  422 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  693  TCGGGTCCTCCACCGAGACCTTAAACCTCAGAATCTGCTTATTAACACAGAGGGGGCCAT  634 
 
Query  423  CAAGCTAGCAGACTTTGGACTAGCCAGAGCTTTTGGAGTCCCTGTTCGTACTTACACCCA  482 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  633  CAAGCTAGCAGACTTTGGACTAGCCAGAGCTTTTGGAGTCCCTGTTCGTACTTACACCCA  574 
 
Query  483  TGAGGTGGTGACCCTGTGGTACCGAGCTCCTGAAATCCTCCTGGGCTGCAAATATTATTC  542 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  573  TGAGGTGGTGACCCTGTGGTACCGAGCTCCTGAAATCCTCCTGGGCTGCAAATATTATTC  514 
 
Query  543  CACAGCTGTGGACATCTGGAGCCTGGGCTGCATCTTTGCTGAGATGGTGACTCGCCGGGC  602 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  513  CACAGCTGTGGACATCTGGAGCCTGGGCTGCATCTTTGCTGAGATGGTGACTCGCCGGGC  454 
 
Query  603  CCTATTCCCTGGAGATTCTGAGATTGACCAGCTCTTCCGGATCTTTCGGACTCTGGGGAC  662 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  453  CCTATTCCCTGGAGATTCTGAGATTGACCAGCTCTTCCGGATCTTTCGGACTCTGGGGAC  394 
 
Query  663  CCCAGATGAGGTGGTGTGGCCAGGAGTTACTTCTATGCCTGATTACAAGCCAAGTTTCCC  722 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  393  CCCAGATGAGGTGGTGTGGCCAGGAGTTACTTCTATGCCTGATTACAAGCCAAGTTTCCC  334 
 
Query  723  CAAGTGGGCCCGGCAAGATTTTAGTAAAGTTGTACCTCCCCTGGATGAAGATGGACGGAG  782 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  333  CAAGTGGGCCCGGCAAGATTTTAGTAAAGTTGTACCTCCCCTGGATGAAGATGGACGGAG  274 
 
Query  783  CTTGTTATCGCAAATGCTGCACTACGACCCTAACAAGCGGATTTCGGCCAAGGCAGCCCT  842 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  273  CTTGTTATCGCAAATGCTGCACTACGACCCTAACAAGCGGATTTCGGCCAAGGCAGCCCT  214 
 
Query  843  GGCTCACCCTTTCTTCCAGGATGTGACCAAGCCAGTACCCCATCTTCGACTCTGA  897 
            ||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  213  GGCTCACCCTTTCTTCCAGGATGTGACCAAGCCAGTACCCCATCTTCGACTCTGA  159 
 
 
 
 
  
 
